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Abstract 
Fabry disease (FD) is caused by mutation in GLA that encodes lysosomal α-
galactosidase-A (α-gal-A). Loss of α-gal-A leads to glycosphingolipid storage in cells. 
Symptoms are life-threatening and current treatment is often enzyme replacement 
with variable therapeutic benefit. Alternative therapies are required. The world’s first 
clinical gene therapy trial was recently approved using lentivirus to integrate GLA into 
target cells for long-term enzyme expression. This thesis examined the efficacy of a 
previously engineered lenti-vector which may inform design of future trials.  
Endogenous α-galA activity was characterised in human and murine tissues. The 
Jurkat lymphoblastic leukaemia cell-line exhibited low α-gal-A activity. Transduction 
of Jurkats resulted in dose-dependent increase of α-galA expression, without 
apparent toxicity. The enzyme produced by cells with 0.4 transgene copies per cell 
(vg/cell) had comparable kinetic properties to wild type. Increasing exposure to 
1.8vg/cell resulted in an apparent increase in Michaelis Constant when compared to 
wild type. Therefore less virus dosage may be more therapeutically efficient. 
Increasing intracellular α-galA activity was accompanied by increased enzyme 
secretion and uptake of the extracellular enzyme into wild-type Jurkats, indicating 
cross-correction between cells. Previous research found deficits in mitochondrial 
function in FD. Here, inhibition of respiratory chain complex I appeared not to effect 
either lentivirus transduction efficiency or uptake of extracellular α-galA, but 
inhibited enzyme secretion. So FD may impede cross-correction. Extending the work 
into patient fibroblasts, this thesis found suggestion of reduced growth rate and 
impaired transduction efficiency. If correct these results may indicate the metabolic 
deficiencies in FD extend beyond complex I deficiency.  
In conclusion, lentivirus-mediated gene delivery is a promising therapeutic option for 
FD. However, excessive enzyme generation could result in a protein that has inferior 
kinetic properties, so dosage requires optimisation. Therapeutic strategies to support 
mitochondrial function may promote efficacy of treatment. 
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Chapter 1 Introduction 
1.1 The lysosome 
The lysosome was first discovered by Christian de Duve in 1955. Based upon early 
experiments measuring acid phosphatase activity in rat liver homogenate following 
centrifugal fractionation, he theorised with others that the enzyme functioned within 
a selectively permeable membrane sac (Berthet et al., 1951). Later de Duve et al 
(1955) discovered these sac-like particles contained multiple acid hydrolases, each 
one displaying enzymatic activity on its own specific substrate. Hence he named the 
particles lysosomes, meaning “lytic body” (Duve et al., 1955). The biochemical 
concept of the lysosome was supported structurally by electron microscopy of the 
mitochondrial fraction of rat liver homogenate by Novikoff et al (1956) (Novikoff et 
al., 1956). They observed acid phosphatase activity located within lipid membrane-
bound bodies which contained electron-opaque granules that were morphologically 
distinct from mitochondria (Essner and Novikoff, 1961). The lysosome concept is 
summarised in Figure 1-1. 
 
Figure 1-1: Lysosomes receive macromolecules for catalysis by a plethora of enzymes to 
recycle basic building-block molecules to the cytoplasm 
The hydrolytic activity of lysosomal enzymes is optimum at an acidic pH, an 
environment that is maintained within lysosomes by the V type ATPase proton pump 
integrated within the lysosomal membrane (Saftig and Klumperman, 2009). Macromolecules 
include redundant, old or damaged cellular components for recycling. Precursor molecules 
may also be sent to the lysosome for activation by one of the hydrolytic enzymes (Settembre 
and Ballabio, 2014b). Lysosomal associated membrane proteins (LAMPs) and lysosomal 
integrated membrane proteins (LIMPs) are important for transport of substrates, hydrolytic 
enzymes and cofactors to the lysosome.  
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Functional studies discovered that the acid hydrolases within lysosomes digest 
extracellular material by the process of endocytosis via fusion with late endosomes, 
and intracellular material by the process of autophagy (de Duve, 1963, de Duve, 
2005). The major autophagic mechanism is macroautophagy which commences with 
two molecular ubiquitin-like conjugation systems that initiate encasement of 
cytoplasm and redundant organelles in a double-membrane bound autophagosome. 
The outer membrane fuses with the lysosome to form an autophagolysosome 
containing the inner-membrane bound autophagic body that undergoes lysosomal 
degradation. A marker of autophagosomes in mammalian cells is microtubule-
associated protein 1 light chain 3 (LC3) (Yang et al., 2005). The products of reactions 
catalysed by hydrolases acting on material within the lysosome are released through 
the lysosomal membrane into the cytoplasm for use in biosynthesis (Settembre and 
Ballabio, 2014a). Lysosomes can also fuse with the plasma membrane to repair 
damage to lipid bilayer components, recycle signalling receptors, membrane 
channels and adhesion molecules, and secrete material into interstitial space by 
lysosomal exocytosis (Settembre et al., 2013).  
All three interactions are regulated by the Ca2+-dependent E box transcription factor 
called TFEB in response to substrate concentrations in the lumen of the lysosome 
(Medina et al., 2011, Sardiello et al., 2009, Settembre et al., 2011, Settembre et al., 
2012, Song et al., 2013).  Amino acids are sensed by V-ATPase and sufficient levels 
activate assembly of the mechanistic target of rapamycin complex one (mTORC1) on 
the lysosomal surface. The membrane complex phosphorylates TFEB to prevent its 
translocation to the nucleus. Conversely depleted amino acid levels allow mTORC1 to 
dissociate from the lysosomal membrane which allows TFEB to dephosphorylate and 
translocate to the nucleus where it facilitates transcription of genes that promote 
lysosomal activity and autophagic pathways which mediate lipid catabolism 
(Settembre and Ballabio, 2014b). Together these interactions comprise the 
endosomal-lysosomal system and are summarised in Figure 1-2.  
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Figure 1-2: Interactions of the lysosome with other cellular organelles including the nucleus 
The lysosome co-ordinates homeostasis between energy demand and supply, and cellular clearance. It fuses with the plasma membrane in order to 
repair damage to lipid bilayer components, recycle signalling receptors, membrane channels and adhesion molecules, and secrete material into interstitial 
space by lysosomal exocytosis. The lysosome receives extracellular material by the process of endocytosis via fusion with late endosomes, and receives 
intracellular material by the process of autophagy. A signalling pathway between nucleus and lysosome regulates these three interactions. These interactions 
form the endosomal-lysosomal system which positions the lysosome as the central hub of cellular metabolic homeostasis (Samie and Xu, 2014, Settembre 
and Ballabio, 2014b). Picture adapted from (Settembre et al., 2013). 
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The essential roles of the lysosome in degrading and recycling intra- and extra- 
cellular components place it central to regulating intracellular signal transduction, 
cellular clearance, antigen presentation at the cell surface, immunity against 
pathogens, and cholesterol homeostasis. The lysosome even signals cell death 
through release of cathepsin (Saftig and Klumperman, 2009).  Through receiving 
cytoplasmic material and aged, damaged or redundant organelles that have been 
segregated into autophagosomes, the lysosome samples the nutrient level and 
health of the cell, and regulates energy metabolism accordingly (Rabinowitz and 
White, 2010). Lysosomal biogenesis and activity are regulated by a coordinated gene 
network under the control of TFEB allowing the lysosome to sense the cellular and 
extracellular environment and adjust its function accordingly (Settembre and 
Ballabio, 2014b). 
Central to the roles of the lysosome are the 60 acid hydrolases it contains (Penati et 
al., 2017). The most common pathway by which both newly synthesised endogenous 
enzyme and exogenous extracellular enzyme are trafficked to the lysosome is by a 
mannose-6-phosphate receptor (M6PR)-dependent pathway (Marchesan et al., 
2012). This pathway is illustrated in Figure 1-3. On their synthesis by ribosomes 
attached to the endoplasmic reticulum (ER) membrane, both secretory and lysosomal 
proteins undergo co-translational N-linked glycosylation of certain asparagine 
residues within the ER lumen (Kornfeld, 1986). In the golgi apparatus (GA) post-
translational modification of the glycoproteins determine their final destination. 
Addition of sialic acid groups target enzymes for secretion; but in most cases, 
precursor enzymes destined for lysosomes acquire phosphomannosyl residues in a 
two-step process illustrated in Figure 1-4. This process is essential for glycoproteins 
to be recognised by the M6PR-dependent pathway (Kornfeld, 1986).  
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Figure 1-3: Lysosomal trafficking pathways 
Precursor lysosomal enzymes undergoes co- and post-translational modification 
including N-linked glycosylation. Within the golgi apparatus most lysosomal enzymes are 
recognised by signal recognition sites on phosphotransferase which results in 
phosphorylation of high mannose residues essential for the enzyme’s trafficking from the 
trans-golgi network (TGN) to the lysosome via a manose-6-phosphate-dependent pathway 
(Hrebicek and Ledvinova, 2010). Once within the lysosome, the enzyme is clipped by 
proteases into mature α-gal A (46kDa) that forms a homodimer with optimum catalytic 
activity at pH 3.8-4.6 (Gal et al., 2011). Overexpression of α-gal A may lead to saturation of 
available mannose-6-phosphate receptors (M6PRs) in the TGN, leading to secretion of 
enzyme expressing the M6P moiety. Such enzymes may then be taken up by other cells by 
M6PRs on their plasma membrane. Image sourced from (Lodish et al., 2000). 
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Figure 1-4: The two-step enzymatic addition of phosphomannosyl residues to pre-enzymes 
essential for M6PR-dependent trafficking to the lysosome 
Phosphomannosyl residues are added to selected mannose residues on glycoproteins 
by a two-step process within the golgi apparatus. Firstly a phosphotransferase transfers N-
acetylglucosamine-1-phosphate from uridine diphosphate N-aceylglucsomaine to mannose 
residues on precursor enzymes destined for the lysosomes. This golgi enzyme exhibits high 
affinity with lysosomal glycoproteins, possibly due to protein-protein interaction at signal 
sequences that are not present in secretory or plasma membrane proteins. Secondly, the N-
acetylglucosamine is removed from the phosphodiester residue by N-acetylglucosamine-l-
phosphodiester α-N-acetyIglucosaminidase to expose mannose-6-phosphate signalling 
moities (Kornfeld, 1986). This has more recently termed the uncovering enzyme (Coutinho 
et al., 2012). GlcAcN: N-acetylglucosamine. UDP: urine diphosphate. 
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Lysosomal enzymes processed in this way are subsequently detected by M6PRs 
expressed in the trans-golgi-network (TGN). M6PR may also be expressed at the cell 
surface, enabling the recapture of secreted enzyme that escaped the lysosomal 
trafficking pathway. The ligand-receptor complex is packaged into clathrin-coated 
transport vesicles that bud from the TGN and merge with the late endosome. A low 
pH microenvironment within late endosomes allows the enzyme to dissociate from 
M6PR. The enzymes enter the lysosomes where they are clipped by proteases into 
their mature, active form (Coutinho et al., 2012, Desnick et al., 2001).  
Other lysosomal trafficking pathways exist which are M6PR-independent, depending 
upon cell-type and hydrolytic enzyme (Prabakaran et al., 2012). For example 
lysosomal integral membrane protein LIMP2 acts as a receptor for localising β-
glucocerebrosidase to the lysosome in various tissues, especially within liver (Reczek 
et al., 2007). Endocytosis of portions of the plasma membrane to the lysosome is 
essential for import of certain lysosomal hydrolytic enzymes that have bypassed the 
intracellular route of newly synthesised lysosomal proteins. Acid phosphatase 
provides an example of a lysosomal protein which is trafficked to the lysosome via 
clathrin-mediated endocytosis at the plasma membrane (Pryor and Luzio, 2009). 
 
1.2 Lysosomal storage disorders 
The lysosome concept introduced by de Duve (1963) first postulated the existence of 
congenital disorders due to enzymatic deficiencies effecting lysosomal function (de 
Duve, 1963). In the same year Hers (1963) showed that a type of α-glucosidase called 
acid maltase was deficient in Pompe disease, a glycogen storage disorder (Hers, 
1963), and LeJeune et al (1963) showed that acid maltase was collocated with acid 
phosphatase which was recognised at the time as a lysosome marker (de Duve, 1963, 
Lejeune et al., 1963). In this light, Hers (1963) hypothesised that the symptoms of 
Pompe disease were due not only to the enzyme deficiency itself, but to the wider 
implications of lysosomal dysfunction, giving rise to the idea of the Lysosomal storage 
disorder (LSD) (Hers, 1963).  
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LSDs impair breakdown, salvage and secretion of cellular components essential for 
membrane integrity, cell-cell signalling, energy metabolism, autophagy, immune 
response and lysosomal biogenesis (Settembre et al., 2013, Das and Naim, 2009). The 
number of identified LSDs has since expanded into a group of approximately 70 
genetically distinct diseases due to mutation in genes which effect the function of 
one or more of the elements of the endosomal-lysosomal system. Although 
individually rare, LSDs have a collective incidence of one in 7,500 live births (Cox and 
Cachon-Gonzalez, 2012).  
LSDs may be classified according to the type of primary storage material which 
accumulates within effected cells (Futerman and van Meer, 2004). This classification 
is most appropriate for disease categories such as sphingolipidosis and 
mucopolyssacharidosis.  In these groups a defect in any of the lysosomal enzymes 
involved in sequential catalysis of glycosphingolipids and glucoaminoglycans (GAGs) 
respectively, directly result in storage of the relevant undigested material. However 
there are many LSDs caused not by direct defects in any lysosomal acid hydrolase but 
defects in the wider endosomal-lysosomal system which result in accumulation of 
multiple types of storage material (Winchester, 2012). So another classification 
system was developed according to the molecular defect causing the disorder 
(Filocamo and Morrone, 2011). Both classification systems are utilised to develop the 
framework currently in use which is summarised in Table 1-1. The main basic 
mechanisms underlying LSDs are illustrated in Figure 1-5 to help interpret Table 1-1.  
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Table 1-1: Classification of Lysosomal Storage Disorders based upon the type of material 
stored and the molecular basis of diseases 
Lysosomal storage disorders may be classified according to the type of storage 
material that accumulates in effected cells. This applies to the first four classifications in the 
table. Where this order is not appropriate, diseases may be subdivided according to whether 
the underlying pathological mechanism is a genetic defect in acid hydrolases, or some other 
factor effecting lysosome function. This applies to the remaining classifications in the table. 
GAGs: glycoaminoglycans. M6PR: mannose-6-phosphate receptor. SUMF1: formylglycine 
generative enzyme which activates lysosomal sulfatases. LIMP: lysosomal integral membrane 
protein. LAMP: lysosomal-associated membrane protein. (Cox and Cachon-Gonzalez, 2012, 
Winchester, 2012). 
 
Classification: Molecular basis of disease class and type of 
material accumulated in storage cells 
Mechanism 
expanded in 
Figure 1.5 
Muco-
polyssacharidoses 
Defects in any of 11 lysosomal enzymes involved 
in systematic catalysis of GAGs. 
1, 4 
Sphingolipidoses 
A group of diseases caused by defects in any of 9 
lysosomal enzymes involved in systematic catalysis 
of glycosphingolipids, or defects in any of four 
sphingolipid activator proteins (saposins A, B, C & 
D) for these enzymes or their precursor 
(prosasposin). 
1, 3, 4 
Glycoproteinoses 
Defects in lysosomal enzymes relating to catalysis 
of glycopeptides, glycolipids and oligo-saccharides. 
1, 4 
Neuronal Ceroid 
Lipofuscinoses 
(NCLs) 
This class comprises diverse defects of the 
endosomal-lysosomal system that result in the 
accumulation of an auto-fluorescent deposit called 
lipofuscin within lysosomes. 
- 
Defects in lysosomal enzymes for glycogen and lipid catalysis, and 
lysosomal proteases 
1, 4 
Defects in post-translational processing of lysosomal enzymes, including 
defects in phosphotransferase and the uncovering enzyme required for 
proteins to follow the M6PR-dependent pathway which causes stuttering. 
Post-translational modifications can also take place within the lysosome 
itself by activator enzymes such as SUMF1 which is defective in multiple 
sulfatase deficiency. 
2, 3 
Defects in specific transporters, receptors and channels within the 
lysosomal membrane essential for correct function, as well as LIMP 
receptor proteins necessary for ingress of certain hydrolytic enzymes, and 
LAMP glycoproteins responsible for fusion with autophagosomes. 
2, 5 
Defects in the biogenesis of lysosomes and their related organelles - 
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Figure 1-5: Classification of LSDs according to their underlying molecular basis 
Lysosomal storage disorders may be due to a wide variety of pathological molecular 
mechanisms where their root causes may extend beyond the lysosome itself to implicate the 
wider endosomal-lysosomal system. 1. Misfolded mutant precursor enzymes may fail quality 
control checks with the ER leading to ERAD. Even if ERAD is avoided, misfolding may prevent 
formation of multi-enzyme complexes required in some cases for transport out of the ER. 2. 
Once within the GA, mutant precursor enzymes may not be correctly glycosylated, resulting 
in aberrant trafficking to the lysosome by the M6PR-dependent pathway. Defects in other 
pathways may prevent transport to the lysosome necessary for function. 3. Activator 
proteins or cofactors may be defective leading to reduced enzyme activity in the lysosome. 
4. Glycosylation defects within the GA, or defects within the enzyme itself, may lead to 
reduced enzyme activity in the lysosome. 5. Defects in lysosomal membrane proteins or 
other regulatory molecules may prevent enzyme transport to the lysosome or interaction 
with endosomes, autophagosomes or the plasma membrane. ERAD: Endoplasmic Reticulum-
associated degradation. ER: Endoplasmic reticulum. GA: Golgi apparatus. M6PR: Mannose-6-
Phosphate receptor. (Futerman and van Meer, 2004). 
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1.3 Sphingolipidosis 
Glycosphingolipids (GSLs) are a family of complex biological macromolecules 
composed of a lipid root which is embedded within the phospholipid bilayer of the 
plasma membrane of all eukaryotic cells. This anchor is most commonly ceramide 
which is a long chain amino alcohol called sphingosine in amide linkage with a fatty 
acid. Alternatively, the anchor may be sphingosine. Attached to the anchor may be a 
glycan moiety. The composition of the glycan moiety, together with the length, 
saturation and hydroxylation of the long chains of the root confer considerable 
variation in structure, and consequently function, of members of the GSL family. As 
a major component of the glycocalix, GSLs have important roles in cell-cell 
interaction, cell surface receptor-mediated signal transduction, immunity, and 
providing a water permeability barrier for skin (Kolter and Sandhoff, 1999, Lingwood, 
2011). 
The GSL family of macromolecule in humans are divided into two main categories: 
those based upon lactosylceramide, and galactosylceramide. Each is further 
subdivided into series according to the content and order of carbohydrate in the 
glycan moiety as shown in Figure 1-6. Sequential catabolism commences from the 
terminal carbohydrate of GSLs by specific acid hydrolases within lysosomes until 
sphingosine remains. Deficient activity of any one enzyme or its activating cofactor 
will result in accumulation of substrate and deficiency in the bioavailability of 
product, leading to sphingolipidosis (Cox and Cachon-Gonzalez, 2012). Figure 
1-6Figure 1-5 shows the enzyme responsible for each catabolic step in the 
degradation of GSL, and the sphingolipidosis which results from its deficiency. 
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Figure 1-6: Catabolic pathway for sphingolipids within lysosomes, and the sphingolipidoses caused by deficiencies in specific enzymes 
The highly diverse family of glycosphingolipids (GSLs) are organised, according to the order of the glycan moiety attached to the ceramide membrane 
anchor, into ganglio, globo and gala series.  The sphingolipid sphingomyelin is highly abundant within lipid membranes. Lysosomal hydrolytic enzymes degrade 
GSLs sequentially from the glycan moiety terminal end. Each enzyme catalyses a specific step in the pathway. Deficiency in either an enzyme, or a prerequisite 
activing cofactor, results in a blockage in the pathway at the relevant step or steps. Boxed in red is the enzyme responsible for catalysing each step in the 
pathway, and emboldened in red is the disease caused by blockage at that step. SAP-A, B or C: Saposin A, B or C required for activating enzyme. GM1, 2 & 3 
contains [sialic acid]. Breakdown of GM2 to GM3 requires β-hexosaminidase A and GM2 activator; deficiency leads to AB-variant Sandhoff disease. (Kolter 
and Sandhoff, 1999, Winchester, 2012). 
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1.4 Fabry disease 
1.4.1 History 
In 1897 the German dermatologist Johannes Fabry and the British clinician William 
Anderson reported independently the first observed cases of “angiokeratoma 
corporis diffusum” (Anderson, 1898, Fabry, 2002, Fabry, 1898). Their patients 
presented with red-purple maculopapular skin lesions focused in the upper thigh and 
trunk regions. Johannes Fabry went on to monitor his patient who developed 
respiratory disease, albuminuria and increased incidence of cutaneous eruptions, 
leading him to suggest the patient was presenting a systemic vasculopathy and 
kidney dysfunction. His theory was supported by others who reported accumulation 
of lipids in vasculature and glomeruli smooth muscle, together with gastroenteritis, 
in patients presenting similar characteristics (Karr, 1959). The condition subsequently 
became known as Fabry’s disease (FD) (OMIM no. 301500).  
Sweeley and Klionsky (1963) identified the biochemical nature of the disease. They 
examined kidney tissue from a FD patient who died following renal failure aged 28 
and found abnormally high concentrations of two glycosphingolipids: 
globotriaocylceramide (Gb3) and, to a lesser extent, galabiocylceramide. Thus FD was 
shown to be a sphingolipidosis (Sweeley and Klionsky, 1963). Examination of 
seventeen FD families by Opitz et al (1965) showed the disease was inherited through 
the maternal line and predominantly effected males. Female carriers were usually 
either asymptomatic or only mildly affected; rarely were females found to present 
symptoms as severely as in males. Sons of effected fathers were asymptomatic. 
Together the data collected suggested an X-linked genetic cause for the accumulation 
of Gb3 in patients (Opitz et al., 1965).  
Through analysing samples of small intestinal mucosa collected from two affected 
brothers and their minimally affected mother with FD, Brady et al (1967) found 
deficient activity of α-galactosidase A (α-gal A), otherwise known as 
ceramidetrihexodase (EC 3.2.1.22), in all three subjects. The acid hydrolase is 
responsible for removal of the terminal galactose from the glycan moiety of Gb3. 
Other enzymes involved in the systematic breakdown of globoside to ceramide 
35 
 
within lysosomes were unaffected (Brady et al., 1967). The gene encoding α-gal A, 
identified as GLA, was mapped to the long arm of the X chromosome (Xq21-22) (Fox 
et al., 1984), and the coding regions of the gene was sequenced for the mature 
lysosomal form of the human enzyme (Bishop et al., 1986).  
Today, FD is only partially understood as a highly progressive, multi-systemic and 
heterogeneous lysosomal storage disease due to inborn error of glycosphingolipid 
metabolism. The GLA genotype does not correlate with disease phenotype observed 
in patients because of the extreme variability in severity and presentation, even 
within families. This complexity is enhanced by the effect of genetic modifiers, partial 
penetrance of GLA mutations in females due to X-inactivation and the central role of 
the lysosome in controlling cellular metabolic homeostasis (Desnick et al., 2001, 
Germain, 2010).  So the history of FD is still in the making.  
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1.4.2 Clinical symptoms and epidemiology 
FD is a complex multi-systemic condition presenting non-specific symptoms that are 
extremely challenging for clinicians to correctly diagnose. Patients may experience 
delay of over ten years from first reporting symptoms to confirmed diagnosis 
(Thomas and Mehta, 2013).  
Early or childhood symptoms of classical FD may include angiokeratoma (skin 
lesions), acroparaethesia (burning discomfort in extremities), anhydrosis (deficient or 
excessive sweating) and proteinuria. Later, or by adulthood, substrate accumulation 
causes worsening of symptoms that may progress to include gastrointestinal 
dysfunction, respiratory disorders, cardiomyopathies, renal disease, neuropathic 
pain and fatigue with a commensurate reduction in quality of life. Patients often 
present cornea verticilata (asymptomatic corneal clouding), vascular ectasia and 
tortuosity (pathological changes to the retina), and may report hearing loss (Brady, 
2010).  
Heterozygous females are not only genetic carriers of a pathogenic mutation in GLA 
but may show signs of disease that in exceptional cases may be as severe as classical 
FD (Pinto et al., 2010, Wang et al., 2007). Classical FD reduces life span by up to 
twenty years in males and fifteen years in females (Mehta and Hughes, 2002); cause 
of death is usually renal failure, myocardial infarction or stroke (Thomas and Mehta, 
2013).  
In a study of seven affected males and five heterozygous females, Morgan et al (1990) 
found numerous cases of abnormal thermal sensation, especially impaired 
electrophysiological response to cold, indicating small myelinated fibre neuropathy. 
The study also revealed occurrence of abnormal brain scans by magnetic resonance 
imaging, even in the absence of obvious neurological/behavioural changes in patients 
(Morgan et al., 1990). Recently FD has also been associated with the 
neurodegenerative disorders (Nelson et al., 2014, Plotegher and Duchen, 2017, Stoka 
et al., 2016). For example, α-gal A-deficiency was found in post-mortem brains from 
late-stage Parkinson’s disease patients, and level of enzyme deficiency correlated 
with α-synuclein accumulation (Nelson et al., 2017). 
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Diagnosis is complicated by non-classical, atypical variants of FD that present later in 
life in milder, mono- or oligo-symptomatic forms (Ko et al., 1996, Sachdev and Elliott, 
2002). The recorded incidence of FD is between 1:117,000 (Meikle et al., 1999) and 
1:4,000 (Spada et al., 2006) in males, suggesting diagnosis is inconsistent. A screening 
study of 171,977 consecutive new-borns in Taiwan reported an incidence of 1:1,250 
and 1:40,000 FD cases amongst males and females respectively (Hwu et al., 2009). A 
systematic review suggested that screening of new-born and high risk populations 
identified individuals with GLA mutation or genetic variants that were of unknown 
significance with regards to FD, highlighting that until diagnostic criteria are 
improved, identifying true incidence of the disease will remain very difficult (van der 
Tol et al., 2014). So there is an urgent need to improve understanding of the 
pathological biochemistry of FD in order to improve early diagnosis. 
  
38 
 
1.4.3 Biochemistry  
Human GLA codes for the 50kDa precursor α-gal A protein. Newly synthesised pre-
enzyme incorporates a 31 residue signal sequence essential for the translocation of 
enzyme from the membrane of the ER into the lumen (Bishop et al., 1986). 
Subsequently it undergoes co- and post-translational modification including N-linked 
glycosylation essential for the enzyme’s trafficking from ER to the lysosome (Hrebicek 
and Ledvinova, 2010). Fibroblasts, but not endothelial cells, appear to predominantly 
use M6PR-dependent trafficking for α-gal A (Marchesan et al., 2012), but podocytes 
use megalin and sortilin receptors as well as M6PR receptors (Prabakaran et al., 2011) 
and renal endothelial cells use sortilin receptors to endocytose extracellular α-gal A 
via LIMP2 lysosomal membrane proteins (Prabakaran et al., 2012). 
On entering the lysosome, the enzyme is clipped by proteases into the mature, active 
form which is 46kDa and organises into homodimers with optimum catalytic activity 
at pH 3.8-4.6 on neutral or synthetic α-galactosyl substrates (Desnick et al., 2001, Gal 
et al., 2011). The structure of a lysosomal α-gal A monomer with α-galactose bound 
to the active site is shown in Figure 1-7. The enzyme is glycosylated at three aspartate 
residues (Hrebicek and Ledvinova, 2010). 
Hydrolysis of substrate is by a double displacement mechanism in which D170 
executes nucleophilic attack upon the anomeric carbon (C1) of α-galactose, cleaving 
its glycosidic linkage with the substrate and creating a covalently bound α-galactose-
enzyme intermediate (Figure 1-7). Then a water molecule deprotonated by D231 
executes a second nucleophilic attack on C1, liberating α-galactose from the active 
site and regenerating the enzyme. So α-gal A allows the anomeric configuration of 
the terminal saccharide molecule of substrate to be retained in the product and is 
called an α-retaining exoglycosidase (Garman and Garboczi, 2004).  
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Figure 1-7: The ribbon structure of monomeric α-gal A with details of its active site with α-galactose bound 
Peptide is illustrated in colours graded from red at the C-terminus to blue at the N-terminus. The C-terminal domains of two monomers interact to 
form a homodimer in the lysosome. The active site of each monomer is located within the N-terminal domain and is shown with bound α-galactose.  The 
active site comprises of 15 remote residues that co-localise by protein folding and interact with the substrate’s terminal α-galactose molecule as shown: 
hydrogen bonds and polar interactions are indicated in red, and van de Waal forces are shown in blue dashed lines. Adapted from (Garman and Garboczi, 
2004).
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The in vivo substrates of α-gal A are glycosphingolipids, shown in Figure 1-8, which 
comprise of a hydrophilic glycosidic tail linked to a hydrophobic ceramide head. This 
general structure suits substrates for inclusion within the lipid membranes of cells 
and subcellular structures. Gb3 is the predominant substrate and has been shown to 
be a diagnostic and prognostic marker for FD (Mills et al., 2002, Young et al., 2005). 
Gb3 is a major component of membrane-bound organelles, vesicles and the outer-
leaflet of plasma membrane where it localises within caveolar-associated lipid rafts 
that are rich in cholesterol and receptor signalling complexes (Das and Naim, 2009).  
The α-gal A substrate Gb3 is named P blood group antigen pk (Marcus et al., 1981) 
and cell surface marker CD77. It has widespread baseline expression in human tissues 
(Table 1-2). Within the haematopoietic system Gb3 expression is restricted to 
germinal centre B lymphocytes (Mangeney et al., 1991); and is an important marker 
for Burkitt lymphoma cells (Nudelman et al., 1983) and megakaryoblastic leukaemia 
cells (Furukawa et al., 2002). Verotoxins released by Escherichia coli are ligands for 
Gb3; ligation triggers endocytosis of the verotoxin that subsequently exerts a 
cytotoxic effect by inhibiting protein synthesis, suggesting that Gb3 is involved in 
signal transduction (Endo et al., 1988). There is evidence that CD77 associates with 
CD19 at the cell surface to induce retrograde transport of CD19 to the nuclear 
membrane to signal apoptosis (Khine et al., 1998), and inhibit growth in response to 
interferon-α (Maloney et al., 1999). 
There is interesting evidence that α-gal A activity may be an essential regulator of 
invariant natural killer T (iNKT) cell response to glycosphingolipids, preventing 
overstimulation to endogenous Gb3 yet, in the presence of exogenous Gb3, 
enhancing iNKT cell stimulation to reach threshold for release of cytokines. The 
presence of microbes appears to inhibit α-gal A activity in antigen presenting cells 
(APC) by a toll-like receptor-induced mechanism, increasing Gb3 expression. Gb3 may 
be trafficked from the lysosome on CD1 for presentation at the APC surface to amplify 
iNKT activity (Darmoise et al., 2010). Thus α-gal A dysfunction may impact iNKT cell 
roles in immunity, autoimmunity and cancer. Gb3 has been shown to inhibit iNKT-cell 
activation in a CD1-dependent manner (Pereira et al., 2016). 
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Figure 1-8: In vivo substrates for α-gal A are neutral glycosphingolipids, predominantly 
globotriaosylceramide (Gb3) and, to a lesser extent, digalactosylceramide (Ga2), blood 
group B antigen and globotriaosylsphingosine (lysoGb3). 
Hydrolysis of terminal α-galactose, highlighted in red, requires the activator 
glycoprotein saposin B which increases solubility of the substrate and accessibility by the 
enzyme (Hrebicek and Ledvinova, 2010). A-gal A can also hydrolyse lysoGb3, a de-acylated 
metabolite of Gb3 which is increased in plasma of FD patients, but with 50-fold less efficiency 
than Gb3 (Aerts et al., 2008). 
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The major sites of glycosphingolipid storage and subsequent cellular pathology in 
humans with FD are also listed in Table 1-2. Histological hallmarks of progressive 
disease include zebra-like lipid aggregates in storage lysosomes and autofluorescent 
ceroid deposition in long-living cell types such as smooth muscle or post-mitotic 
cardiomyocytes. Ceroid is thought to be an indicator of irreversible cellular damage 
(Elleder, 2010). 
 
Table 1-2:  The distribution of Gb3 in human health and disease 
The glycosphingolipid globotriaosylceramide (Gb3) is normally found in the cellular 
membranes of a diverse range of tissue types and organs, all of which are highly vascular 
(Pallesen and Zeuthen, 1987, Hughes et al., 2002, Kojima et al., 2000). The distribution 
reflects the sites of storage observed in Fabry disease (FD) (Desnick et al., 2001, Elleder, 2010, 
Hozumi et al., 1990). 
Human tissues with high baseline 
amount of Gb3  
Major sites of Gb3 storage in Fabry 
disease  
Vascular endothelial & smooth muscle cells 
Kidney 
Liver 
Pancreas 
Lungs 
Neurons of CNS 
Gastrointestinal system 
Male reproductive system 
Heart 
Placenta 
Vasculature:  
endothelium; 
underlying perivascular and smooth muscle 
cells; 
Renal glomeruli and distal tubules;  
Cardiomyocytes; 
Neurons; 
Fibroblasts of skin and heart; 
Macrophages; 
Epithelial cells lining bronchioles. 
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1.4.4 Genetics 
Human GLA, located within the long arm of the X chromosome at position Xq22, 
contains seven exons comprising 1418 nucleotides (NCBI: NM_000169.2). Within the 
non-coding intronic regions between exons are located 12 Alu transposable repeat 
elements. The International Human Genome Sequencing Consortium (2001) found 
that these elements are common locations for mutations (Lander et al., 2001). It is 
not surprising therefore that the Human Gene Mutation Database (Stenson et al., 
2009) details  approximately 900 FD-causing mutations identified within GLA, and the 
number is increasing. These mutations can be categorised as shown in Table 1-3.  
Table 1-3: Categories of GLA variants 
Gene rearrangements involving large deletions and insertions usually translate to a 
severe disease phenotype for patients. Small insertions or deletions that were often frame-
shift mutations leading to premature termination of transcripts frequently result in the 
classical disease phenotype in males. The most common point mutations include N215S, 
R227Q, R227X, R342Q, and R342X (Eng and Desnick, 1994). A new born screening study in 
Taiwan found a very high incidence of mutation c.639+919G>A (Hwu et al., 2009), which 
results in alternative transcriptional splicing  and reduced α-gal A activity (Ishii et al., 2002). 
Category of GLA mutation Example Genotype 
Large gene rearrangements 
Partial gene deletions or insertions 
involving multiple introns and exons 
Small deletions and insertions Usually within exons 
Mutations causing defects in transcript 
processing 
Mutations at splice sites usually located 
within introns or at the edge of exons 
Point mutations 
Missence and nonsence mutations within 
exons 
No clear correlation between genotype and phenotype has yet been discerned. 
Generally, missense mutations result in residual enzyme activity and are associated 
with non-classical FD. This is because these mutations may cause the tertiary 
structure of α-gal A to be unstable, leading to protein misfolding and subsequent 
degradation by ERAD quality control, or failure to be trafficked to the lysosomal, or 
reduced substrate affinity. Nonsense, splice or frame-shift mutations, and missense 
mutations at functionally significant sites, are associated with classical FD and less 
than 10% normal α-gal A activity (Gal, 2010). For example, N215S was a common 
44 
 
missense mutation linked with non-classical variant FD effecting mainly the heart. 
R227X was the most common nonsense mutation linked with the classical phenotype 
(Eng et al., 1993). 
One of the challenges posed by the heterogeneous nature of FD is differentiating 
between mutations resulting in non-classical disease phenotypes and non-disease 
causing polymorphisms (Schiffmann et al., 2016). The relationship between GLA 
variants and α-gal A activity is shown in Figure 1-9, which illustrates that there are 
two groups of variants with enzyme activity above 20%, and 40%, of normal 
presenting highly variable phenotypes.  For example, the GLA variant R118C is 
associated with over 30% residual α-gal A and no Gb3 storage within tissues, yet 
reports vary regarding the clinical presentation. The mutation was associated with a 
cerebrovascular disease (Rolfs et al., 2013), cardiac hypertrophy (Caetano et al., 
2014) and non-FD phenotypes (Ferreira et al., 2015). 
 
Figure 1-9: The relationship between GLA genotype and phenotype 
The relationship between GLA genotype and phenotype is dependent upon various 
risk factors including the genetic/epigenetic background, gender and environment to which 
the individual is exposed. The influence of these factors increase with increasing residual α-
gal A activity. Image sourced from (Schiffmann et al., 2016). 
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The phenotype resulting from GLA genotypes within these groups is variably 
influenced by epigenetic factors and modifier-genes such as those coding for 
interleukin-6, endothelial nitric oxide synthase (eNOS), factor V and protein Z 
(Schiffmann et al., 2016, Heltianu et al., 2002). For example, the Factor V Leiden 
mutation is associated with thromboembolic events in FD patients (Lenders et al., 
2015), and polymorphisms in the gene for eNOS are associated with increased cardiac 
hypertrophy in FD patients (Rohard et al., 2008).  
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1.4.5 Pathophysiology 
From the nature of FD discussed so far, it is logical to propose several 
pathophysiological mechanisms cascading from the primary enzyme deficiency to 
impair global cellular function. Identification and understanding of these mechanisms 
may lead to explanations for the extreme variability observed between patients and 
across tissue-types within patients (Germain, 2010). Pathological processes 
evidenced in FD are summarised in Figure 1-10 and will be discussed here. 
 
Figure 1-10: Pathophysiological mechanisms involved in the clinical manifestations of Fabry 
disease 
The major substrate of α-gal A is globotriaosylceramide (Gb3). Fabry disease causes 
accumulation of Gb3 which alters lipid composition of cell membranes leading to metabolic 
deficits. Secondary metabolites globotriaosylsphingosine (lyso-Gb3) and sphingosine-1-
phosphate (S1P) also increase and signal pathological processes. Lyso-Gb3 appears to be a 
better biomarker than Gb3 for differentiating classical from variant phenotypes in patient 
plasma. Storage of material in lysosomes may effect functions including autophagy. 
Increased pressure on endoplasmic reticulum associated degradation (ERAD) due to 
misfolded or unstable α-gal A mutants may cause wider implications for cellular quality 
control.  
Firstly there are the effects of impaired recycling of glycosphingolipids Gb3 and 
galabiosylceramide (Ga2) on membrane dynamics, cell-cell interactions including 
immune response, and general receptor-mediated signal transduction. In patient 
fibroblasts, impaired lipid raft dynamics prevented the co-localisation of α-gal A with 
LAMP2 at the plasma membrane resulting in impaired trafficking of α-gal A to the 
lysosome, further exaggerating the accumulation of Gb3 (Maalouf et al., 2010). 
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Accumulation of Gb3 in the lysosomal-endosomal compartments of cultured GLA-
deficient vascular endothelial cell-lines increases production of reactive oxygen 
species (ROS) which cause oxidative stress (Shen et al., 2008).  Gb3 also accumulates 
within plasma membrane lipid rafts where it displaces cholesterol, and cholesterol-
associated caveolin-1 (cav1) (Shu and Shayman, 2007). Cav1 is an essential regulator 
of eNOS that converts arginine to nitric oxide (NO) and citruline, dependent upon the 
cofactor of eNOS, tetrahydrobiopterin (BH4). Reduced cav1 content within lipid rafts 
may lead to eNOS:BH4 imbalance and eNOS uncoupling, resulting in production of 
superoxide instead of NO. Superoxide converts NO to peroxynitrite, a potent ROS 
which destabilises BH4 leading to enhanced eNOS uncoupling (Kietadisorn et al., 
2012, Shayman, 2010). Reduced NO bioavailability will impair vasoresponse, 
promoting a pro-thrombotic and pro-atherosclerotic state and endothelial 
dysfunction (Shen et al., 2008, Forstermann and Munzel, 2006, Kang et al., 2014).  
Accumulation of Gb3 will also disrupt the lipid and cholesterol composition of cellular 
membranes which is important for membrane permeability, integrity and key 
membrane associated processes such as the mitochondrial respiratory chain (Das and 
Naim, 2009). Lucke et al (2004) observed reduction in the activity of respiratory chain 
complexes I, IV and V in skin fibroblasts from FD patients compared to controls. 
Cellular content of ADP, AMP and creatine phosphate (CR) also reduced, but ATP only 
fell marginally. The authors attributed this to ATP replenishment by CR (Lucke et al., 
2004).  
Oxidative stress and eNOS uncoupling are probable further contributors to reduced 
energy metabolism. Increased ROS production will exert a deleterious effect on 
mitochondrial respiration by damaging enzymes, transporters, receptors, and 
mitochondrial DNA (Ventura et al., 2002, Heales et al., 1996, Lenaz et al., 2002, Shen 
et al., 2008). Consistent with this, cardiac energy metabolism was reduced in patients 
(Machann et al., 2011), and associated with increased rate of left ventricular 
hypertrophy over an eight year follow-up period following diagnosis (Palecek et al., 
2010). Significantly reduced glucose consumption was found in the brains of α-gal A 
knock-out mice compared with controls, suggesting that cerebral energy metabolism 
also may be impaired in FD (Itoh et al., 2001).  
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The mitochondria is the site of cellular respiration and regulates cell growth, division 
and death (Osellame et al., 2012). In their paper reporting autopsy results in three 
patients having undergone varying lengths of treatment, Negano et al discovered 
mitochondrial content in myocardial tissue inversely correlated with Gb3 deposition 
in the cytoplasm of cardiomyocytes. There was a significant decrease in 
mitochondrial content in the patients who received two years therapy or none at all 
compared with patient who received fourteen years of therapy (Nagano et al., 2016). 
Next, since plasma Gb3 do not correlate well with severity, especially in females, and 
clearance of stored Gb3 from cells resulting from treatment do not always result in 
remission, there is evidence that other factors besides the predominant substrate 
contribute to pathophysiology (Togawa et al., 2010, Young et al., 2005). Failure of 
cells to catabolise Gb3 by the systematic process described earlier, leads to 
employment of alternative pathways available to cells to rectify accumulated 
substrate.  Acid ceramidase de-acylates the ceramide anchor to release fatty acid and 
globotriaosylsphingosine (lysoGb3). LysoGb3 is less  polarised and therefore more 
soluble than Gb3 (Hrebicek and Ledvinova, 2010). Aerts et al (2008) discovered that 
lysoGb3 levels were increased in plasma of FD male patients by over ten-times that 
of Gb3, but this increase did not correlate with severity (Aerts et al., 2008). In females, 
lysoGb3 levels correlated with disease severity. LysoGb3 may present a suitable 
biomarker for assessment of clinical significance of genetic variants of GLA: whether 
they are pathological mutations or non-pathological variants (Niemann et al., 2014). 
LysoGb3 competitively inhibits α-gal A, and promotes proliferation of cultured 
smooth muscle cells (Aerts et al., 2008). In cultured human podocytes lysoGb3 
increased expression of secondary mediators of tissue injury, inflammation and 
fibrosis (Sanchez-Nino et al., 2011). Fibrosis indicates poor prognosis for response to 
treatment and may explain the link between lysoGb3 and disease progression 
(Weidemann et al., 2013). Lyso-Gb3 is also linked to increased sensitivity to pain in 
C57/BL6 mice. Murine cells in culture exposed to lyso-Gb3 at concentrations 
equivalent to those found in plasma of pre-treated FD patients, showed ingress of 
calcium via voltage-gated calcium channels in nociceptors. Lyso-Gb3 may therefore 
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be the causative factor of neuropathic pain experienced by FD patients (Choi et al., 
2015). 
Another sphingolipid metabolite associate with FD is Sphingosine-1-phosphate (S1P). 
S1P is formed from phosphorylation of sphingosine and predominantly is bound to 
circulating high density lipoproteins. Plasma S1P was significantly increased in male 
patients compared with healthy subjects and may be a potential biomarker of 
cardiovascular remodelling associated with FD (Brakch et al., 2010). S1P stabilises 
hypoxia inducible factor (HIF) 1α, the oxygen sensing subunit of HIF1 transcription 
factor which is also increased in patients (Hadjimichael et al., 2013). There is cross 
talk between HIF1 and mitochondria to co-regulate cellular energy metabolism and 
oxygen availability; HIF1 regulates transcription of complex IV of the respiratory chain 
(Semenza, 2011).  
Thirdly, accumulation of substrates within lysosomes leads to lysosomal dysfunction. 
The lysosome degrades and recycles cellular and extracellular components, and 
regulates energy metabolism in response to nutrient levels by sampling cytoplasmic 
and organelle content isolated by autophagy. Cultured fibroblasts from untreated FD 
patients expressed the autophagolysosome marker LC3 more than controls, 
suggesting blockage in autophagy (Yang et al., 2013), and impaired autophagosome 
maturation (Chevrier et al., 2010). There is evidence that increased biogenesis of 
dysfunctional lysosomes and autophagosomes cause lysosomal lipid accumulation 
secondary to the main storage material. This may lead to disrupted energy 
metabolism and membrane permeability, and reduced expression of lysosomal 
membrane proteins which are important for catabolite export and maintenance of 
low pH within the lysosome (Samie and Xu, 2014). Finally there is the potential effect 
of accumulation of misfolded α-gal A protein leading to saturation of ERAD-
associated quality control and widespread pathology due to unfolded protein 
response (Thomas and Mehta, 2013). 
To help in the investigation of FD pathophysiology a mouse model was developed in 
1997 by Ohshima and colleagues. The model contained a large deletion within murine 
GLA resulting in total inactivation of α-gal A in liver, kidney and fibroblast cells. By 10 
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weeks of age, Gb3 accumulation was observed in lysosomes of renal tubular, liver 
and fibroblast cells of these mice, as in FD patients (Desnick et al., 2001, Ohshima et 
al., 1997). Substrate accumulation plateaued in liver and kidney tissues at 20 weeks 
age. Histological examination of tissues at 60 weeks found lipid inclusions in skin; and 
by 80 weeks Gb3 was stored in cardiac connective tissue macrophages, 
cerebrovascular endothelium and smooth muscle cells. However no clinical 
symptoms associated with human FD were observed in these mice, possibly because 
globoside is absent from murine erythrocytes preventing significant accumulation in 
vascular endothelium and smooth muscle (Ohshima et al., 1999). Globoside is a major 
component of erythrocyte plasma membranes in humans (Brady, 2010). 
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1.4.6 Diagnosis 
The diagnosis of FD is made based upon the clinical picture and α-gal A activity in 
plasma and leucocytes (Gal et al., 2011) or dried blood spots (Gasparotto et al., 2009). 
Concentrations of the enzyme’s substrate, Gb3 in urine and plasma can be used to 
monitor disease progression using tandem mass spectrometry (MS/MS) using 
appropriate internal standards (Mills et al., 2002, Young et al., 2005). However, in 
non-classical FD in hemizygote males and heterozygous females, enzyme activity 
and/or substrate levels may be within normal range (Winchester, 2014). In this 
context Gb3 concentration in urine was found to be a more useful diagnostic 
biomarker than in plasma in heterozygous females (Young et al., 2005). 
Lyso-Gb3 may be used as a biomarker in plasma (Aerts et al., 2008, Rombach et al., 
2010, Togawa et al., 2010). An ultra-performance liquid chromatography (UPLC) 
MS/MS assay was developed and validated for measuring lyso-Gb3 concentration in 
plasma (Boutin et al., 2016). A recent study showed that plasma lyso-Gb3 can identify 
heterozygote patients confirmed by GLA-mutation analysis, despite normal leukocyte 
α-gal A activity, using highly-sensitive electrospray ionisation liquid chromatography 
together with MS/MS (Nowak et al., 2017). Lyso-Gb3 is detectable in urine from FD 
patients using time of flight MS, but absent in controls.  Urinary concentrations of the 
metabolite correlates with urine Gb3 levels, gender, treatment status and disease 
severity assessed by mutation analysis (Auray-Blais et al., 2010).  
Figure 1-11 shows that lysoGb3 levels in plasma clearly differentiates between classic 
Fabry in males, heterozygous females and healthy controls, however this is not the 
case for Gb3 in plasma, especially between either non-classical variant of FD in males 
or female carriers and controls (Rombach et al., 2010, Togawa et al., 2010, Young et 
al., 2005). In light of the apparent usefulness of plasma lyso-Gb3 in diagnosis, a 
multiplexed UPLC-MS/MS assay has been developed for quantitation of lyso-Gb3 in 
dried blood spots (Sirka et al., 2015). In urine, the sensitivity of lyso-Gb3 levels as a 
biomarker of disease in children is lower than for Gb3 levels, especially in females 
(Auray-Blais et al., 2015).  
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Figure 1-11: Concentrations of Gb3 and deacylated metabolite lyso-Gb3 in human plasma 
Gb3 and lyso-Gb3 concentration in plasma is shown for males (A), and females (B). 
Plasma lyso-Gb3 concentration is able to distinguish FD patients from controls amongst male 
hemizygotes and most female heterozygotes. The concentration of plasma Gb3 is high in the 
majority of male patients, but in female there is no difference in plasma Gb3 levels between 
carriers and controls. Plasma lyso-Gb3 therefore represents a good biomarker for diagnosis 
(Source: Rombach et al., 2010). 
 
 
The chemical structures of Gb3 and lyso-Gb3 cater for a potentially wide variety of 
analogues because of the long carbon chains of fatty acid and sphingosine. Variation 
in length and non-saturation give rise to analogues which may have significance as 
biomarkers for FD. The predominant Gb3 analogue detected in human plasma was 
C16:0, i.e. 16 carbon, fully saturated fatty acid tail; but human urine contained C22:0, 
C24:0 or C24:1, i.e. 24 carbon fatty acid tail with a single double bond. The urinary 
analogues were also found in liver, spleen, brain, heart, kidney and urine of the GLA-
knock out mouse model (Mills et al., 2002, Young et al., 2005). This information 
illustrates that analogues of Gb3 and lyso-Gb3 may indicate the source, and thus scale 
of tissue involvement. A study by Manwaring et al (2013) identified seventeen Gb3 
analogues in plasma that were previously found by the same group to be excreted in 
urine at different relative concentrations. The excretion of these plasma biomarkers 
varied between FD patients and controls (Manwaring et al., 2013). Similarly, 
modifications in the sphingosine tail of lyso-Gb3 were detected in urine from patients 
but not controls. Furthermore, levels of secretion correlated with gender. In males, 
levels also correlated with treatment (Lavoie et al., 2013). Specific analogues of 
lysoGb3 in urine have higher sensitivity than Gb3 as a whole, highlighting the 
importance of MS in biomarker discovery for both diagnosis and treatment 
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monitoring (Auray-Blais et al., 2015). Metabolomics has also identified analogues of 
lyso-Gb3 which appeared in patient plasma but which were absent in controls 
(Dupont et al., 2013). Analogues of Ga2 were identified as potential novel biomarkers 
in urine for FD (Boutin and Auray-Blais, 2015), and most recently, analogues of Gb3 
accumulated in kidney persisted in young GLA knockout mice despite treatment 
(Kodama et al., 2017). Substrate analogues may therefore have important utility not 
only in diagnosis but also in optimising and monitoring treatment.  
The clinical picture is dependent upon the genotype of GLA and the modulating 
effects of epigenetics and interacting genes, and environmental factors. Nonetheless 
genetic analysis of GLA may provide useful confirmation for diagnostic purposes (Gal 
et al., 2011). Heterozygous carrier females may be asymptomatic or present organ-
specific symptoms possibly due to skewed or random X-inactivation (Whybra et al., 
2001, Pinto et al., 2010); so diagnosis must be confirmed by GLA genotyping (Gal et 
al., 2011). Genetic analysis may also be helpful in prognosis and disease classification 
(Lukas et al., 2013). 
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1.4.7 Treatment 
On diagnosis, there are currently two forms of treatment available to patients: 
enzyme replacement therapy (ERT) (Schiffmann et al., 2001, Eng et al., 2001) and 
small molecule chaperone therapy (Markham, 2016). Since 2001 ERT was available 
to FD patients by intravenous administration biweekly (Schiffmann et al., 2001, Eng 
et al., 2001). Two preparations are currently approved for marketing within the EU: 
agalsidase alfa (Replagal, Shire Human Genetic Therapies) manufactured in a human 
cell line by gene activation technology; and agalsidase beta (Fabrazyme, Genzyme 
Corporation, a Sanofi company) manufactured within Chinese hamster ovary cells 
using recombinant technology (Motabar et al., 2010b, Hughes et al., 2013). Clinical 
response to ERT display considerable variation across patients, tissue-types, age and 
disease severity (El Dib et al., 2016, Ortiz et al., 2016, Rombach et al., 2013).  
A recent trial compared the efficacy of long-term (median five year) ERT in patients 
with and without prior history of FD-associated cardiac, cerebrovascular and renal 
symptoms. The research showed that patients who commenced treatment with no 
prior history of major symptoms were at lower risk of developing life-threatening 
complications during their treatment (Rombach et al., 2013). This suggests 
therapeutic benefit of ERT is significantly reduced in patients whose disease has 
progressed, which is currently when the majority of FD cases are diagnosed (Meikle 
et al., 1999). In some cases, but not all, this is a poor return for the psycho-social and 
physical burden of biweekly intravenous administration of recombinant protein that 
ERT imposes on patients.  
The second treatment option is currently available only to certain patients with 
missense and other mutations in GLA that result in unstable protein folding. 
Consequently α-gal A is not effectively trafficked to the lysosome but degraded by 
ERAD. Research found that a potent competitive inhibitor of α-gal A called 1-deoxy-
galactonojirimycin (DGJ), when administered at concentrations lower than necessary 
to inhibit the enzyme, was able to enhance α-gal A activity in cultured lymphoblasts 
with the GLA mutation R301Q (Fan et al., 1999). R301Q translates to a later-onset, 
mild cardiac variant of FD (Sakuraba et al., 1990). Further investigation found that the 
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reason for the enhanced activity was that DGJ stabilised the protein synthesised from 
mutated GLA by binding to the active site, rescuing enzyme from degradation and 
increasing its transport to the lysosome. At low pH the enzyme is activated and 
showed higher affinity to natural substrates than DJG, so the inhibitor was released 
from the active site. Oral administration of DJG to R301Q mutant mice resulted in 
enhanced α-gal A activity, especially in the heart (Fan et al., 1999).  
Chaperone treatment using DJG is limited to patients with compatible mutations, so 
a cell-based assay has been developed to test amenability (Benjamin et al., 2017, Wu 
et al., 2011). The small molecule, marketed as migalastat (Galafold, Amicus 
Therapeutics) was recently granted approval for use in treating FD caused by 
amenable mutations (Markham, 2016). In phase 3 clinical trials in ERT-naive male 
patients, migalastat produced clinical benefit in those with amenable mutations in 
terms of kidney function, left ventricular mass and gastrointestinal symptoms (Feldt-
Rasmussen et al., 2017, Germain et al., 2017a, Germain et al., 2017b, Germain et al., 
2016). Liquid chromatography-tandem mass spectrometry was used to show that 
plasma lyso-Gb3 concentration fell in both male and female patients in response to 
migalastat and remained low for the subsequent 18 months, independent of whether 
they were previously on ERT (Hamler et al., 2015). There was also evidence of Gb3 
clearance from renal podocytes of male patients following 6 months of migalastat 
treatment (Mauer et al., 2017). However amenable mutations only account for 35% 
- 50% of pathogenic mutations in GLA (Hughes et al., 2016). So, at least half of all 
Fabry disease patients will not benefit from this mode of treatment.  
Alternative therapies are therefore urgently required to treat Fabry disease. 
Substrate reduction therapy (SRT), an orally administered glucosylceramide synthase 
inhibitor called lucerastat, has recently completed its first early-stage clinical trial in 
patients receiving ERT (Guerard et al., 2017). Glucosylceramide synthase catalyses 
the formation of glucocerebroside and is the initial reaction in the synthesis of both 
ganglio- and globo- series glycosphingolipids. So lucerastat has potential applications 
as an SRT for numerous other LSDs including Gaucher disease and Sandhoff disease 
(Arenz, 2017). Preliminary results in FD patients receiving ERT showed that plasma 
Gb3, lactosylceramide and glucocerebroside concentrations reduced significantly 
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over a 12 weeks course of lucerastat. There was no change in plasma concentration 
of lyso-Gb3, but this may be due to levels already being rapidly reduced by ERT.  
Furthermore, the lucerastat study was of insufficient duration to observe any clinical 
benefits of reduction of Gb3 levels in plasma (Guerard et al., 2017). 
Biomarkers play a vital role in monitoring patient response to treatment (Beirao et 
al., 2017, Young et al., 2005). Within Great Ormond Street Hospital (GOSH) (London, 
UK), both urine Gb3 and plasma lyso-Gb3 are measured for this purpose by Dr Kevin 
Mill’s laboratory at Great Ormond Street Institute of Child Health (GOSICH) (London, 
UK). Figure 1-12, Figure 1-13 and Figure 1-14 show the biomarker profiles collated 
and graphed for four male patients with confirmed FD, two of whom were brothers 
(Figure 1-14). The profiles demonstrate that the concentration of lyso-Gb3 in plasma 
appears to be a more exacting parameter of treatment efficacy. This is shown in both 
Figure 1-13 and Figure 1-14B where plasma lyso-Gb3 remains very high and urine Gb3 
is beneath normal threshold. The reason for the inconsistency between the two 
biomarkers remains to be resolved. The second point that Figure 1-14 show is the 
absence of correlation between both biomarkers and genotype. The profiles of two 
siblings with presumably the same GLA genotype are quite different. The younger 
brother (Figure 1-14A) shows declining concentrations of both plasma lyso-Gb3 and 
urine Gb3 from a very elevated starting point at diagnosis and commencement of 
treatment. The older brother (Figure 1-14B) started with comparably high levels of 
plasma lyso-Gb3, but in contrast, normal urine Gb3 concentration. In this patient, 
treatment resulted in decline in plasma lyso-Gb3, similar to his brother. Perhaps 
specific analogues of these biomarkers may reveal closer correlation with genotype.  
Since FD is due to monogenic loss-of-function mutations, it is a good candidate for 
gene therapy (Friedmann and Roblin, 1972). Recently a clinical trial application for a 
“first in the world” gene therapy trial for FD using ex vivo lentivirus-mediated 
transgene delivery to haematopoietic stem cells (HSCs) was recently accepted (Huang 
et al., 2017). So the next section will introduce this form of treatment in more detail. 
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Figure 1-12: Biomarker profile over a 15 year period in a male patient aged 22 years old on 
diagnosis 
The patient was diagnosed biochemically in October 2002 with α-gal A activity in 
leucocytes of 0.35 nmol/hr/mg protein, and in plasma of 0.03 nmol/hr/ml, both within the 
affected range. Urine Gb3 gradually increased over four years from 0.09 to 0.86 mg/mmol 
creatinine. In June 2006 the patient commenced ERT. Over the subsequent 11 years urine 
Gb3 fluctuates but gradually declines. However, as of October 2017 the urine Gb3 
concentration is above normal. Plasma Gb3 monitoring did not commence until June 2014. 
Despite a considerable spike in concentration in December 2014, the plasma lyso-Gb3 level 
markedly declined, but remained above the normal threshold. Time as shown on the x axis is 
not linear and shows dates of sampling in month and year. Data courtesy of Dr Kevin Mills, 
GOSICH, London, UK.  
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Figure 1-13: Biomarker profile over a 3 year period in a male patient aged 11 years old on 
diagnosis 
The patient was diagnosed biochemically at close of 2014 with α-gal A activity in 
leucocytes of 1.8 nmol/hr/mg protein, and in plasma of 0.04 nmol/hr/ml, both within the 
affected range. Genotyping found mutation c.401A>C (Y134S) in GLA. ERT appeared to 
markedly reduce plasma lyso-Gb3 concentration in the first month, after which levels 
gradually settled but remained above the normal threshold. Over this latter period, urine 
Gb3 remained consistently within the normal threshold. Time as shown on the x axis is not 
linear and shows sampling dates as month and year. Data courtesy of Dr Kevin Mills, GOSICH, 
London, UK. 
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Figure 1-14: Biomarker profiles for two brothers diagnosed with Fabry disease 
The brothers were aged 1 (A) and 2 (B) on biochemical diagnosis early 2002. The 
younger brother (A) was identified first with α-gal A activity in leucocytes of 0.85 nmol/hr/mg 
protein, and in plasma of 0.03 nmol/hr/ml, both parameters within the affected range for 
FD. Subsequently the older brother (B) was diagnosed with α-gal A activity in leucocytes of 
2.5 nmol/hr/mg protein, and in plasma of 0.04 nmol/hr/ml, both within the affected range. 
A. Urine Gb3 fluctuated considerably with a slight downward trend. Concentration remains 
above the normal threshold. Plasma lyso-Gb3 levels show clearer general decline, but 
concentration remains very high. B. Urine Gb3 concentration was below the normal 
threshold on diagnosis and remained so except occasional spikes. In marked contrast in this 
patient, plasma Gb3 was very high despite a general decline. Time as shown on the x axis is 
not linear and shows dates of sampling in month and year. Data courtesy of Dr Kevin Mills, 
GOSICH, London, UK. 
A 
B 
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1.5  Gene therapy 
1.5.1 Background 
In 1928 the Griffith’s experiment reported the first genetic transformation of 
pneumococcal bacteria from a non-virulent to virulent type. He mixed living non-
virulent bacteria with virulent bacteria that had been killed by heat inactivation and 
inoculated mice with the mixture. Subsequently the mice died of pneumonia and 
virulent bacteria was cultured from their blood. He concluded that the living non-
virulent bacteria was transformed into a virulent type by an unknown agent from the 
dead virulent bacteria (Griffith, 1928). It was not until 1944 that Avery, MacLeod and 
McCarty discovered that the transforming agent was DNA (Avery et al., 1944). This 
genetic transfer phenomenon was later applied to a human bone marrow-derived 
cell line. A metabolic defect in a mutant strain was corrected by transformation with 
wild type DNA from wild type cells. Furthermore, the correction was inherited by 
daughters of the transformed cells, demonstrating the potential therapeutic benefit 
of gene transfer to treat hereditary disorders in humans (Szybalska and Szybalski, 
1962, Wirth et al., 2013). 
The utility of viruses as vehicles for transfer of DNA was first demonstrated in 
Salmonella. Zinder and Lederberg discovered that transfer of hereditary traits 
occurred between bacterial strains when separated by a glass filter that prevented 
direct cell-cell interaction. When examining the filterable agent they found it did not 
contain DNA but particles identified by electron microscopy, which they argued were 
bacteriophages. They termed this virus-mediated genetic transfer, transduction 
(Wirth et al., 2013, Zinder and Lederberg, 1952). 
The first evidence that DNA within a virus may correct an enzyme deficiency in human 
cells was made by Rogers et al, 1973. Skin fibroblasts cultures derived from a patient 
with hyperarginaemia, due to deficient arginase activity, were grown in media with 
Shope rabbit papilloma virus. This virus was shown previously to induce viral arginase 
activity in rabbit skin and human cells (Rogers, 1966). Seven months after inoculation, 
the cells showed increased arginase activity, and increased ornithine levels following 
addition of arginine to culture media (Rogers et al., 1973). Furthermore, 
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immunofluorescence microscopy showed increased expression of viral arginase in 
the treated cells compared with controls, addressing concerns raised by Friedmann 
and Roblin, (1972) that virus infection only stimulated endogenous arginase activity 
in humans (Rogers et al., 1973). Together this suggested that virus mediated gene 
transfer may have long term therapeutic benefit for metabolic disorders. 
Later, recombinant DNA technology enabled transfer of a foreign gene into human 
cells. The first gene transfer experiments in humans were approved in December 
1988 for patients with metastatic melanoma (Wirth et al., 2013). A proof of principle 
trial was carried out using retrovirus to deliver a neomycin resistance gene into 
tumour infiltrating lymphocytes (TILs) extracted from patients ex vivo. The modified 
TILs were re-introduced to the patients. Neomycin resistance gene expression was 
found in TILs from all patients up to three weeks after delivery without any adverse 
events, which demonstrated the feasibility and safety of retrovirus-mediated gene 
therapy (Rosenberg et al., 1990). Encouraged by this, Rosenberg et al used the same 
method to deliver the human tumour necrosis factor (TNF) gene to TILs ex vivo 
(Rosenberg et al., 1993). Three weeks after re-introduction of the modified cells to 
patients there was no detectable tumour around the injection site (Wirth et al., 
2013). 
The above evidence that virus-mediated gene transfer may be used to reprogram 
human cells by introducing a therapeutic gene ex vivo for autologous transplantation 
raises the question whether this can be applied as a potential therapy for FD. The 
rationale behind this form of treatment, and the progress made towards gene 
therapy for FD is discussed next.  
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1.5.2 Rationale behind gene therapy for Fabry disease 
Since FD is due to a loss of function, single gene mutation, it is a good candidate for 
gene therapy (Penati et al., 2017, Ruiz de Garibay et al., 2013). The major classes of 
virus recently used as vectors for gene delivery include retrovirus (Medin et al., 1996, 
Sugimoto et al., 1995, Takenaka et al., 1999a, Takenaka et al., 2000, Takenaka et al., 
1999b, Takiyama et al., 1999) and lentivirus (Yoshimitsu et al., 2006, Yoshimitsu et 
al., 2007, D'Costa et al., 2003, Lee et al., 2011, Yoshimitsu et al., 2004), both single-
stranded RNA viruses containing reverse transcriptase and capable of inserting pro-
viral DNA into the host cell genome for long term, stable expression of a therapeutic 
transgene (Sakuma et al., 2012); and adeno associated virus (AAV) which are non-
enveloped, single-stranded DNA viruses (Ruiz de Garibay et al., 2013, Jung et al., 
2001). AAV is usually non-integrating so that the viral genome may persist transiently 
as episomal DNA (Flotte et al., 1994) within host liver and muscle cells (Goncalves, 
2005). AAV therefore carries reduced risk of mutagenesis developing in transduced 
cells, but high viral titres are required for clinically significant transgene expression 
(Ruiz de Garibay et al., 2013). Non-viral gene delivery strategies, which generally offer 
improved clinical safety with limited transduction efficiency, have also been explored 
but with limited success (Ruiz de Garibay et al., 2013). In all cases, vector delivery 
may be either intra-parenchymal, or systemic in vivo or ex vivo (Ruiz de Garibay et al., 
2013). 
Gb3 accumulation impacts nearly all cell types, so pluripotent haematopoietic stem 
cells (HSCs) that give rise to all the cell types of blood and tissue macrophages 
including microglial are a potential target for gene delivery (Huang et al., 2017). The 
therapeutic potential of healthy HSCs was shown when Gb3 storage was reduced in 
a murine model of α-gal A deficiency following transplantation of bone marrow from 
healthy control mice (Ohshima et al., 1999). Virus-mediated gene transfer to HSCs 
was first demonstrated in mice by Williams et al, (1984). The bacterial neomycin 
resistance gene was successfully delivered into murine HSCs from bone marrow ex 
vivo using retrovirus. Subsequently the transduced cells were transplanted into 
lethally irradiated mice, resulting in engraftment as shown by pro-viral sequences 
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found within DNA from spleen, an important site of haematopoiesis in transplant 
mice (Williams et al., 1984).  
Since 1999, virus-mediated gene transfer to HSCs as the route and means of ex vivo 
gene delivery of GLA to treat FD has been explored using retrovirus (Takenaka et al., 
1999a, Takenaka et al., 2000, Takenaka et al., 1999b, Takiyama et al., 1999), and then 
lentivirus (Yoshimitsu et al., 2007). Later it was reported, using lentivirus, that 
transplant of HSCs transduced with GLA resulted in greater reduction in Gb3 storage 
within heart and kidney of α-gal A-deficient mice than HSCs transduced with the 
green fluorescent protein gene GFP (Pacienza et al., 2012). This suggests lentivirus-
mediated ex vivo HSC-targeted gene therapy may be more effective than allogeneic 
bone marrow transplant (Ruiz de Garibay et al., 2013).  
Research suggests only 5% of enzyme activity is required for a therapeutic benefit 
(Biffi, 2016), suggesting a low level of transduction may be sufficient for a clinically 
relevant benefit. Lentivirus is able to transduce both dividing and non-dividing cells 
with high transduction efficiency for long-term stable expression (Sakuma et al., 
2012), and is the vector of choice for the first and only clinical trial to date of gene 
therapy for FD (Huang et al., 2017). So lentivirus vector technology will be discussed 
in more depth.  
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1.5.3 Lentivirus vector technology 
Lentivirus offers a potent method of gene delivery to both dividing and non-dividing 
cells with high transduction efficiency. This type of virus is a member of the retrovirus 
family: viruses that consist of an enveloped capsid containing double-stranded RNA. 
The general structure is shown in Figure 1-15. On entering a target cell, the virus 
mRNA is reverse-transcribed and integrated into the cell’s chromosomal DNA for 
long-term stable integration. Host cell machinery transcribes the viral genome and 
synthesises lentivirus which buds from the cell surface to repeat the life cycle as 
shown in Figure 1-16 (Byrne et al., 2012).  
 
Figure 1-15: Schematic showing the basic structure of lentivirus 
Lentivirus is an enveloped retrovirus that expresses transmembrane and surface 
glycoproteins that confer tissue tropism. The capsid contains two macromolecules of single 
stranded RNA containing the virus transcriptome, viral proteins Vif, Vpr and Nef, integrase, 
protease and reverse transcriptase to enable the virus to integrate the genetic instructions 
for itself within a host cell genome (Sakuma et al., 2012). Image sourced from (ABM, 2015). 
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Figure 1-16: Self-replication of lentivirus within host cells 
Host cell infection is mediated by glycoproteins expressed on the surface of lentivirus 
which confer broad tissue tropism. Within the cell, reverse transcriptase synthesises the 
provirus genome from the viral RNA, and integrase integrates it into the host cell genome. 
Integration is at long terminal repeat (LTR) regions either end of the provirus genome: The 
5’LTR contains an enhancer/promoter site to which host cell RNA polymerase II binds and 
transcribes the provirus genome; and the 3’LTR R region is a polyadenylation signal to 
stabilise transcripts. Between the LTRs the provirus genome contains structural, regulatory 
and accessory genes which are expressed in multiply spliced transcript variants by the host 
cell machinery. The first genes to be transcribed are expressed in multiply-spliced transcripts 
and are regulatory: tat and rev. Tat protein trans-activates the 5’LTR for enhanced 
transcription of rev. Once cytoplasmic Rev protein levels reach threshold it promotes 
expression of single- and un-spliced transcript variants that encode envelop and structural 
proteins respectively. The virus assembles at the cell surface and buds from the host cell 
(Sakuma et al., 2012). Image sourced from (Sakuma et al., 2012). 
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As shown in Figure 1-16, the singly-spliced transcripts translate into envelop surface 
proteins which determine the target cell population of the virus. Broad tissue tropism 
is enabled by the G glycoprotein which is expressed on the surface of the vesicular 
stomatitis virus and encoded by vsv-g. Structural genes are gag and pol which are 
expressed through un-spliced transcripts as core and functional proteins respectively. 
Core proteins include components for the matrix, capsid and nuclear capsid of the 
virus; and functional proteins include reverse transcriptase and integrase necessary 
for stable replication and integration of the viral genome into target cells. The un-
spliced transcript includes a packaging sequence (ψ) that promotes inclusion of 
complete single-stranded RNA sequence within the virus assembly at the cell surface. 
Once the daughter virus buds from the host cell it is able to transduce other cells and 
repeat the life cycle described (Sakuma et al., 2012).  
To utilise the potential of lentivirus to integrate a transgene into the genome of target 
cells, the ability of virus to self-replicate and to transduce other cells must be 
controlled (Wirth et al., 2013). Disease-causing accessory genes which are not 
necessary for target cell transduction, but confer pathogenicity on the virus particle, 
are removed. The virus genome is split over three separate plasmids, as shown in 
Figure 1-17. The plasmids are co-transfected into 293T cell line “producer cells” that 
subsequently synthesise replication-incompetent lentivirus. Only the vector plasmid, 
which contains the transgene, expresses the packaging sequence Ψ which signals 
packaging of the vector transcript within the lentivirus capsid. The packaging 
plasmids contain structural, functional, regulatory and envelop genes necessary to 
synthesise infectious lentivirus capsid. So lentivirus manufactured by the “producer 
cells” contains only the transcript for the transgene flanked by LTRs; no further life 
cycles are possible. If random recombination within the producer cell genome were 
to align the DNA sequences of vector and packaging plasmids to enable synthesis of 
replication competent virus, then  the self-inactivating long terminal repeats (LTR) 
illustrated in Figure 1-17 prevent transcriptional activation (Sakuma et al., 2012). 
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Figure 1-17: Typical structural configuration packaging and vector plasmids used for generating lentivirus capable of transducing target cells to express a 
transgene such as GLA used in this project 
Plasmids used to co-transfect cells to produce replication-incompetent lentivirus containing a transgene. Second generation packaging plasmids lack 
HIV-1 associated accessory genes to prevent pathogenicity. After transfection, the vector plasmid expression is driven by the rous sarcoma virus (RSV) 
promoter. The transgene is expressed by an internal promoter such as the human phosphoglycerate kinase (hPGK) promoter within transduced cells (Sakuma 
et al., 2012). Adapted from (Sakuma et al., 2012).
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The third generation lentivirus vector plasmid shown in Figure 1-17 contains two 
additional elements that improve transduction efficiency. The central polypurine 
tract (cPPT), together with PPT, allow reverse transcription and formation of a central 
overlap of DNA that increases transduction efficiency and may promote nuclear 
import. The woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE) increases transcription of unspliced RNA and transgene expression (Sakuma 
et al., 2012); but contains a truncated gene for woodchuck hepatitis virus protein X 
(WHX) that is a transcriptional activator of peptides associated with hepatocellular 
carcinoma in mice. To mitigate risk of functional WHX activity and tumourigenesis, 
six point-mutations were inserted into the WHX promoter region of the WPRE 
element. Research showed the mutation reduced WHX expression without 
abrogating transgene delivery and expression (Zanta-Boussif et al., 2009). 
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1.5.4 Design of a lentivirus vector to treat Fabry disease 
A third generation pRRLSIN.cPPT.PGK-GLA.WPRE lentivirus vector plasmid, 
containing a transgene encoding mature human α-gal A regulated by the human 
phosphoglycerate kinase (hPGK) promoter, was constructed at UCL GOSICH (Bishop 
et al., 1986, Rajaraman, 2013). The transgene contains a 93 base pair sequence which 
translates into the 31 amino acid pro-peptide signalling sequence necessary for 
trafficking the enzyme from the ER, followed by the 1194 base pair complementary 
DNA sequence identified by Bishop et al, 1986. This vector plasmid is compatible with 
second generation packaging plasmids pMDG.2 and pCMV-dR8.74 that contain 
lentiviral envelop, and regulatory, functional and structural genes respectively. 
Together the vectors provide a safe method for overexpressing GLA in target cells 
(Sakuma et al., 2012). The plasmids are shown in Figure 1-18. 
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Figure 1-18: Schematics of packaging and vector plasmids used to produce lentivirus in this project 
(A) Vector plasmid containing the transgene GLA encoding mature human α-gal A called GLA; (B) Same as A except the transgene is GFP (green 
fluorescent protein gene); (C) & (D) Packaging plasmids pMDG.2 and pCMV-dR8.74 respectively which are compatible with the vector plasmids (Rajaraman, 
2013).
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1.6 Project aims and thesis outline 
The overall aim of the project was to examine the effectiveness of lentivirus-
mediated GLA gene transfer to overexpress α-gal A in human cells. The thesis 
commences in Chapter 3 with characterisation of α-galactosidase in human 
fibroblasts and cell-lines, CD1 murine tissues and plasma samples from patients. The 
α-gal A assay was established, relative contributions of A and B isozymes to total α-
galactosidase activity studied, and prognostic value in standardising α-gal A for 
lysosomal content in different cell types examined. 
Utilising a previously constructed lentivirus vector containing the cDNA sequence for 
mature human α-gal A, Chapter 4 reports the manufacture, harvest and use of 
lentivirus to transduce Jurkats. The effect on various lysosomal hydrolases and cell 
toxicity was explored. Enyzme kinetic studies on α-gal A from wild type and 
transduced Jurkats were used to explore their relative affinity with synthetic 
substrate 4-methylumbelliferyl-α-D-galactopyranoside (4MUG), revealing that 
enzyme produced by higher virus doses may clear substrate less effectively.  
Manifestations of the disorder are multi-systemic, so the efficacy of gene therapy 
depends upon ability of cells to cross-correct. Chapter 5 shows transduced Jurkat cells 
release α-gal A into culture media, and wild type Jurkats take-up α-gal A from media. 
Fabry disease is associated with reduction in the activity of respiratory chain 
enzymes, raising the research question: do mitochondrial deficits effect the ability of 
cells to cross-correct? This was addressed by inhibiting respiratory chain complex I of 
Jurkats and measuring the effect on lentivirus transduction efficiency, enzyme 
release and uptake. The results suggest potential therapeutic options may enhance 
cross correction. 
Finally the work was extended to primary skin fibroblasts in Chapter 6. Patient cells 
showed reduced α-gal A activity. Transduction resulted in supra-physiological 
overexpression, albeit with apparently reduced transduction efficiency compared 
with controls. These results raise important questions which pave the way for future 
research. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 DNA Plasmids 
pRRLSIN.cPPT.PGK-GLA.WPRE: Competent E. coli Stbl3 cells transformed with 3rd 
generation HIV-1 SIN lentiviral plasmid expressing GLA driven by the human PGK 
promoter, and the ampicillin resistance gene. Stored in glycerol at -80°C and provided 
by Srinath Rajaraman (UCL GOSICH, London, UK) (Rajaraman, 2013).  
pMDG.2: Second generation packaging construct expressing VSV envelope 
glycoprotein for broad tissue tropism, driven by the CMV promoter. Purchased from 
Addgene plasmid repository (Cambridge, MA, USA).  
pCMVdR8.74: Second generation packaging construct expressing lentivirus structural 
proteins gag-pol-tat-rev, driven by the CMV promoter. Purchased from Addgene 
plasmid repository (Cambridge, MA, USA).  
pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene plasmid #12252, gifted by D. Trono, 
unpublished): Competent E. coli Stbl3 cells transformed with 3rd generation HIV-1 
SIN lentiviral plasmid expressing GFP driven by the human PGK promoter, and the 
ampicillin resistance gene. Stored in glycerol at -80°C and provided by Dr Conrad Vink 
(UCL GOSICH, London, UK).  
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2.1.2 Human cells 
The human cell-lines and primary cells used are shown in Table 2-1. 
Table 2-1: The source for human cells used to generate this thesis 
 
Cell ID Tissue of origin Cell type Source 
HEK-293T 
(CRL-3216) 
Embryonic kidney Cell-line 
American Type Culture Collection 
(ATCC, Teddington, UK) 
SH-SY5Y Neuroblastoma Cell-line 
Kindly donated by Derek Burke, 
Chief Biomedical Scientist 
(Department of Chemical 
Pathology, GOSH, London, UK) 
Hu-H7 Hepato-carcinoma Cell-line 
Kindly donated by Miguel Calero, 
PhD student (UCL GOSICH, 
London, UK) 
Jurkat 
(TIB-152) 
T-lymphoblastoid Cell-line 
American Type Culture Collection 
(ATCC, Teddington, UK) 
Fibroblast 
Fibroblasts cultured 
from non-Fabry 
disease patients 
Primary 
Derek Burke (Department of 
Chemical Pathology, GOSH, 
London, UK) 
 
2.1.3 Cell culture reagents 
LB broth       Sigma (Poole, UK) 
Ampicillin       GOSICH (London, UK) 
Dulbecco’s Modified Eagle Medium with Glutamax (DMEM); Life (Paisley, UK) 
RPMI 1640 medium with Glutamax (RPMI)   Life (Paisley, UK) 
Fetal bovine serum (FBS)      Sigma (Poole, UK) 
Penicillin streptomycin (pen-strep)    Life (Paisley, UK) 
0.05% trypsin in EDTA      Life (Paisley, UK) 
Dulbecco’s phosphate buffered saline (DPBS)  Life (Paisley, UK) 
 74 
 
Trypan blue solution      Sigma (Poole, UK) 
 
2.1.4 Murine Tissue Samples 
Four adult male wild type CD-1 mice, non-inbred to International Genetic Standards 
to prevent genetic drift and ensure genetic standardization between colonies, kindly 
provided by Dr Simon Waddington, UCL Institute of Women’s Health (London, UK).  
 
2.1.5 Plasmid preparation 
QIAprep Spin Miniprep kit     Qiagen (Manchester, UK) 
QIAGEN plasmid maxi kit     Qiagen (Manchester, UK) 
 
2.1.6 Lentivirus production 
Reduced serum medium (Opti-MEM)   Life (Paisley, UK) 
Polyethylenimine (PEI)     Sigma (Poole, UK) 
 
2.1.7 Quantitative polymerase chain reaction (qPCR) 
DNEasy blood and tissue kit     Qiagen (Manchester, UK) 
Platinum qPCR Supermix-UDG with ROX universal mastermix; Life (Paisley, UK) 
Standard (plasmid pBTW2L), kindly donated by Dr Steven Howe, GOSICH (London, 
UK) 
The primers and probes used for qPCR are shown in Table 2-2.  
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Table 2-2: Primers and probes used for quantitative PCR 
 
Target Identity Sequence Source 
WPRE 
Forward primer 
TGG ATT CTG CGC GGG 
A 
Kindly 
donated by Dr 
Steven Howe, 
GOSICH 
(London, UK) 
Reverse primer 
GAA GGA AGG TCC GCT 
GGA TT 
Probe (5’ FAM reporter and 
3’ TAMRA quencher) 
CTT CTG CTA CGT CCC 
TTC GGC CCT 
Βeta-
actin 
Forward primer 
TGA GGA TCT TCA TGA 
GGT AGT CAG 
Reverse primer 
TCA CCC ACA CTG TGC 
CCA TCT ACG A 
Probe (5’ FAM reporter and 
3’ TAMRA quencher) 
ATG CCC TCC CCC ATG 
CCA TCC TGC GT 
 
2.1.8 Reagents 
Solvent used in preparation of all reagents was distilled H2O, unless otherwise stated. 
2.1.8.1 Reagents for the BCA Protein assay 
Bovine serum albumin (BSA) 1mg/ml standard  Sigma (Poole, UK) 
Bicinchoninic acid (BCA), pH 11.25    Sigma (Poole, UK) 
4% (w/v) copper (II) sulphate solution   Sigma (Poole, UK) 
2.1.8.2 Reagents for α-galactosidase A activity assays 
4-methylumbelliferyl-α-D-galactopyranoside (4MUG),  Melford (Ipswich, UK) 
MWt 356.3  
Concentrated (18M) Acetic acid, MWt 60   VWR (Lutterworth, UK) 
Sodium acetate trihydrate, MWt 136.08   VWR (Lutterworth, UK) 
Sodium dihydrogen phosphate, MWt 156   VWR (Lutterworth, UK) 
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Di-sodium hydrogen phosphate, MWt 141.96  VWR (Lutterworth, UK) 
N-acetyl-D-galactosamine (NAGA), MWt 221.2  Sigma (Poole, UK) 
2.1.8.3 Reagents for β-galactosidase and total β-hexosaminidase activity assays 
4-methylumbelliferyl-2-acetaminido-2-deoxy  Melford (Ipswich, UK) 
-β-D-glucopyranoside, MWt 379  
4-methylumbelliferyl-β-D-galactopyranoside, MWt 338 Sigma (Poole, UK) 
Human serum albumin (HSA)     Sigma (Poole, UK) 
Sodium chloride (NaCl), MWt 58.4    VWR (Lutterworth, UK) 
Di-sodium hydrogen phosphate, MWt 141.96  VWR (Lutterworth, UK) 
Citric acid (monohydrate), MWt 210.14   VWR (Lutterworth, UK) 
2.1.8.4 Reagents for citrate synthase activity assay 
All reagents were kindly donated by Dr Mesfer Al Shahrani, Neurometabolic Unit, 
University College London Hospital (UCLH) (London, UK): 
100mM Tris/0.1%v/v Triton; pH 8 (assay buffer) 
10mM acetyl-CoA 
20mM 5,5’ dithio-bis (2-nitrobenzoic acid ) (DTNB) 
20mM oxaloacetate 
2.1.8.5 Reagents for mitochondrial respiratory chain complex I activity assay 
All reagents were kindly donated by Dr Mesfer Al Shahrani, Neurometabolic Unit, 
UCLH (London, UK): 
Potassium dihydrogen phosphate 
Di-potassium hydrogen phosphate 
Magnesium chloride hexahydrate 
100mM potassium cyanide (KCN) 
50mg/mL bovine serum albumin, fatty acid free (BSA) 
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5mM ubiquinone 
1mM rotenone in ethanol 
5mM nicotinamide adenine dinucleotide (NADH), pH>7 
 
2.1.9 Solutions 
The solutions used throughout this thesis are shown in Table 2-3. 
Table 2-3: The content of assay solutions 
 
Solution Content Used in assay 
0.1M acetate 
buffer 
0.1M acetic acid, 0.1M sodium acetate 
trihydrate, pH 4.5 
Intracellular α-
galactosidase A 
activity assay 20mM sodium 
phosphate buffer 
20mM sodium dihydrogen phosphate, 
20mM di-sodium hydrogen phosphate, pH 
6.4 
0.5M acetate 
buffer 
0.5M acetic acid, 0.5M sodium acetate 
trihydrate, pH 4.8 
Extracellular α-
galactosidase A 
activity assay 
HSA/NaCl solution 0.4% (w/v) HSA in 0.4M NaCl 
Intracellular β-
galactosidase 
activity assay 
McIIvaine 4.1 
buffer (MV4.1) 
0.1M citric acid, 0.2M di-sodium hydrogen 
phosphate, dilute 1:1 in H2O, pH 4.1 
McIIvaine 4.5 
buffer (MV4.5) 
0.1M citric acid, 0.2M di-sodium hydrogen 
phosphate, pH 4.5 
Total β-
hexosaminidase 
activity assays 
25mM potassium 
phosphate buffer 
25mM potassium dihydrogen phosphate, 
25mM di-potassium hydrogen phosphate, 
pH 7.2 
Mitochondrial 
respiratory chain 
complex I activity 
assay 
Complex I buffer 
10mM magnesium chloride hexahydrate in 
25mM potassium phosphate buffer, pH 7.2 
1M stopping buffer 
1.6mol glycine, 2mol sodium hydroxide, in 
2L H2O, pH 10.2-10.4 
Lysosomal enzyme 
activity assays 
0.25M stopping 
buffer 
IM stopping buffer diluted 1 in 4 with H2O, 
pH 10.2-10.4 
4MU standard 
1nmol 4-methylumbelliferone (4MU), MWt 
176, in 200µL H2O 
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2.1.10 Western blotting 
M-Per lysis buffer     Fisher (Loughborough, UK) 
Halt protease inhibitor cocktail   Life (Paisley, UK) 
Laemmli loading buffer    Sigma (Poole, UK) 
4-12% Bis-Tris NuPage polyacrylamide gel  Life (Paisley, UK) 
MOPS SDS running buffer    Life (Paisley, UK) 
NuPage transfer buffer    Life (Paisley, UK) 
PVDF membrane     Fisher (Loughborough, UK) 
Methanol      Fisher (Loughborough, UK) 
Tween 20      Sigma (Poole, UK) 
Skimmed milk powder    Fisher (Loughborough, UK) 
Phosphate buffer saline tablets   Fisher (Loughborough, UK) 
Super signal West Pico chemiluminescent substrate; Life (Paisley, UK) 
Re-blot plus strong solution (stripping buffer) Fisher (Loughborough, UK) 
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2.1.11 Antibodies 
The antibodies used in this thesis are detailed in Table 2-4. 
Table 2-4: Details of antibodies used 
 
IgG antibody Function Raised in: Dilution Source 
α-gal A (sc-25823) Primary Rabbit 1/200 
Santa Cruz 
Biotechnology 
(Santa Cruz, USA) 
NAGA (sc-367199) Primary Rabbit 1/200 
GAPDH (sc-25778) Primary Rabbit 1/600 
Anti-rabbit (sc-
2313) 
HRP-conjugated 
secondary 
Donkey 1/7000 
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2.2 Methods 
2.2.1 Purification and measurement of plasmid DNA  
A starter-culture of competent E. coli Stbl3 cells transformed with DNA plasmid 
pRRLSIN.cPPT.PGK-GLA.WPRE or pRRLSIN.cPPT.PGK-GFP.WPRE was incubated 
overnight on a shaker at 250rpm (Innova 44) at 37°C in 10mL LB broth, 0.1% 
ampicillin. Plasmid DNA was subsequently purified from 1mL starter-culture, using 
the QIAprep Spin Miniprep kit according to manufacturer’s instructions, for 
approximate plasmid DNA yields of 100ng/µL H2O.  For larger-scale purification of 
plasmid DNA (approximately 1μg/μL H2O), 5ml starter-culture was seeded into 
500mL LB broth, 0.1% ampicillin, and incubated overnight as above. Plasmid DNA was 
extracted from the entire culture using the QIAGEN Plasmid Maxiprep kit according 
to manufacturer’s instructions. The purity and yield of harvested DNA was measured 
using NanoDrop ND1000 spectrophotometer (LifeTech International). 
 
2.2.2 Restriction enzyme digestion and gel electrophoresis 
Approximately 1μg purified plasmid DNA, 1μL restriction enzyme and 10x restriction 
buffer were made up to 20μL with RNase-free water on ice and incubated at 37°C for 
2 hours. The resulting DNA fragments were applied with 5x loading dye to 1% (w/v) 
agarose gel in TAE, 0.01% Sybr Safe DNA gel stain, and electrophoresed alongside 
10μL 1kb Plus DNA ladder at 75volts for 1 hour. DNA fragments were visualised by 
exposure to ultraviolet light using the UVITech system. Fragment lengths were 
compared with those calculated from the theoretical nucleotide sequences using 
Vector NTI software (Invitrogen). 
 
2.2.3 Sanger Sequencing 
The complete DNA sequence of pRRLSIN.cPPT.PGK-GLA.WPRE was analysed by 
Sanger sequencing carried out by Source Biosciences (Cambridge, UK). The forward 
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and reverse primers were designed to ensure the entire length of the vector plasmid 
was accurately sequenced. The primer binding-sites were approximately located as 
shown in Figure 2-1. Table 2-5 details the sequence of primers which were ordered 
from Life Technology (Paisley, UK). 
 
 
Figure 2-1: Primers and primer binding sites used for sequencing the lentivirus vector 
plasmid pRRLSIN.cPPT.PGK-GLA.WPRE 
 
 
Table 2-5: Primer sequences used for sequencing the lentivirus vector plasmid 
pRRLSIN.cPPT.PGK-GLA.WPRE 
 
Symbol Primer Name Oligo Sequence (5’ – 3’) Designer 
1F pT7_01F GTAAGACCACCGCACAGCA Dr C Vink 
2F pT7_02F AGGCAGGGATATTCACCATT Dr C Vink 
3F pT7_03F GTTCCGCATTCTGCAAGC Dr C Vink 
4aF pRRL-gla4a TGTGTACTCCTGTGAGTGGCCTC J Lambert 
4bF pRRL-gla4b ATGAGGAGTTGTGGCCCGTTG J Lambert 
5F pT7_05F GGCTAATTCACTCCCAACGA Dr C Vink 
6F pT7_06F GTAATAGCGAAGAGGCCCG Dr C Vink 
7F pT7_07F TGCTGAAGATCAGTTGGGTG Dr C Vink 
8F pT7_08F GCATTGGTAACTGTCAGACCAA Dr C Vink 
9F pT7_09F GAGCCTATGGAAAAACGCC Dr C Vink 
10F pRRL-gla10 CCACTGAATTGCCGCATTGCAG J Lambert 
9.2R pRRL-gla rev 
primer 9.2 
CTCTCCTTCTAGCCTCCGCTAGTC J Lambert 
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2.2.4 Cell Culture 
HEK-293T and Hu-H7 cell-lines were grown in DMEM,10% FBS, 1% pen-strep. The 
cells formed an adherent monolayer so 0.05% trypsin in EDTA was used to dissociate 
the cells for passaging 1:10 whenever the cells were confluent. Jurkats were cultured 
in suspension in RPMI, 10% FBS, 1% pen-strep; and passaged 1:10 whenever the cells 
were confluent. All cells were grown by incubation in their relevant media at 37°C, 
5% CO2.  
 
2.2.5 Transfection of HEK-293T cells 
HEK-293T cells were cultured to 80% confluence in T125 flasks. Vector plasmid DNA 
(pRRLSIN.cPPT.PGK-GLA.WPRE or pRRLSIN.cPPT.PGK-GFP.WPRE) and second-
generation packaging constructs pMDG.2 and pCMVdR8.74, were added to Opti-
MEM in a 50mL centrifuge tube labelled solution A in the proportions shown in Table 
2-6. 
Table 2-6: Volumes required in solution A for transfection of HEK-293T cells 
 
Content of solution A Amount per T175 flask 
Opti-MEM 5mL 
Vector Plasmid DNA 40μg 
pMDG.2 10μg 
pCMVdR8.74 30μg 
In a second 50mL tube labelled solution B: 5.5μl 10mM PEI was added to 27.5mL Opti-
MEM. Both solutions A and B were passed through a separate 0.22μm filter and then 
combined and incubated at room temperature for 20 minutes to allow PEI-DNA 
complexes to form. To the culture media of each T125 flask, 10mL PEI-DNA complex 
was added and the HEK-293T cells incubated for 4 hours. The media was then 
removed from each flask and replaced with 18mL fresh culture media, and the cells 
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were incubated for 48 hours to produce lentivirus containing either GLA or GFP, 
depending on the vector plasmid co-transfected. 
 
2.2.6 Harvesting of lentivirus 
Culture media was collected from HEK-293T cells 48 hours post-transfection and 
centrifuged at 3,345 g for five minutes to remove cell debris, and the supernatant 
passed through 0.22μm filter. The filtrate was centrifuged at 71,793 g for 2 hours and 
supernatant removed and excess allowed to drain from the virus pellet. The virus 
pellet was suspended in 150μl Opti-MEM, incubated on ice for 20 minutes, and re-
suspended before 30μl aliquots were prepared for storage at -80°C. Fresh culture 
media was added to the transfected HEK-293T cells before incubation for a further 
24 hours to obtain a second harvest using the same protocol.  
 
2.2.7 Cell counting 
Cells in media suspension were stained with trypan blue solution at 1:1. A 
haemocytometer was loaded with 10μl cell-stain mixture and live and dead cells in 
four 0.1mm3 grids were counted and labelled X. The number of cells per mL of 
suspension was calculated as: 
=
𝑋
4
× 2 × 104 
 
2.2.8 Transduction of cells with lentivirus 
Jurkats were transduced as follows: To each well of a 12-well plate 200,000 Jurkats 
were seeded in 1.5mL culture media with (10μL-1μL) lentivirus containing either GLA 
or GFP. The well plates were incubated for three days; after one day, a further 1.5mL 
fresh culture media was added to each well.  
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Human primary fibroblasts were transduced as follows: To each well of a 6-well plate 
300,000 fibroblasts were seeded in 3mL culture media and incubated overnight to 
adhere to well base. Media was replaced with 1.5mL fresh media with (5μL-1μL) 
lentivirus containing GLA; after one day, a further 1.5mL fresh culture media was 
added to each well.  
All cells were washed three times in DPBS to thoroughly remove virus before 
reseeding in fresh flasks for expansion before experiments. 
 
2.2.9 Multiplicity of Infection 
If the titre of the lentivirus suspension, defined as the number of infective plaque 
forming units (pfu)/mL, was already know, the exact volume of virus used, and the 
number of cells transduced, was chosen based upon the required multiplicity of 
infection (MOI) which is defined as the predicted pfu/cell: 
𝑀𝑂𝐼 =
𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑟𝑒 × 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑡𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑒𝑑
 
 
2.2.10 Cell and media harvesting 
When sufficient estimated cell volume for experiments was expanded in culture, 
media and cells were collected centrifuged at 832g for 10 minutes at 4°C. Media was 
harvested and placed on dry ice, and cells were washed in DPBS on ice three times. 
After final wash the cells were aliquoted in 200μL DPBS and placed on dry ice. Media 
and cells were stored at -20°C for experiments. 
  
 85 
 
2.2.11 Quantitative polymerase chain reaction (qPCR) 
Genomic DNA was extracted from cells transduced with lentivirus containing either 
GLA or GFP using the QIAGEN DNEasy blood and tissue kit according to 
manufacturer’s instructions for cultured cells. Absolute quantification of lentivirus 
WPRE and genomic β-actin sequences were measured against a plasmid pBTW2L 
standard curve using the Bio-Rad c1000 Touch thermo-cycler. Amplification of β-actin 
and WPRE sequences were used to calculate cell number and viral copy number 
respectively using Bio-Rad CFX manager software. The reaction mixture in Table 2-7 
was made in a 96-well plate and exposed to the following thermal cycle: 
 50°C for 2 minutes prevents carryover contamination using uracil-DNA glycosylase 
(UDG) 
 95°C for 10 minutes deactivates UDG; 
 95°C for 15 seconds double strand melt; 
 60°C for 1 minute primer annealing and DNA extension; 
 Repeat 3-4 for forty cycles. 
This method was used to measure the titre of virus suspensions and the actual 
number of viral genomes (vg) per cell in transduced cells, which may be different to 
the predicted MOI. 
 
Table 2-7: Preparation of reaction mixture for real time PCR 
 
 TaqMan 
Universal 
Master-
mix (x2) 
Fwd 
Primer 
Rvs 
Primer 
Probe 
(FAM 
reporter; 
TAMRA 
quencher) 
Water DNA 
Template 
Total 
reaction 
mixture 
Volume 
per 
reaction 
well 
(μL) 
12.5 0.23 0.23 0.05 7.00 5.00 25.00 
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2.2.12 Cell lysis  
Cells were thawed on ice, centrifuged at 600g for 10 minutes at 4°C. For Western 
blot, cells were re-suspended in 100μl M-Per lysis buffer containing Halt protease 
inhibitor cocktail (10μL/mL). Lysate was vortexed for 10 minutes, centrifuged at 
16,200g for 15 minutes at 4°C, and supernatant collected and kept on ice. For 
lysosomal enzyme activity assays, cells were re-suspended in distilled H2O and lysed 
by sonication using a Soniprep 150 for 10 seconds at 6μm amplitude. For 
mitochondrial enzyme activity assays, cells were exposed to three fast freeze-thaw 
cycles using dry ice in liquid nitrogen and 37°C water bath. Samples were vortexed 
between cycles. 
 
2.2.13 Murine tissue homogenisation 
Heart, kidney, liver, spleen, lung, brain and skeletal muscle organs were removed 
from four adult male wild type CD-1 mice. Organs were diced on ice and immediately 
stored at -20°C. Samples were homogenized in cold distilled H2O using pre-chilled 
glass pestle and mortar, followed by three fast freeze-thaw cycles using dry ice in 
liquid nitrogen and 37°C water bath.  
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2.2.14 Measurement of protein concentration 
Protein concentration in cell lysate or tissue homogenate were measured using the 
BCA method (Smith et al., 1985). Samples were diluted to two concentrations 
between 1/10 and 1/5 in distilled H2O, final volume was 50µL. The protein standard 
(1mg/mL) was diluted to five concentrations between 1/10 and 1/1 in distilled H2O 
up to 50µL final volume. Samples and standards were incubated with 1mL BCA at 
37°C for ten minutes, and 20µL copper (II) sulphate solution for a further twenty 
minutes. The biuret reaction between protein and Cu2+ to form Cu1+ in alkaline 
solution was detected by absorbance of light at 562nm wavelength, due to 
interaction between BCA and Cu1+, using the Cecil 2040 spectrophotometer. An 
example standard curve is shown in Figure 2-2: Example calibration curve for the BCA 
protein assay. 
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Figure 2-2: Example calibration curve for the BCA protein assay. 
The curve was obtained using a standard containing 1mg/mL bovine serum albumin in 
water supplied by Sigma (Poole, UK). Absorbance of light at 562nm wavelength was detected 
using the Cecil 2040 spectrophotometer. 
 
2.2.15 Western blot 
2.2.15.1 SDS PAGE gel electrophoresis 
A volume of supernatant containing 20μg protein was made to 20μl with H2O and 5μl 
Laemmli loading buffer (x4) was added before incubating for 5 minutes at 95°C. The 
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sample proteins were electrophoresed in 4-12% Bis-Tris NuPAGE polyacrylamide gel 
with MOPS SDS (x20) running buffer at 150V for 1.5 hours. 
2.2.15.2 Western blot 
Phosphate buffered solution (PBS) was made up using PBS tablets according to 
manufacturer’s instructions. Proteins were transferred onto PVDF blotting 
membrane with 5% NuPAGE transfer buffer, 10% methanol in H2O at 25V for 1 hour. 
The membrane was blocked for 1 hour in milk solution (PBS, 5% milk powder, 0.1% 
Tween 20), washed in PBS, 0.1% Tween 20 three times for 10 minutes, and incubated 
overnight at 4°C in milk solution with primary antibody at relevant dilution (see 
2.1.11). After further washing, the membrane was incubated at room temperature 
for 2 hours in milk solution with 0.014% anti-rabbit IgG horse radish peroxidase 
(HRP)-linked secondary antibody. Following further washing, target expression on the 
membrane was measured by detection of HRP using Pierce enhanced 
chemiluminescent Western blot substrate. The signal was detected photographically 
using UVI Chem software with wide aperture over a range of exposure times. 
 
2.2.16 Total α-galactosidase and α-galactosidase A activity assays 
2.2.16.1 In cultured cell lysate and tissue homogenate 
Total α-galactosidase activity was measured using the synthetic substrate 4MUG 
(Donnai et al., 1981). Sample protein was diluted 1:1 with 20mM phosphate buffer 
pH 6.4, final protein concentration 0.3-0.4mg/mL. The sample solution (50µL) was 
mixed with 50µL 10mM 4MUG in 0.1M acetate buffer pH 4.5 (substrate solution) and 
incubated for 30 minutes at 37°C. The reaction products were galactose and 4-
methylumbelliferone (4MU). Catalysis was stopped by addition of 1.1mL 0.25M 
stopping buffer which causes 4MU to fluoresce at 450nm following excitation at 
365nm. Fluorescence was quantified using the Perkin Elmer LS55 fluorimeter 
calibrated against a 1nmol 4MU standard made up to 1.2mL with 0.25M stopping 
buffer. Enzyme activity was reported in nmol/hr/mg total protein.   
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The activity of α-galactosidase A was determined by two methods: 
 The residual α-galactosidase activity of the B isoform was measured by 
incubating the sample solution for one hour at 50°C to heat-inactivate the A 
isoform prior to measuring enzyme activity as above (Beutler et al., 1973). 
Subtracting α-galactosidase B from total α-galactosidase activity determined 
α-galactosidase A activity. 
 Activity of α-galactosidase A was measured directly by competitively 
inhibiting the B isoform with 200mM NAGA in the 4MUG substrate solution 
as above (Mayes et al., 1981) 
2.2.16.2 In cell culture supernatant 
Total α-galactosidase activity was measured using the method described by Morgan 
et al., 1990 for plasma α-galA (Morgan et al., 1990). Accordingly 100µL substrate 
solution (10mM 4MUG in 0.5M acetate buffer, pH 4.8) was added to100µL 
supernatant. To measure α-galactosidase A activity, the B isoform was competitively 
inhibited by adding 200mM NAGA to the substrate solution (Mayes et al., 1981). The 
supernatant/substrate mixture was incubated at 30°C for 2 hours and hydrolysis of 
4MUG was stopped by addition of 1mL 1M stopping buffer which causes 4MU to 
fluoresce at 450nm following excitation at 365nm. Fluorescence was quantified using 
the Perkin Elmer LS55 fluorimeter calibrated against a 1nmol 4MU standard made up 
to 1.2mL with 0.25M stopping buffer. Enzyme activity was reported in nmol/hr/mL 
supernatant. 
2.2.17 β-galactosidase activity assay in cultured cells 
β-galactosidase activity was measured in cultured cells based upon the method 
described by (Young et al., 1987). Approximately 4-7µg sample protein was made up 
to 50µL with HSA/NaCl solution. The sample solution was added to 150µL 1mM 4-
methylumbelliferyl-β-D-galactopyranoside dissolved in MV4.1 substrate solution. 
The mixture was incubated at 37°C for 15 minutes and hydrolysis was terminated 
immediately by adding 1mL 0.25M stopping buffer which causes 4MU to fluoresce at 
450nm following excitation at 365nm. Fluorescence was quantified using the Perkin 
Elmer LS55 fluorimeter calibrated against a 1nmol 4MU standard made up to 1.2mL 
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with 0.25M stopping buffer. Enzyme activity was reported in nmol/hr/mg total 
protein. 
2.2.18 Total β-Hexosaminidase activity assays 
2.2.18.1 In cultured cell lysate and tissue homogenate 
The method to measure total β-hexosaminidase activity was modified from (Brett et 
al., 1973). Sample containing 5µg protein was diluted in 500µL 0.2% (w/v) HSA in 
MV4.5. A substrate solution containing 3mM 4-methylumbelliferyl-2-acetamido-2-
deoxy-β-D-glucopyranoside in MV4.5 was prepared. 100µL sample solution and 
100µL substrate solution were mixed and incubated at 37°C for ten minutes. 
Hydrolysis was terminated immediately by adding 1mL 0.25M stopping buffer which 
causes 4MU to fluoresce at 450nm following excitation at 365nm. Fluorescence was 
quantified using the Perkin Elmer LS55 fluorimeter calibrated against a 1nmol 4MU 
standard made up to 1.2mL with 0.25M stopping buffer. Enzyme activity was 
reported in nmol/hr/mg total protein.   
2.2.18.2 In cell culture supernatant 
The method to measure total β-hexosaminidase activity was modified from (O'Brien 
et al., 1970). A reaction mixture containing 5µL supernatant, 95µL MV4.5 and 100µL 
3mM 4-methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyranoside in MV4.5 was 
incubated at 37°C for twenty minutes. The reaction was terminated by adding 1mL 
0.25M stopping buffer which causes 4MU to fluoresce at 450nm following excitation 
at 365nm. Fluorescence was quantified using the Perkin Elmer LS55 fluorimeter 
calibrated against a 1nmol 4MU standard made up to 1.2mL with 0.25M stopping 
buffer. Enzyme activities were reported in nmol/hr/mL supernatant. 
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2.2.19 Citrate synthase activity assay 
Citrate synthase activity was determined according to the method of Shepherd and 
Garland (1969) (Shepherd and Garland, 1969). The assay buffer was pre-warmed to 
30°C. The volumes shown in Table 2-8 were added to spectrophotometer cuvettes. 
 
Table 2-8: Volumes of reagents used in the citrate synthase assay 
 
 Sample cuvette volume (µL) Reference cuvette volume 
(µL) 
Assay buffer 950 960 
Sample cell lysate 20 20 
Acetyl CoA 10 10 
DTNB 10 10 
Oxaloacetate 10 - 
Citrate synthase in the sample protein catalyses: 
acetyl coenzyme A  + oxaloacetate → citric acid + CoA-SH 
DTNB + CoA-SH → Thionitrobenzoic acid (TNB) + CoA-S-S-TNB 
The reaction product TNB absorbs light at 412nm wavelength, so increase in 
absorbance per minute was measured using the Kontron Uvikon XL 
spectrophotometer over 5 minutes once reaction rate settled at 30°C. Enzyme 
activity (nmole/min/mL lysate) was calculated by Beer-Lambert’s law using 
coefficient of absorption = 13.6 x 103 and light path length through sample = 1cm. 
 
2.2.20 Respiratory chain complex I (NADH-ubiquinone oxidoreductase) activity assay 
Complex I activity was assessed as described previously by Schapira et al. (1990) 
(Schapira et al., 1990). The assay buffer was pre-warm to 30°C. The volumes shown 
in Table 2-9 were added to spectrophotometer cuvettes.  
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Complex I oxidizes NADH and delivers an electron pair via iron-sulphur clusters to 
reduce ubiquinone. KCN inhibits complex IV, thereby preventing oxidation of 
ubiquinol by complex III. The cuvettes were warmed to 30°C in the Kontron Uvikon 
XL spectrophotometer before adding 10µL ubiquinone to the sample cuvette. 
Absorbance of light at 340nm wavelength was measured over five minutes once 
reaction rate settled. Non-complex I-catalyzed NADH oxidation was then isolated by 
addition of 20µL rotenone to the sample cuvette to inhibit reduction of ubiquinone. 
Absorbance at 340nm wavelength was subsequently measured over a further five 
minutes, after allowing 2-3 minutes for the rotenone to take effect. The difference 
between change in absorbance min-1 before and after rotenone treatment was 
proportional to NADH oxidation rate in the sample lysate. Enzyme activity 
(nmole/min/mL lysate) was calculated by Beer-Lambert’s law using coefficient of 
absorption = 6.81 x 103 and light path length through sample = 1cm. 
Table 2-9: Volumes of reagents used in the respiratory chain complex I activity assay 
 
 Sample cuvette volume (µL) Reference cuvette volume 
(µL) 
Assay buffer 800 800 
BSA 50 50 
NADH 30 30 
KCN 10 10 
Sample cell lysate 20 20 
H2O 80 90 
 
2.2.21 Software 
Electrophoresis gel images were processed with ImageJ 1.47v (National Institute of 
Health, USA). Statistical testing was performed using Prism 5.01v (GraphPad 
Software, USA). 
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2.2.22 Statistical analysis 
Bar charts show mean value of replicates (n), with standard deviation (SD) indicated 
by error bars. Dot plots show mean value of n as horizontal lines. Scatter plots show 
single data-points unless otherwise stated. The n value is defined as the number of 
repeat, independent cell culture preparations analysed. In cell-toxicity experiments, 
the number of live and dead cells in each preparation was counted in duplicate. In 
enzyme assays, each preparation was measured in duplicate. Virus copy number of 
each preparation was measured in triplicate. Difference between two data-sets was 
analysed by Student’s t-test; difference between three or more data-sets was 
measured by one-way analysis of variance (ANOVA) and Bonferroni’s post hoc tests. 
Cell toxicity data was analysed by two-way ANOVA to take account of both duration 
of incubation and virus dosage. Scatter plots were analysed by linear regression (R2) 
if significant correlation was found. In method comparison work, the mean linear 
regression slope and SD was reported. The effect of rotenone in cell cultures was 
analysed by comparison of mean linear regression slope and standard deviation using 
the Student’s t-test. In all cases P<0.05 was considered to be significant. Before 
statistical analysis of percentage and ratio data, values were transformed: 
sin−1 √
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑑𝑎𝑡𝑎
100
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Chapter 3 Characterisation of α galactosidase A 
3.1 Introduction 
3.1.1 Overall aim 
The hallmark of Fabry disease is deficient activity of the lysosomal acid hydrolase α-
gal A. Treatment is currently available, predominantly in the form of ERT but clinical 
response displays considerable variation across patients, tissue-types, age and 
disease severity (El Dib et al., 2016, Ortiz et al., 2016, Rombach et al., 2013). 
Alternative therapies are therefore urgently required. Since the condition is due to a 
loss of function, single gene mutation, it is a good candidate for gene therapy (Biffi, 
2016, Friedmann and Roblin, 1972). Before the efficacy of GLA delivery to human cells 
can be explored, it is essential to baseline the characteristics of α-gal A activity in a 
range of wild-type cells and tissues. The enzyme distribution across tissue types may 
correlate with regions of substrate accumulation, clinical symptoms or response to 
ERT. This work will also enable identification of a suitable cell type in which to 
overexpress GLA in future experiment. 
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3.1.2 Laboratory methods 
In vitro α-gal A hydrolyses synthetic substrates without the activator glycoprotein 
saposin B present (Hrebicek and Ledvinova, 2010). At least two synthetic substrates 
are available to measure α-gal A activity: a chromogenic assay is available using 4-
Nitrophenyl α-D-galactopyranoside (4NPαGal); and a fluorometric assay using 4-
methylumbelliferyl-α-D-galactopyranoside (4MUG). Absorbance-based assays are 
generally less sensitive compared with assays based on fluorescence (Motabar et al., 
2010a), so here 4MUG was used according to the protocol described in Chapter 2 
Materials and Methods (Donnai et al., 1981). Hydrolysis of 4MUG by α-gal A releases 
4-methylumbelliferone (4MU) that fluoresces at a significantly different wavelength 
from the un-hydrolysed substrate after addition of alkaline buffer to stop the 
reaction. This allows the amount of 4MU produced to be measured in the presence 
of excess 4MUG; excess substrate is essential to ensure the enzyme operates at 
optimum activity over the period of time the assay is run. Fluorescence was measured 
relative to a 1nmol 4MU standard, and protein concentration of sample preparations 
determined by the BCA method, allowing enzyme activity to be reported in 
nmol/hr/mg total protein. 
A-gal A shares residual α-galactosidase activity with the hydrolytic lysosomal enzyme 
α-N-acetyl-galactosaminidase (α-gal B). A-gal B is considered an isoenzyme of α-gal A 
because both are α-retaining galactosidases; but the primary function of α-gal B is 
hydrolysis of terminal N-acetylated saccharides (α-GalNAc) from glycolipids and 
glycoproteins such as N-acetyl-galactosamine (NAGA), and has distinct thermo-
stability (Beutler et al., 1973, Dean and Sweeley, 1979a). There are at least two 
methods to distinguish α-gal A activity from total α-galacotosidase activity. Firstly, 
heat inactivation of α-gal A allows α-gal B activity to be measured and subtracted 
from total α-galactosidase activity to determine α-gal A activity for the following 
reason. Figure 3-1A shows the effect of incubation time at 45°C on α-galactosidase 
activity in human leucocytes. Fabry disease patients who lack functional α-gal A show 
no change in α-galactosidase activity, whereas healthy controls show a sharp drop in 
activity after one hour to the same level as in Fabry disease patients (Beutler and 
Kuhl, 1972). This illustrates that α-gal A is thermolabile and α-gal B is thermostable 
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after one hour at 45°C. Secondly, α-gal A activity can be measured directly by 
competitively inhibiting α-gal B using NAGA (Mayes et al., 1981). Figure 3-1B shows 
that α-galactosidase activity of isoform A is uninhibited, but that of isoform B is 94% 
inhibited, when assayed with 0.1M NAGA.  
 
 
 
Figure 3-1: Evidence for two methods for distinguishing alpha galactosidase activity due to 
A and B isoforms 
A. Total α-galactosidase activity in leucocytes of classic FD patient and normal control 
subject following incubation over a range of durations at 45°C, pH7. Enzyme activity in 
leucocytes from normal subjects fall to the level measured in FD patients after 45 minutes 
incubation, demonstrating that the deficient enzyme in FD, α-gal A, is thermolabile and that 
α-gal B, which exhibits the residual α-galactosidase activity, is thermostable at 45°C, pH7 
(Beutler and Kuhl, 1972). B. Competitive inhibition of α-galactosidase activity in α-gal B (line 
B) by N-acetyl galactosamine (GalNAc). Optimum GalNAc concentration (0.1M) inhibits 94% 
of α-galactosidase activity in α-gal B. GalNAc does not inhibit α-gal A activity (line A) (Mayes 
et al., 1981). 
  
A B 
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Although α-gal B is unable to compensate for deficient α-gal A activity in patients, it 
is feasible that they may share in a common regulatory network, especially since they 
are thought to share a common ancestral gene (Tomasic et al., 2010). However, 
research to date does not typically report the contribution of α-gal B to total α-
galactosidase activity; potentially overlooking valuable information that may throw 
light on the apparent lack of correlation between α-gal A activity, substrate 
accumulation, clinical picture and response to ERT. 
In an attempt to take account of variation in lysosomal content between cell and 
tissue types, the ratio of activity of α-gal A was calculated against the activity of at 
least one other hydrolytic lysosomal enzyme. This is a similar concept to that used for 
measuring mitochondrial respiratory chain enzyme activities; values are usually 
reported as a ratio with citrate synthase activity for comparison across samples that 
may have different mitochondrial content. 
The enzymes used were β-galactosidase and total β-hexosamindase. The normalised 
ratio of α-gal A activity was calculated as: 
α galactosidase A activity
𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝛽𝑔𝑎𝑙𝑎𝑐𝑡𝑜𝑠𝑖𝑑𝑎𝑠𝑒 𝑜𝑟 𝑡𝑜𝑡𝑎𝑙 𝛽 ℎ𝑒𝑥𝑜𝑠𝑎𝑚𝑖𝑛𝑖𝑑𝑎𝑠𝑒
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3.1.3 Human cells and plasma 
The human cells listed in Table 3-1 were analysed for α-galactosidase and β-
galactosidase activities. Cell-lines were selected for their potential susceptibility to 
pathology resulting from α-gal A deficiency, based upon their tissue of origin. 
Peripheral neurons, renal cells and both skin and heart fibroblasts are important sites 
of Gb3 accumulation in humans (Desnick et al., 2001). Only a low degree of storage 
is observed in hepatocytes, and liver involvement in symptoms is often absent 
(Elleder, 2010). Leucocyte α-gal A activity is commonly used for laboratory diagnosis 
(Gal et al., 2011). These cells are a potential target for therapeutic GLA delivered via 
ex-vivo HSC-based gene therapy, and may subsequently act as a factory for 
production and delivery of functional α-gal A to tissues via the vascular system 
(Medin et al., 1996, Takenaka et al., 1999a, Takenaka et al., 1999b). Plasma α-gal A is 
also used for laboratory diagnosis. In the present study, plasma was analysed from 
patients at GOSH (London, UK), with and without confirmed Fabry disease. This was 
in order to identify any difference between the two patient groups with regards to α-
galactosidase activity of both A and B isoforms.  
Table 3-1: Cell-line tissue of origin 
 
 
  
Identity Tissue of origin Morphology 
SH-SY5Y Neuroblastoma cell line Epithelial 
293T Adenovirus-transformed embryonic kidney cell line Epithelial 
Fibroblasts Primary culture Fibroblast 
Jurkat Lymphoblastic T cell leukaemia cell line Lymphoblast 
Hu-H7 Hepatocarcinoma cell line Epithelial 
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3.1.4 Murine tissue 
Human tissues other than skin fibroblasts are difficult to acquire, so in the present 
study samples of heart, kidney, liver, spleen, lung, brain and skeletal muscle were 
isolated from four adult male wild-type CD1 mice in order to characterise tissue 
distribution of α-gal A activity. These organs were selected based upon their 
differential involvement in the pathophysiology of Fabry disease. Cardiovascular, 
renal and cerebrovascular symptoms predominate, but respiratory disease and 
substrate accumulation in spleen and liver are also reported. In contrast skeletal 
muscle appears to have little if any involvement (Elleder, 2010, Germain, 2010). 
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3.1.5 Objectives 
This chapter characterises α-galactosidase activity in human cells, murine tissues and 
human plasma through the following objectives:  
 To establish and validate the α-gal A assay. Linearity of the assay was 
demonstrated over a range of incubation times and total protein content of 
samples. This defines the parameters within which subsequent experiments 
were conducted to ensure consistency of laboratory results;  
 To validate the method to accurately distinguish the activity of α-gal A from 
total α-galactosidase activity in human cells. A-gal A activity measured over a 
range of concentrations by competitive inhibition was compared with α-gal A 
activity measured using heat inactivation; 
 To check the α-gal A assay for murine tissues. A method to prepare murine 
tissue homogenate was optimised, and the level of agreement between heat 
inactivation and competitive inhibition methods to determine α-gal A activity 
was examined using murine heart tissue; 
 To characterise α-galactosidase activity of A and B isoforms in a variety of 
human cells in order to baseline activity and select the cell type with the 
lowest α-gal A activity for future overexpression studies; 
 To characterise the distribution of α-galactosidase activity of A and B isoforms 
in murine tissues. This work may help correlate the activity of these enzymes 
with disease phenotype; 
 To characterise the endogenous α-galactosidase activity of α-gal A and B in 
human plasma from unaffected (control) patients and patients with Fabry 
disease.  
3.2 Methods 
The methods are as described in Chapter 2 Materials and Methods. 
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3.3 Validation of the α galactosidase A assay 
3.3.1 Linearity over incubation time and sample protein content 
The total α-galactosidase and α-gal A activity assays were as used in the diagnostic 
chemical pathology laboratory at GOSH, London, UK, and are fully validated 
according to UK Accreditation Service standard ISO 15189: 2012. It was necessary 
however to confirm a range of linearity of the assays with respect to incubation time 
at 37°C and total protein content of the enzymatic reaction for the specific purposes 
of this project. The source of protein chosen for this was the human T lymphoblastic 
leukaemia cell-line called Jurkat. Cells were lysed in water by sonication. The results 
showed that the amount of reaction product (4MUG) formed by a reaction mixture 
containing 20µg total protein increased linearly with incubation times from 20 to 50 
minutes (Figure 3-2A). Similarly the amount of 4MUG formed in 20 minutes increased 
linearly in reaction mixtures containing 5 to 25µg total protein (Figure 3-2B). These 
data demonstrate the ranges over which the assay provides consistent results and 
are valid for all future investigations. 
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Figure 3-2: Linearity of alpha galactosidase assay determined using Jurkat homogenate 
The linearity of the α-galactosidase assay was assessed in order to determine the range 
of total protein amount and incubation time that may be used in later experiments. Linearity 
was confirmed over a range of: (A) incubation times carried out in 20µg total protein, 
R2=0.990 (P<0.0001, n=4); (B) amounts of total protein that were incubated for 31 minutes, 
R2=0.991 (P<0.0001, n=4). 
 
  
A 
B 
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3.3.2 Limits of agreement between heat inactivation and competitive inhibition in 
human cells  
A-gal A activity was distinguished from total α-galactosidase activity in Jurkat cells 
using the heat inactivation method at 50°C for 1 hour. A-gal A activity of the same 
samples were then measured directly by using the competitive inhibitor of α-gal B 
called N-acetyl-galactosamine (NAGA) at 0.05M, 0.1M and 0.5M concentrations. 
These concentrations were chosen based on the range over which α-gal B was at least 
90% inhibited according to Figure 3-1. This was firstly to ascertain whether heat at 
50°C for 1 hours was sufficient to fully inactivate α-gal A over a range of activity. 
Secondly it was important to confirm the concentration of inhibitor which best 
agreed with heat inactivation method. Figure 3-3A shows that, over the range of α-
gal A activity measured, the relationship between methods is linear, suggesting that 
the heating protocol is sufficient to fully inactivate α-gal A. The slope with 95% 
confidence interval and linear regression R2 values for all inhibitor concentrations 
assessed is shown in Figure 3-3B. Best agreement between methods is shown with 
0.1M NAGA because the linear slope is closest to unity. Since assay pH is an important 
factor effecting enzyme activity, the effect of NAGA concentration was found not to 
influence the pH of the reaction mixture from 0.0 to 1.0M NAGA (n=4). 
To confirm that competitive inhibition using 0.1M NAGA gave comparable α-gal A 
activity to the heat inactivation method, Figure 3-4 shows the level of agreement 
between the two methods using 0.05M, 0.1M and 0.5M competitive inhibitor 
concentrations by Bland and Altman plots. The dotted lines show ±2SD of the mean 
difference in α-gal A activity measured by the two methods. At 0.1M inhibitor 
concentration there is no bias between methods because the average difference in 
activity measured is close to zero, and there is no evidence of skewing of 
measurement below 2.5µmol/hr/mg protein. In comparison, at both 0.05M and 0.5M 
NAGA, the difference with heat inactivation increases with enzyme activity. 
Therefore competitive inhibition with 0.1M NAGA and heat inactivation methods 
provide comparable results for α-gal A activity in human Jurkat cells. Since Jurkat is a 
human cell-line, this result will be applied to all human cell types considered in future 
work.  
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NAGA 
concentration 
(M) 
Slope R2 95% confidence 
interval of slope 
0.05M 1.252 0.999 1.227 to 1.278 
0.1M 0.993 0.998 0.980 to 1.007 
0.5M 0.884 0.998 0.870 to 0.897 
 
Concentration of competitive inhibitor 
NAGA 
0.0M 0.1M 1.0M 
Alpha galactosidase assay pH 4.47±0.05 4.51±0.01 4.50±0.05 
 
Figure 3-3: Comparison of methods to measure α-galactosidase A activity in human Jurkat 
cells 
A range of enzyme activities were measured using both heat inactivation and 
competitive inhibition methods in order to confirm agreement over between methods. To 
check that inhibitor concentration over the range assessed did not affect assay pH and 
therefore enzyme activity, the pH of the assay was also measured. (A) Heat inactivation at 
50°C for one hour was compared with competitive inhibition using N-acetylgalactosamine 
(NAGA) over a range of concentrations. Dotted lines show 95% confidence intervals. (B) 
Linear regression analysis was used to determine the slope of the line comparing heat 
inactivation with different inhibitor concentrations. The 95% confidence intervals show that 
the slope of the line comparing competitive inhibition method using 0.1M inhibitor with heat 
inactivation method crosses unity and therefore shows closest agreement (P<0.0001). (C) 
There was no statistical difference in assay pH with a range of competitive inhibitor 
concentrations (n=4) 
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Figure 3-4: Levels of agreement between methods to determine alpha galactosidase A 
activity in human Jurkat cells. 
Bland and Altman plots comparing heat inactivation and competitive inhibition over a 
range of inhibitor concentrations: (A) 0.05M; (B) 0.1M; (C) 0.5M. The wide dotted lines show 
mean difference, and the short dotted lines show 2SDs either side of mean. 
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3.3.3 Assessment of methods to homogenate murine tissues 
The method of murine tissue homogenisation was selected based upon a preliminary 
experiment comparing total α-galactosidase activity measured in murine heart 
tissue. To be as consistent as possible between human cells and murine tissues, water 
was used in all tissue homogenisation methods considered as shown in the table 
within Figure 6. Manual grinding of samples using pestle and mortar followed by 
three cycles of fast freeze-thaw using dry-ice in methanol and 37°C water-bath 
released the highest total α-galactosidase activity (Figure 3-5A). This method was 
selected for preparation of all murine tissue samples. 
To ensure that, in tissues with high enzyme content, total enzyme activity was not 
limited by substrate concentration at high protein concentrations, α-galactosidase 
activity was measured in 5% and 1% w/v homogenates of murine spleen samples. 
Previous research showed murine spleen had especially high α-galactosidase activity 
(Ohshima et al., 1999). Figure 3-5B shows there was no difference in enzyme activity 
measured in the two preparations, suggesting substrate concentration was not 
limiting activity in 5% compared with 1% w/v homogenates. So, it was decided to 
carry out all murine tissue analysis using homogenate with 5% w/v tissue in water in 
future experiments. 
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A. 
Method Detail 
Water 
(man) 
Grinding  samples in 
H2O using glass pestle 
and mortar 
Water 
(man) with 
PI 
Grinding  samples in 
H2O and protease 
inhibitor cocktail 
(Complete-mini, Roche) 
using glass pestle and 
mortar 
Water 
(man) with 
fast freeze-
thaw cycles 
Grinding  samples in 
H2O using glass pestle 
and mortar, followed by 
three fast freeze-thaw 
cycles 
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Figure 3-5: Optimisation of protein isolation for measurement of α-gal A activities in 
murine tissue samples. 
(A) Total α-gal activity in murine heart using various tissue homogenisation methods 
detailed in table. PI: protease inhibitor. One-way ANOVA showed no statistical difference 
between methods, but water (man) with Fast freeze thaw cycles gave the highest yield of 
enzyme activity. (B) Mean total α-galactosidase activity measured in murine spleen using 5% 
and 1% w/v tissue homogenate in water. There was no statistical difference in mean enzyme 
activity between homogenates. Bar charts shown mean of four samples; error bars show SD. 
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3.3.4 Limits of agreement between heat inactivation and competitive inhibition in 
murine tissues 
So far agreement was demonstrated between methods to distinguish α-gal A from 
total α-galactosidase activity in human cells only. To check whether agreement 
between competitive inhibition with 0.1M NAGA and heat inactivation holds true in 
murine tissue, both methods were used to determine α-gal A in murine tissues. 
Samples from all tissue types listed above were homogenised using the method 
established in the previous section. The results are compared in Figure 3-6, showing 
that they are inconsistent because the slope of the linear regression line in Figure 
3-6A is considerably above unity. The Bland and Altman plot at Figure 3-6B shows 
competitive inhibition method directly measured α-gal A activity on average 
16nmol/hr/mg higher than heat inactivation. At higher α-gal A activity the difference 
between methods increased above 2SD of the mean. Since competitive inhibition 
measures α-gal A activity directly, is therefore more accurate, and is the method 
predominantly used in the literature, murine tissues will be analysed using 0.1M 
NAGA.  
In summary, the validation work gives license to use either heat inactivation or 
inhibition to measure α-gal A in human cells lysed by sonication in water, and human 
plasma. Consequently characterisation of α-gal A in a range of human cell types was 
carried out using the heat inactivation method. To be consistent, characterisation of 
α-gal A activity in murine tissues was measured using 0.1M NAGA to inhibit α-gal B 
using a water-based homogenisation protocol. All future assays used an amount of 
protein and incubation period within the linear range established herein. 
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Figure 3-6: Comparison of methods to distinguish alpha galactosidase activity in murine 
tissues. 
Comparison of methods to distinguish α-gal A from total α-galactosidase activity in 
murine tissues. (A) Dot plot of α-gal A activity measured using competitive inhibition (0.1M 
NAGA) against α-gal A calculated using the heat inactivation method. Table shows slope is 
significantly above unity. Linear regression R2=0.911. Dotted lines show 95% confidence 
interval. (B) Bland and Altman plot shows level of agreement. Dotted lines show mean 
difference between methods ± 2SD. 
A 
B 
 110 
 
3.4 Characterisation of α-gal A in human cell lines 
The α-galactosidase activity in A and B isoforms were characterised in human cells 
listed in Table 3-1, using the heat inactivation method validated in the previous 
section. The purpose was to baseline activity and select the cell type with the lowest 
α-gal A activity for future overexpression studies. Figure 3-7A shows the distribution 
of α-gal A and α-gal B, and Jurkat (human T lymphoblastic leukaemia) cells display the 
lowest absolute α-gal A activity of all cell types examined. The inset table in Figure 
3-7A shows mean and standard deviation of the percentage of total α-galactosidase 
activity due to isoform A. One-way analysis of variance performed on transformed 
percentage data identified that fibroblasts exhibit a significantly lower proportion of 
α-galactosidase activity due to isoform A compared with all other cell-lines tested 
(P<0.0001).  
To correct α-gal A activity for variation in lysosomal content, β-galactosidase activity 
was also measured in all cell-lines (Figure 3-7B), and the normalised ratio of α-gal A 
to β-galactosidase activity was reported in Figure 3-8. Embryonic kidney 293Ts were 
the only cells exhibiting mean ratio of α-gal A to β-galactosidase activity greater than 
one; a statistical difference was observed in the transformed ratio across all the cell-
lines (P<0.05).  
The transformation applied to percentage and ratio data is given in Chapter 2 
Materials and Methods. 
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Cell Line 
Mean percentage of total α-
gal activity due to A isoform 
SH-SY5Y 90.4 ± 1.0 
293T 92.8 ± 1.5 
Fibroblasts 65.6 ± 3.4  
Jurkat 91.2 ± 1.3 
Hu-H7 94.9 ± 0.5 
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Figure 3-7: Activity of α-galactosidase A and B isoforms, and β-galactosidase, in a range of 
cultured human cell-lines (n=6) 
A. Characterisation of α-galactosidase activity show the contribution of A and B 
isoforms to total α-galactosidase activity. Primary fibroblasts show significantly lower 
percentage contribution of A isoform compared to all other cell types measured after data 
was transformed (P<0.0001) (table inset). Survey of α-gal A activity showed 293T cells exhibit 
higher activity than all other cell types (P<0.0001). B. Survey of β-galactosidase activity in 
cell-lines. 
*** 
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Figure 3-8: Alpha galactosidase A activity standardised for variation in lysosomal content 
using Beta galactosidase (n=6) 
Ratio of α-gal A activity to β-galactosidase activity was calculated in an attempt to 
standardise α-gal A activity for variation in lysosomal content within the various cell-lines. 
The resulting survey showed significant difference in standardised activity between 293T and 
all other cell types assessed after data was transformed (P<0.05). 
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3.5 Characterisation of alpha gal A in murine tissues 
To investigate any differences in activity between α-gal A and B isoforms in different 
tissues, heart, kidney, liver, spleen, lung, brain and skeletal muscle were isolated from 
four adult male CD1 wild type mice. The organs were selected based upon their 
differential involvement in the pathophysiology of Fabry disease. Consistent with the 
optimisation studies reported above, collected tissues were homogenised (5%w/v) in 
water using pestle and mortar and three fast freeze-thaw cycles. In line with previous 
research (Ohshima et al., 1999), the α-galactosidase activity of A and B isoforms was 
analysed using 0.1M NAGA to competitively inhibit α-gal B. The activity of two other 
lysosomal hydrolytic enzymes β-galactosidase and total β-hexosaminidase were also 
measured to confirm sample protein viability and to standardise α-gal A activity for 
variation in lysosomal size and content across samples and tissue types.  
For each tissue type, the mean and standard deviation in enzyme activities of four 
mice are shown in Figure 3-9 and Figure 3-10. Up to three samples were measured 
from each mouse in duplicate and standard deviation was calculated from the mean 
of each mouse; variations within mice are not shown. In spleen, both α-gal A and B 
activity was significantly higher than in all other tissues analysed (P<0.0001). The 
percentage contribution of the A isoform to total α-galactosidase activity was highest 
in skeletal muscle (P<0.0001). The ratios of α-gal A activity against β-galactosidase 
and total β-hexosaminidase activity are shown in Figure 3-11. The ratio in skeletal 
muscle is significantly higher than in brain, liver, kidney and spleen using either of the 
standardising enzymes chosen. However, with β-galactosidase, the ratio in skeletal 
muscle is significantly higher than in all the other tissue types examined (P<0.01). 
Previous studies found skeletal muscle accumulate very little if any Gb3 resulting 
from α-gal A deficiency and display little, if any, pathological involvement in Fabry 
disease. 
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Murine Tissue Mean percentage of total alpha gal 
activity due to A isoform 
Skeletal muscle 94 ± 3 
Brain 86 ± 4 
Lung 77 ± 2 
Liver 68 ± 13 
Kidney 64 ± 2 
Heart 69 ± 6 
Spleen 73 ± 4 
 
Figure 3-9: Alpha-galactosidase activity in murine tissues (n=4) 
The contributions of α-gal A and α-gal B to total α-galactosidase activity are shown. 
The heat inactivation method was used to distinguish the relative activity of A and B isoforms. 
One way ANOVA of activity of A and B isoforms across all the tissues analysed suggested that 
activity in spleen was significantly high (P<0.0001). The table inset shows the mean 
percentage of total activity due to the A isoform. One way ANOVA of transformed 
percentages showed that skeletal muscle contained significantly higher isoform A 
contribution to total α-galactosidase activity than in lung, liver, kidney, heart and spleen 
(P<0.0001). 
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Figure 3-10: Activity of two additional hydrolytic lysosomal control enzymes in various 
murine tissues (n=4). 
Two other enzymes involved in glycosphingolipid catabolism were measured in order 
to verify murine tissue sample viability and to standardise α-gal A activity for variations in 
lysosomal content of tissues. (A) β-galactosidase activity. (B) Total β-hexosaminidase activity. 
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Figure 3-11: Ratio of α-gal A activity against the activity of two other lysosomal hydrolytic 
enzymes in various murine tissues (n=4) 
Ratios were transformed before statistical analysis was performed. (A) β-
galactosidase. There was significant difference between skeletal muscle and all other tissues 
types (P<0.01). (B) Total β-hexosaminidase. There was significant difference between skeletal 
muscle and brain, liver, kidney and spleen (P<0.05). 
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3.6 Characterisation of α-gal A in human plasma 
To assess whether the α-galactosidase activity was able to differentiate between 
humans affected and unaffected by Fabry disease, α-gal A activity was measured in 
plasma from male patients at Great Ormond Street Hospital, London, UK, with and 
without Fabry disease. The α-galactosidase activity of A and B isoforms was 
determined using 0.1M NAGA to competitively inhibit α-gal B. This is consistent with 
the standard operational procedure employed within the ISO15189:2012 accredited 
Department of Chemical Pathology, GOSH (London, UK). Furthermore the validation 
work above showed this method gave α-gal A activity results comparable with the 
heat inactivation method, demonstrating a consistent approach across human cells 
and plasma.  
Results in Figure 3-12 show a significant reduction in α-gal A activity, and a slight but 
significant reduction in α-gal B activity, in affected patients compared with 
unaffected patients. The inset table in Figure 3-12 compares the contribution of α-
gal A to total α-galactosidase activity in affected and unaffected patients. Figure 
3-13A shows there was no difference in total β-hexosaminidase activity between the 
two groups. Figure 3-14 show the standardised ratios of α-gal A and B against total 
β-hexosaminidase respectively.  
To examine whether the observed drop in α-galactosidase activity of the B isoform 
was due to a change in enzyme expression or functionality, N-
acetylgalactosaminidase activity was measured in the plasma samples.  N-
acetylgalactosaminidase is the dominant activity belonging to α-gal B, and Figure 
3-13B shows no difference between the patient groups. 
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Cultured Cell 
Line 
Mean percentage of total α-gal 
activity due to A isoform 
Fabry patients 
(n=5) 
22.4 ± 12.5 
Controls 
(n=10) 
91.0 ± 2.0 
 
Figure 3-12: Characterisation of α-gal A in plasma of male Fabry patients naive to treatment 
and non-Fabry control patients.  
Activity of isoforms A and B of α-galactosidase. Alpha gal A activity was significantly 
reduced in Fabry disease patients compared with controls (P<0.0001); isoform B activity 
reduced slightly but significantly (P<0.001). The table inset shows the mean percentage 
contribution of α-gal A to total α-galactosidase activity. There is a significant drop in the 
contribution of the A isoform in Fabry patients compared with controls (P<0.0001). 
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Figure 3-13: Characterisation of control lysosomal enzymes in plasma of Fabry patients 
naive to treatment.  
The activity of two lysosomal hydrolytic enzymes were measured in order to confirm 
sample viability and to take account of variation in lysosomal content between patients and 
controls. There was no difference detected in either total β-hexosaminidase (A) or N-
acetylgalactosaminidase (B) activity between the sample groups. 
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Figure 3-14: Characterisation of α-gal A standardised for variation in lysosomal content in 
plasma of Fabry patient naive to treatment. 
Ratio of α-gal A and α-gal B activity to total β-hexosaminidase activity was calculated 
in an attempt to standardise α-gal A activity for variation in lysosomal content within patient 
and control plasma samples. A. There was highly significant difference in standardised α-gal 
A activity between patients and controls (P<0.0001). B. There was a significant difference in 
standardised α-gal B activity between patients and controls (P<0.001) 
*** 
** 
A 
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3.7 Conclusions 
In this chapter, an α-gal A activity assay method was established and validated which 
is consistent across human cell and murine tissue types. Consistent with the range of 
linearity demonstrated in Figure 3-2 using human Jurkat cells as a source of protein, 
all measurements of enzyme activity in this thesis were carried out using 15µg total 
protein and 30 minutes incubation at 37°C. To differentiate α-gal A activity from total 
α-galactosidase activity, competitive inhibition (using 0.1M NAGA) and heat 
inactivation methods were compared. In human cells the methods gave consistent α-
gal A results, using the Jurkat cell-line as a model (Figure 3-3 & Figure 3-4). However 
the methods were not consistent in murine tissues taken from wild type male CD1 
adult mice (Figure 3-6). Consequently the heat inactivation method was used to 
determine α-gal A activity in all human cell types in this chapter, but in future 
chapters the competitive inhibition method using 0.1M NAGA was employed because 
the methods are consistent. In murine tissues the competitive inhibition method was 
used because it is the more accurate method and consistent with previous literature. 
Manual homogenisation of 5% (w/v) tissue in water with pestle and mortar, followed 
by three fast freeze-thaw cycles, was selected as the optimal sample preparation 
method prior to enzymatic assays (Figure 3-5).  
Using the above established methods the activity of α-gal A and B enzymes were 
measured in human cell-lines originating from tissues known previously to have 
differential involvement in the pathophysiology of Fabry disease (Table 3-1). There 
was significant variation in α-gal A activity across the cell-lines (Figure 3-7A): 
lymphoblastic Jurkat cells exhibit low α-gal A activity relative to all other human cell-
lines tested; and embryonic kidney 293T cells show significantly high α-gal A activity 
compared with Jurkat activity. The table within Figure 3-7A shows that the 
percentage of α-galactosidase activity due to the A isoform is significantly lower in 
primary fibroblasts than in all the other cell-lines tested. The relatively high 
contribution of the B isoform to total α-galactosidase activity in fibroblasts may be 
expected to result in resilience to Fabry disease in this cell type because α-gal B 
possesses some residual α-galactosidase activity and may be able to compensate for 
α-gal A deficiency. However there is no apparent evidence of resilience since 
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fibroblasts of both skin and heart accumulate Gb3 in Fabry disease patients (Elleder, 
2010).  
The inability of α-gal B to compensate for α-gal A deficiency is consistent with the 
literature (Hrebicek and Ledvinova, 2010). Alpha-gal B shares 49% sequence 
homology with α-gal A, with complete agreement in active site residues except within 
the 2-position recognition loop shown in Figure 3-15 (Garman and Garboczi, 2004). 
The enlarged space created by serine and alanine in α-gal B reduces its affinity with 
α-galactose (20-fold higher Km) compared with α-GalNAc.  The smaller active site 
created by glutamate and leucine in α-gal A provides no affinity to α-GalNAc (Clark 
and Garman, 2009). (Tomasic et al., 2010), showed that through interconverting 
these active site residues they were able to increase enzyme specificity of α-gal B and 
α-gal A to α-galactose and α-GalNAc substrates respectively. So molecular 
engineering of autologous α-gal B within fibroblasts may represent an effective 
source of non-immunogenic ERT for Fabry disease patients (Germain, 2010) 
The ratio of α-gal A activity against a second lysosomal enzyme, β-galactosidase, was 
used to standardise cell-line samples for variations in lysosomal content (Figure 3-8). 
Embryonic kidney 293T cells exhibited a significantly high ratio, and both 
neuroblastoma SH-SY5Y and lymphoblastic Jurkat cells were also raised compared 
with primary fibroblasts and hepatocarcinoma Hu-H7 cells. Possibly a high 
standardised ratio for α-gal A in tissues is a risk indicator for involvement in Fabry 
pathophysiology. One of the major organs effected by the disease is kidney (Lee et 
al., 2012, Sanchez-Nino et al., 2011, Thomaidis et al., 2009, Germain, 2010, Park et 
al., 2008, Shayman, 2010, Shu and Shayman, 2007); alterations in peripheral neurons 
due to lysoGb3 accumulation cause pain (Choi et al., 2015, Germain, 2010); and 
vascular involvement may be exacerbated by release of the accumulated substrate 
Gb3 from leukocytes (Germain, 2010, Park et al., 2008, Shayman, 2010, Shu and 
Shayman, 2007). In contrast fibroblasts and hepatocytes are less involved (Elleder, 
2010). This hypothesis is limited because cell-lines often possess morphology 
different to that expected for the tissue of origin (Table 3-1).  
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Figure 3-15: Topology of α-gal A and B active sites are designed for ligation with α-
galactose and α-GalNAc respectively. 
The two amino acids within the 2-position recognition loop are ringed by red dotted 
lines. Serine and alanine in α-gal B accommodate the N-acetyl group of α-GalNAc. They are 
replaced by the larger residues glutamate and leucine respectively in α-gal A which reach 
the hydroxyl group of α-galactose (Adapted from Tomasic et al, 2010). 
 
 
To examine whether α-gal A activity in tissues is associated with their potential 
susceptibility to pathological processes involved in Fabry disease, various organs 
were removed from four wild type CD1 mice, processed and analysed according to 
the methods established above. The distribution across the tissues analysed was 
similar for all three lysosomal hydrolytic enzyme activities measured: total α-
galactosidase, β-galactosidase and total β-hexosaminidase (Figure 3-9 and Figure 
3-10). The spleen showed the highest activity, and the heart and skeletal muscle 
showed the lowest activities which is consistent with previous research (Ohshima et 
al., 1999). The relative percentage contribution of α-galA to total α-galactosidase 
activity does not correlate with absolute α-gal A: skeletal muscle shows the highest 
and heart, kidney and liver show the lowest percentage contributions.  The ratio of 
α-gal A activity against β-galactosidase or total β-hexosaminidase was calculated to 
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standardise results for variation in lysosomal content. Results showed with both 
standardising enzymes that the highest ratio was observed in skeletal muscle (Figure 
3-11) which is relatively unaffected by Gb3 accumulation compared with the other 
tissues assessed (Germain, 2010, Ohshima et al., 1999, Elleder, 2010). This suggests 
the ratio of α-gal A activity to either β-galactosidase or total β-hexosaminidase 
activity may be an important parameter correlated with tissue susceptibility to 
disease-associated pathological mechanisms. The results here appear to be the first 
evidence that normalisation of α-gal A activity for lysosomal content in tissues is 
necessary to assess risk of clinical involvement in Fabry disease.  
Finally α-galactosidase activity was measured in male human plasma samples from 
Fabry disease and non-Fabry disease patient controls using the competitive inhibition 
method (0.1M NAGA). Alpha-gal A activity was almost absent in Fabry disease 
patients, significantly reduced from 7nmol/hr/mL plasma in controls (Figure 3-12 and 
Figure 3-14). The normal reference range used at GOSH (London, UK), is 4.0 – 21.9 
nmol/hr/ml plasma. Alpha-gal B was significantly reduced by a small amount in Fabry 
disease patients compared with controls (Figure 3-12 and Figure 3-14), but only 22% 
of total α-galactosidase activity was due to α-gal A in disease patients compared to 
91% in controls. Since only α-gal A and total α-galactosidase activities were actually 
measured, the result for α-gal B in the control group may be relatively inaccurate.  
Furthermore there was no difference in NAGA activity between Fabry disease 
patients and controls, suggesting the observed reduction in α-gal B was an artefact 
of experimental method (Figure 3-13B).  
Together, the work in this chapter establishes the α-gal A activity assay and baselines 
the activity in a range of murine tissues, human cell-lines and plasma. Key findings 
suggest firstly that, whilst heat inactivation method is valid in human cell-lines, it is 
not valid in murine tissues; and secondly that the use of a second hydrolytic lysosomal 
enzyme against which to standardise α-gal A activity across tissue and cell types may 
provide data that correlates with involvement in the pathophysiology of Fabry 
disease. In murine tissues, the ratio of α-gal A to β-galactosidase activity was lower 
in brain, kidney and heart, relative to skeletal muscle, suggesting low ratio correlates 
with high risk of pathology in the event of α-gal A deficiency. In the human embryonic 
 125 
 
kidney 293T cell-line, the standardised ratio was significantly high compared with 
other cell-lines assessed, suggesting high ratio correlates with high risk. Possibly the 
reversal in correlation explains why there is an absence of clinical symptoms of Fabry 
disease in GLA-deficient mice. 
This chapter has shown that human T lymphoblastic Jurkat cells contain a relatively 
low baseline α-gal A activity. Looking forward, this cell-line will be used to 
overexpress GLA using a self-inactivating, third generation lentivirus vector, in order 
to explore the potential efficacy of gene delivery to treat Fabry disease. 
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Chapter 4 Efficacy of lentivirus-mediated GLA gene transfer on α-gal A 
activity in the Jurkat human cell line 
4.1 Introduction 
The work presented so far in this thesis establishes the methods for measuring α-gal 
A activity in various cell and tissue types and shows, amongst other findings, that in 
human plasma the activity of the enzyme is significantly reduced in patients with 
Fabry disease compared with controls. The underlying cause of this disorder is loss of 
function mutation affecting the single gene called GLA, leading to deficient α-gal A 
activity in nearly all cell types and extracellular space (Desnick et al., 2001). One 
potentially curative mode of treatment is delivery of the correct gene to patient cells, 
equipping them to manufacture endogenous α-gal A that may be subsequently 
trafficked to the lysosome to complete maturation and activation of the functional 
enzyme (Friedmann and Roblin, 1972, Ruiz de Garibay et al., 2013).  
Lentivirus is a retrovirus able to integrate proviral DNA into a host cell genome for 
long term stable expression. The virus can target both dividing and non-dividing cells 
with high transduction efficiency. So lentivirus offers a potent method of gene 
delivery (Sakuma et al., 2012). Previously a lentivirus vector containing the cDNA 
sequence encoding mature human α-gal A was engineered and denoted 
pRRL.cPPT.PGK-GLA.WPRE (Rajaraman, 2013). The overall aim of this chapter is 
therefore to assess the potential catalytic efficacy of the viral α-gal A manufactured 
by cells transduced by the lentivirus produced by this vector. This is important 
because the ability of any future gene therapy regime for Fabry disease depends 
upon optimisation of gene dosage for maximal clearance of storage material (Huang 
et al., 2017). 
In this chapter the structure of pRRL.cPPT.PGK-GLA.WPRE (Rajaraman, 2013) and the 
green fluorescent protein (GFP) control vector pRRL.cPPT.PGK-GFP.WPRE (UCL 
GOSICH, London, UK) were inspected using gel electrophoresis and sanger 
sequencing. Results were compared with the reference plasmid DNA sequence used 
in the Vector NTI software model built by Dr Conrad Vink (UCL GOSICH, London, UK). 
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The GLA transgene sequence included in this model was identical to that discovered 
by Bishop et al (1986) that codes for mature human α-gal A (Bishop et al., 1986). 
The human lymphoblastic leukaemia cell line Jurkat contained the lowest α-gal A 
activity of cell types surveyed in the previous chapter and consequently may be 
considered a representative model of Fabry disease patient cells. Furthermore, 
patient leukocytes are routinely used to diagnose Fabry disease (Winchester, 2014), 
and represents the final target of ex vivo HSC-directed gene therapy (Penati et al., 
2017). So Jurkat was selected as the target cell line on which to assess the functional 
effect of lentivirus-mediated GLA delivery by the structurally validated vector 
plasmids on lysosomal enzyme expression, activity and cell survival. Jurkats 
transduced with various doses of lentivirus throughout this thesis are termed as GLA-
Jurkats. 
The catalytic performance of α-gal A produced by both wild type and GLA-Jurkats are 
dependent upon the enzyme’s structure and the identity of its substrate, given 
constant physiological temperature and pH. In investigating the efficacy of lentivirus-
mediated gene delivery to overexpress α-gal A, it is therefore important to assess the 
enzymes performance through studying its kinetic characteristics. By comparing the 
kinetics of α-gal A from wild type and treated Jurkats the efficiency of gene therapy 
may be investigated (Voet et al., 2006). 
The enzymatic reaction catalysed by enzyme E on substrate S, releasing product P, is 
shown below: 
𝐸 + 𝑆 ↔ 𝐸𝑆 → 𝐸 + 𝑃 
The initial rate for this reaction (vo) is described by the Michaelis-Menten equation: 
𝑣𝑜 =
𝑣𝑚𝑎𝑥[𝑆]
𝐾𝑚 + [𝑆]
 
The equation assumes the enzyme kinetics are steady state such that the 
concentration of the enzyme-substrate intermediate (ES) is constant with respect to 
time. This assumption holds true only when there is a vast excess of substrate 
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compared with enzyme. Initial reaction rate applies until 10% of the substrate is 
hydrolysed, at which point the enzyme kinetics may be influenced by enzyme 
inactivation due to limited substrate, enzyme inhibition by the product or reversal of 
the reaction. The maximum initial rate of reaction (vmax) for a given amount of 
enzyme occurs when all active sites are occupied such that further increases in 
substrate concentration do not increase rate of product formation. Michaelis 
Constant (Km) equates to the substrate concentration at which the initial reaction rate 
is half vmax. It is therefore indicative of the affinity of the enzyme to its substrate and 
a good measure of enzymatic efficiency. The lower the Km the higher the affinity (Voet 
et al., 2006). 
So to assess the efficiency of α-gal A to hydrolyse the synthetic substrate 4MUG, 
substrate saturation was analysed by plotting reaction rate against substrate 
concentration. The Michaelis-Menten equation was applied to the data points by the 
least-square best fit function, and vmax and Km values were computed, using Prism 5 
software, by extrapolation. However, due to the difficulty of accurately determining 
Vmax as substrate concentration tends to infinity, three different linear 
transformations were applied to the substrate saturation curve measured from wild 
type Jurkat cells to confirm the Km and Vmax values measured by Prism 5. These 
transformations are described under the methods section of this chapter.  
In summary, the objectives of this chapter were to: 
 Validate the genetic structure of the third generation lentivirus vector 
plasmids pRRLSIN.cPPT.PGK-GLA.WPRE and pRRLSIN.cPPT.PGK-GFP.WPRE. 
 Harvest self-inactivating lentiviruses produced by a cell line containing the 
vector plasmids. Observe the functional effect of transduction by the viruses 
into Jurkat cells on α-gal A expression and activity. 
 Explore the kinetic characteristics of intracellular α-gal A from wild type 
Jurkats and GLA-Jurkats for any differences in their affinity to the synthetic 
substrate 4MUG. 
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4.2 Methods 
The materials and methods used were as described in Chapter 2 Materials and 
methods of this thesis with the following additions.  
As established in the previous chapter, the intracellular activity of α-gal A was 
measured in human tissues with competitive inhibition using NAGA to isolate α-
galactosidase activity of the A isoform from that of α-gal B. As in the previous chapter, 
β-galactosidase and total β-hexosaminidase activity were also measured in Jurkats as 
control lysosomal enzymes to confirm that infection of cells by engineered lentivirus 
was not causing pan-overexpression of lysosomal enzymes. In addition, intracellular 
N-acetyl galactosaminidase activity of α-gal B was also measured because of its 
residual ability to hydrolyse α-linked galactose from globo-series glycosphingolipids 
(Dean and Sweeley, 1979b). It was therefore necessary to check that over-activity of 
α-galactosidase was specifically due to increased α-gal A expression in response to 
GLA gene delivery alone, and not contributed to by α-gal B.  
 
4.2.1 Protocol for intracellular N-acetyl galactosaminidase activity 
N-acetyl galactosaminidase activity was measured in cultured Jukat cells using the 
synthetic substrate 4-methylumbelliferyl-α-N-acetyl-galactosaminide (4MU-α-
GalNAc) (Chabas et al., 1994). Sample protein (1-3mg/mL in 10μL) was mixed with 
20µL 6mM 4MU-α-GalNAc in McIlvaine citrate-phosphate pH 4.5 (MV4.5) and 
incubated for 30 minutes at 37°C. Catalysis was stopped by addition of 1.170mL 
0.25M stopping buffer (see Chapter 2: Materials and Methods), which causes 4MU 
to fluoresce at 450nm following excitation at 365nm. Fluorescence was quantified 
using the Perkin Elmer LS55 fluorimeter calibrated against a 1nmol 4MU standard 
made up to 1.2mL with 0.25M stopping buffer. Enzyme activity was reported in 
nmol/hr/mg total protein. 
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4.2.2 Substrate saturation curve methodology 
Firstly the double reciprocal of the Michaelis-Menten equation gave the Lineweaver-
Burk plot: 
1
𝑣𝑜
=
1
𝑣𝑚𝑎𝑥
+
𝐾𝑚
𝑣𝑚𝑎𝑥
(
1
[𝑆]
) 
The linear slope equals Km/vmax and the line intersects the y axis at 1/vmax. The 
limitation of this plot is that it places more weight on lower substrate concentrations 
and reaction rates which are inherently less accurate (Voet et al., 2006). The second 
transformation produces the Eadie-Hofstee plot: 
𝑣𝑜 = 𝑣𝑚𝑎𝑥 − 𝐾𝑚 (
𝑣𝑜
[𝑆]
) 
The linear slope equals –Km and the y axis intersect equals vmax, but the method 
enhances error in reaction rate (Voet et al., 2006). The last transformation produces 
the Hanes plot: 
[𝑆]
𝑣𝑜
=
𝐾𝑚
𝑣𝑚𝑎𝑥
+ (
1
𝑣𝑚𝑎𝑥
) [𝑆] 
Since substrate concentration is a factor on both x and y axes this method enhances 
inaccuracies which may occur due to pipetting errors (Voet et al., 2006). By 
comparing all three linear transformation methods with the extrapolation method 
used by Prism 5, the limitations of each method are taken into account. 
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4.3 Structural validation of lentivirus vectors containing GLA and GFP 
Plasmid DNA was extracted from cultured STBL3 bacteria transformed with either 
pRRL.cPPT.PGK-GLA.WPRE or pRRL.cPPT.PGK-GFP.WPRE lentiviral plasmids. 
Restriction digest analysis compared fragment lengths with the reference sequence 
held on VectorNTI courtesy of Dr Conrad Vink (UCL GOSICH, London, UK) (Figure 4-1). 
Positions at which HindIII was predicted to cut the GLA lentiviral plasmid are shown 
in Figure 4-1C with reference to the structure shown in Figure 4-2. In both plasmids, 
the transgenes are contained within the second largest fragments, and so the results 
suggest both are approximately correct. However, within the GLA lentiviral plasmid 
there appears to be a large insert between the 3’ LTR at position 2114 and just 
upstream of 5’ LTR at position 5455. 
To investigate the apparent insert further, the entire pRRL.cPPT.PGK-GLA.WPRE 
plasmid was sequenced. The resulting sequence was aligned with the reference 
plasmid model using Vector NTI software and mutations were identified at the 
positions shown in Figure 4-2. Additional sequencing was performed using plasmid 
DNA of pRRL.cPPT.PGK-GFP.WPRE to confirm whether the unexpected nucleotide 
differences in Figure 4-2 were also present in the GFP plasmid; results showed that 
all mutations were present except the 777 base insertion at position 5402, a finding 
consistent with the restriction digest results in Figure 4-1. 
  
 132 
 
 
Figure 4-1: Gel electrophoresis of vector plasmid fragments following restriction digest  
Gel electrophoresis of restriction digested plasmid DNA. (A) Plasmid pRRL.cPPT.PGK-
GLA.WPRE was longer than expected according to the plasmid model, as shown by the largest fragment 
in the table. (B) Plasmid pRRL.cPPT.PGK-GFP.WPRE fragment sizes approximately agree with those 
expected. (C) Table show expected fragment lengths in number of nucleotide bases. 
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Figure 4-2: Location of mutations within the vector plasmid containing the GLA transgene 
The mutations in the vector plasmids containing both GLA and GFP transgenes were found using restriction digest followed by SDS-PAGE and gene sequencing (Source 
Biosciences). The mutations in plasmid pRRL.cPPT.PGK-GLA.WPRE are shown with reference to the plasmid model. All mutations except the 777 base insertion at position 
5402 were also present in plasmid pRRL.cPPT.PGK-GFP.WPRE. 
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4.4 Functional validation of the GLA lentivirus vector in the Jurkat human cell line 
4.4.1 Dose-dependent over-expression and over-activity of α-gal A 
To find out whether the mutations within the pRRL.cPPT.PGK-GLA.WPRE and 
pRRL.cPPT.PGK-GFP.WPRE DNA sequences were functionally deleterious, the 
plasmids were transfected, together with second generation packaging plasmids 
shown in Figure 1-18, into HEK-293T cells. The cells released self-inactivating 
lentivirus which was subsequently harvested, concentrated and the viral titre was 
measured to be 2.80 x 10
7
 plaque forming units (pfu)/mL obtained in Jurkat cells using 
qPCR. In the previous chapter, the Jurkat human cell line was found to have low 
endogenous α-gal A activity relative to other human cell-types examined. Hence this 
cell line was transduced with various doses of lentivirus containing the GLA vector 
sequence within their transcriptome.  
The level of expression of α-gal A and α-gal B was examined by Western blot as shown 
in Figure 4-3. The result showed that endogenous levels of both enzymes were 
undetectable, and expression of the A isoform, detected at approximately 50kDa, 
increased dependent upon the virus dose. A-gal B expression remained undetectable 
at the expected molecular size of 47kDa up to 0.45 virus genomes (vg)/cell. To ensure 
that the primary antibodies against the endogenous human enzymes were 
functional, strong expression of α-gal A was detected in untransduced HEK-293T cells 
as expected from characterisation of enzyme activity in Chapter 3. The positive 
control used by the manufacturers of the antibody to α-gal B was the human 
epidermoid carcinoma cell line A431. The expression of α-gal B in A431 cell 
homogenate shown in Figure 4-3 confirms that antibody was detecting the enzyme 
correctly, confirming that α-gal B expression was not influenced by GLA-
overexpression. 
 
 135 
 
 
 
Figure 4-3: Western blot analysis of α-galactosidase isozymes A and B in total protein from GLA-Jurkats. 
Alpha galactosidase A (α-gal A) expression was undetectable in wild type Jurkats but increased slightly in GLA-Jurkats dependent upon viral dose. Alpha 
galactosidase B (α-gal B) expression was undetectable in both wild-type and GLA-Jurkats. To show that the anti-α-gal A and anti-α-gal B antibodies were 
functioning correctly, a moderate expression is demonstrated in 293T cells and A431 cells respectively; the cell types were used as positive control by 
manufactures. Glyceraldehyde-6-phophate dehydrogenase (GAPDH) was used a positive control of sample viability and success of the assay. The number of 
viral genomes per cell were not presented linearly because doses were not fully quantified until after the Western blot was run. 
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Next, the intracellular α-gal A activity was measured in the transduced Jurkats and 
increased linearly dependent upon the dose of viral genome, and therefore GLA copy 
number, delivered to the cells as shown in Figure 4-4. There was no relationship 
between GLA transgene dose and activity found in β-galactosidase, total β-
hexosaminidase or N-acetyl galactosaminidase (α-gal B), showing that the increase in 
α-gal A expression and activity with virus dose was specific to the enzyme and not 
due to general increase in lysosomal content or biogenesis. In order to confirm that 
GLA alone was responsible for this increase, and not another component of the 
vector plasmid, fresh Jurkats were transduced with lentivirus manufactured using the 
pRRL.cPPT.PGK-GFP.WPRE vector and containing the GFP transgene. The titre of 
lentivirus containing this transgene was measured to be 2.5x107vg/mL, obtained in 
Jurkats using qPCR. Neither the activity of α-gal A nor β-galactosidase appeared to be 
effected by virus dose as shown in Figure 4-5, suggesting it is GLA over-expression 
that is causing increase in α-gal A activity. 
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Figure 4-4: Activity of lysosomal hydrolytic enzymes α-gal A, α-gal B (on predominant substrate NAGA), β-gal and total β-hexosaminidase in GLA-Jurkats 
Jurkats were transduced with lentivirus containing GLA (2.80 x 10
7
 pfu/mL). (A) A-gal A activity increased with virus dose. Linear regression R2=0.835, 
P<0.0001. (B – D) The activity of three other lysosomal enzymes were measured and show that correlation with virus dose was not statistically significant.  
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Figure 4-5: Activity of lysosomal hydrolytic enzymes α-gal A and β-gal in Jurkats transduced 
with lentivirus containing GFP 
Jurkats were transduced with lentivirus containing the transgene encoding green 
fluorescent protein (GFP). Both α-galactosidase A (α-gal A) (A) and β-galactosidase (β-gal) 
activity (B) did not correlate with virus dose. 
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4.4.2 No evidence for GLA transgene cellular toxicity 
To see whether the efficacy of lentivirus-mediated GLA delivery to Jurkats is 
diminished by cellular toxicity, fresh jurkats were transduced with lentivirus 
manufactured using the pRRL.cPPT.PGK-GLA.WPRE vector plasmid. The viral genome 
copy number within treated cells was measured by quantitative PCR. Approximately 
3x105 GLA-Jurkats were seeded and the number of live and dead cells counted every 
24 hours for three days. This experiment was carried out in triplicate. Cell viability 
was calculated as: 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) = 100 ×
𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑎𝑛𝑑 𝑑𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠
 
The results, shown in Figure 4-6, show that the rate of cell growth over the three days 
reduced dependent upon the virus dose (P<0.001), but the cell viability remains over 
90%, suggesting that the dosage of harvested lentivirus is not toxic to Jurkats up to 
1.8vg/cells. 
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Figure 4-6: Cell growth and percentage viability in Jurkats during the first three days following transduction with lentivirus containing GLA.  
Jurkats were transduced with lentivirus containing GLA. 3x105 cells were seeded and live and dead cells were counted in triplicate every subsequent 24 
hours up to three days. The bar chart of absolute cell count shows dead cell counts superimposed on the live cell counts. Two way ANOVA found the rate of 
cell proliferation was different across virus doses (P<0.001). After 72 hours incubation there was significant difference between live cell count in GLA-Jurkats 
containing ≥ 1.3vg/cell compared with controls (P<0.01). Cell viability was calculated as the percentage of total number of cells (live and dead) that were alive 
when counted. Two way ANOVA of transformed percentage cell viability data found that change in viability over time was not altered by virus dose. 
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4.5 Kinetic properties of α-galactosidase A in wild type and treated Jurkats 
In order to evaluate the structure and catalytic mechanism of α-gal A in the Jurkat 
cell line, the relationship between the initial reaction velocity of the enzyme and the 
concentration of synthetic substrate 4MUG was examined. Since the enzyme’s kinetic 
properties are specific to the substrate it reacts with, it is important to note that the 
substrate saturation curves produced here may not hold true for the natural 
substrates to α-gal A, predominately Gb3. However, by using 4MUG to measure α-
gal A activity, any change in saturation curve parameters between wild type Jurkats 
and Jurkats transduced with GLA over a range of lentivirus doses, may suggest 
differences in the catalytic performance of the enzyme. This may have important 
implications for the design of future protocols for lentivirus-mediated delivery of 
therapeutic GLA to Fabry disease patient cells.  
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4.5.1 Michaelis Constant for intracellular α-gal A in wild type Jurkats using synthetic 
substrate 4MUG 
The activity of α-gal A was measured from sonicate of wild type Jurkats at constant 
total protein concentration (15mg/ml) over a range of final substrate concentrations 
from 0.25M to 9M. Higher final concentrations (15M and 30M) were attempted but 
4MUG precipitated from solution at 37⁰C. A series of best-fit substrate saturation 
curves were plotted through the data using least-squares non-linear regression 
analysis obeying the Michaelis-Menton equation as shown in Figure 4-7.  
Due to the asymptotic character of the curve in Figure 4-7 as reaction rate 
approaches Vmax, Km was estimated using four different methods: direct 
extrapolation of the substrate saturation curve as initial reaction rate tends to Vmax 
using Prism5 software, and three linear transformation methods for which results are 
shown in Figure 4-8 that allow direct measurement of Vmax and Km based upon the 
assumptions discussed earlier. The 95% confidence intervals for Km and Vmax 
estimated by each method was compared in Table 4-1 and show no statistical 
difference between methods for both kinetic parameters. Therefore all subsequent 
enzyme kinetic analysis in this chapter was carried out using non-linear regression 
analysis and extrapolation of substrate saturation curves to estimate Km in order to 
avoid skewing of results due to high Vmax.  
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Figure 4-7: Substrate saturation curve for endogenous α-gal A from wild type Jurkats using the flurogenic synthetic substrate 4MUG 
The data from experimental measurement (n=4) was plotted and non-linear regression analysis used to best fit to the Michaelis-Menton equation using 
Prism 5 statistical software (R2 = 0.978). Estimation of maximum reaction velocity (Vmax), and consequently Michaelis constant (Km), requires extrapolation 
of the curve as substrate concentration tends to infinity because the curve is asymptotic to Vmax. 
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Figure 4-8: Linear transformations of the substrate saturation curve for endogenous α-gal 
A from wild type Jurkats using the synthetic substrate 4MUG 
(A) Lineweaver-Burk plot showing 1/v0 versus 1/[S], R2=0.993 (P<0.0001). (B) Eadie-
Hofstee plot showing v0 verses v0/[S], R2=0.942 (P<0.0001) (C) Hanes plot showing [S]/v0 
versus [S], R2=0.987 (P<0.0001). 4MUG: 4-methylumbelliferyl-α-D-galactopyranoside; v0: 
initial reaction rate (nmol/hr); [S]: substrate concentration (mM) 
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Table 4-1: Comparison of kinetic parameters, estimated by non-linear regression analysis 
of substrate saturation curves and three linear transformation methods, for endogenous 
α-gal A from wild type Jurkats using 4MUG as substrate 
Substrate saturation curves (n=4) for α-gal A measured experimentally using 15µg total 
cell protein per assay were analysed by four methods in order to estimate kinetic parameters 
Km and Vmax for the enzyme from wild type Jurkats. The 95% confidence intervals for Km 
and Vmax are shown for the four methods. There is no statistical difference between 
methods. Km: Michaelis Constant; Vmax: maximum reaction rate; 4MUG: 4-
methylumbelliferyl-α-D-galactopyranoside 
 
Methods to analyse substrate saturation curves 
for α-gal A using 4MUG as substrate 
Wild type Jurkat 95% 
confidence intervals 
Km (mM) vmax (nmol/hr) 
Extrapolation of Michaelis-Menten equation 1.355 to 1.788 1.872 to 2.021 
Lineweaver-Burk plot 1.639 to 1.972 1.903 to 2.172 
Eadie-Hofstee plot 1.549 to 1.808 1.904 to 2.046 
Hanes plot 1.332 to 1.811 1.861 to 1.998 
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4.5.2 Over-expression of α-gal A may lead to decreased substrate affinity 
Characterisation of the kinetic properties of endogenous α-gal A from wild type 
Jurkats in the previous section was next repeated for the enzyme produced by GLA-
Jurkats following transduction with 10µL of the harvested lentivirus (titre 2.8 x 105 
pfu/mL). The volume of virus used for this experiment equated to an expected 
multiplicity of infection (MOI) of 1pfu/cell. Jurkats were transduced in duplicate and 
the resulting virus copy numbers within the GLA-Jurkats were 1.5vg/cell and 
2.0vg/cell. For both set of cells, α-gal A activity was measured (n=3) using final 
substrate concentrations from 0.25M to 9M. The resulting substrate saturation 
curves obeying the Michaelis-Menton equation are shown in Figure 4-9. Vmax and 
Km were estimated from the curves using the non-linear regression analysis and 
extrapolation method, consistent with the wild type analysis in the previous section, 
and shown in Table 4-2. Comparing the kinetics of α-gal A from wild type Jurkats and 
GLA-Jurkats shows that the Km was significantly increased in both 1.5vg/cell and 
2.0vg/cell GLA-Jurkats. Vmax of α-gal A from the GLA-Jurkats were over 30 fold higher 
than for the enzyme from wild type Jurkats.  
To check that high Vmax in GLA-Jurkats was not affecting the apparent rise in Km, 
fresh Jurkats were transduced again with virus dose of MOI 1pfu/cell resulting in GLA-
Jurkats containing 1.8vg/cell. The total protein extracted from these cells was then 
diluted so that Vmax of α-gal A would approximate to the maximum reaction rate 
observed in the wild type Jurkats. The reaction rate of α-gal A was measured for 
substrate concentrations from 0.5M to 5M and the resulting substrate saturation 
curve (n=6) is shown in Figure 4-9. The kinetic parameters, estimated by 
extrapolation, are shown in Table 4-2 and confirm that the Km of α-gal A in GLA-
Jurkats at the viral doses shown is increased, even when Vmax is reduced to wild type 
levels.  
The results so far suggest that GLA-Jurkats transduced with over 1.5 copies of viral 
GLA per cell manufacture α-gal A with a higher Km against 4MUG than wild type 
Jurkats. In other words, lentivirus-mediated overexpression of α-gal A may increase 
the concentration of 4MUG required for maximal catalytic activity and reduce the 
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apparent affinity between enzyme and substrate. This raises the question whether at 
a lower virus dose the enzyme activity may be increased without a subsequent 
decline in overall catalytic efficiency. To explore this question Jurkats were 
transduced with the lentivirus at an MOI of 0.5pfu/cell, resulting in GLA-Jurkats 
containing 0.4vg/cell. Again, the substrate saturation curve for α-gal A was measured 
using from 0.5M to 9M 4MUG. The Michaelis-Menton equation was fit to the data-
points and kinetic parameters Vmax and Km were estimated by extrapolation. The 
results are presented in Figure 4-9 and Table 4-2, and show that the Km of the enzyme 
in these cells was similar as in wild type Jurkats. 
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Figure 4-9: Substrate saturation curves for hydrolysis of 4MUG by α-gal A produced by Jurkats transduced with the GLA transgene 
The Michaelis-Menten equation was fitted to the data points using non-linear regression analysis. Reaction velocity against substrate concentration is 
shown for GLA-Jurkats containing (A) 0.4vg/cell, R2=0.972, n=3; (B) 1.5vg/cell, R2=0.994, n=3; (C) 1.8vg/cell, R2=0.957, n=6; and (D) 2.0vg/cell, R2=0.995, n=3. 
The substrate saturation curve for α-gal A from GLA-Jurkats containing 1.8 vg/cell was measured after total protein content of assay was diluted so that the 
maximum reaction velocity (Vmax) was approximately equal to Vmax estimated in wild type Jurkats. Vg/cell: virus copy number per cell; 4MUG: 4-
methylumbelliferyl-α-D-galactopyranoside 
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Table 4-2: Kinetic properties of α-gal A from wild type Jurkats and GLA-Jurkats, measured 
using 4MUG as substrate 
Michaelis constant (Km) and maximum reaction rate (Vmax) was estimated by 
extrapolation of the Michaelis-Menton equation following non-linear regression analysis of 
experimental date. Km of α-gal A for GLA-Jurkats containing 1.8 vg/cell was estimated after 
total protein content of assay was diluted so that the maximum reaction velocity (Vmax) was 
approximately equal to Vmax estimated in wild type Jurkats. Vg/cell: virus copy number per 
cell; 4MUG: 4-methylumbelliferyl-α-D-galactopyranoside 
 
 Wild type 
Jurkat 
(n=4) 
GLA-transduced Jurkats 
0.4vg/cell 
(n=3) 
1.5vg/cell 
(n=3) 
1.8vg/cell 
(n=6) 
2.0vg/cell 
(n=3) 
Km (mM) 
1.572 +/- 
0.107 
1.527 +/- 
0.130 
2.429 +/- 
0.121 
2.531 +/- 
0.287 
2.305 +/- 
0.102 
Vmax 
(nmol/hr) 
1.946 +/- 
0.037 
8.31 +/- 0.23 67.3 +/- 1.12 1.170 +/- 
0.064 
82.1 +/- 1.20 
R2 0.978 0.972 0.994 0.957 0.995 
 
 
Figure 4-10: Michaelis Constants for α-gal A from wild type and GLA-Jurkats using 4MUG as 
substrate 
This graph compares the Michaelis constants (Km) estimated for the hydrolysis of the 
florigenic substrate 4MUG by α-gal A produced from wild type (untreated) Jurkats and GLA-
Jurkats containing a range of virus genomes per cell (vg/cell). The Km of 4MUG to α-gal A 
manufactured by GLA-Jurkats transduced with a low virus dose (0.4vg/cell) was the same as 
α-gal A from wild type Jurkats, but Km significantly increased in α-gal A produced by GLA-
Jurkats transduced with high virus doses of 1.5 and 2.0 vg/cell (P<0.01). Km of α-gal A for 
GLA-Jurkats containing 1.8 vg/cell was estimated after total protein content of assay was 
diluted so that the maximum reaction velocity (Vmax) was approximately equal to Vmax 
estimated in wild type Jurkats. This was to ensure that significant differences were not due 
to large changes in Vmax. The Km of α-gal A using 4MUG was still significantly higher than 
wildtype (P<0.05). 4MUG: 4-methylumbelliferyl-α-D-galactopyranoside.  
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4.6 Conclusions 
The overall aim of this chapter was to investigate the potential catalytic efficacy of 
virus-mediated overexpression of α-gal A by utilising a previously engineered 
lentivirus vector plasmid (Rajaraman, 2013) containing the complementary DNA 
sequence of GLA which encodes human mature α-gal A (Bishop et al., 1986). As both 
a negative and positive control for the work in this chapter, an identical lentivirus 
vector plasmid containing the GFP gene for green fluorescence protein in place of 
GLA was acquired from Dr Conrad Vink (UCL GOSICH, London, UK). Genetic 
verification of the structures of both vectors by gel electrophoresis and DNA 
sequencing (Source Biosciences, Nottingham, UK) revealed numerous minor 
deviations from the expected sequences (Rajaraman, 2013), but none were within 
the transgene region of the plasmids (Figure 4-2).  
Successful transfection of 293T cells by the vector plasmids, and subsequent titration 
of lentiviruses containing the GLA transgene using Jurkat cells (2.80 x 10
7
 vg/mL), 
confirmed that the genetic anomalies in Figure 4-2 did not interfere with the 
functionality of either vector. Jurkats, showed in the previous chapter to have a 
relatively low endogenous α-gal A activity, also showed increase in α-gal A expression 
(Figure 4-3) and activity (Figure 4-4), dependent upon the dose of lentiviral-GLA they 
contained. Furthermore, there was no evidence of cell toxicity resulting from 
lentivirus transduction or α-gal A overexpression in Jurkats (Figure 4-6).  
These results suggest that the transgene was successfully translated by Jurkats into a 
precursor enzyme that matures into fully activated α-gal A within the lysosomal 
compartment. The process of cellular sorting of α-gal A for the lysosome is manose-
6-phosphate-dependent, so the results shown here suggest the overexpressed 
enzyme is being appropriately modified post-translation within wild type Jurkats and 
GLA-Jurkats. 
Investigations into the kinetic properties of α-gal A, both endogenous native to 
Jurkats and following lentivirus-mediated overexpression in Jurkats, revealed further 
important observations that qualify the above conclusions. First the Km value in wild 
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type Jurkats for the hydrolysis of the synthetic florigenic substrate 4MUG by α-gal A 
measured here (Km = 1.6mM) was compared with that seen in various human tissues 
(Km range from 1.6 to 2.9mM) reported in the literature and summarised in Table 
4-2. A relatively low Km suggests the enzyme possesses high affinity with 4MUG and 
operates at maximal catalytic efficiency at low substrate concentrations.  Table 4-3 
shows that the Km derived from Jurkats is similar to that found in human tissues, 
suggesting that α-gal A from the various sources are of similar catalytic effectiveness 
and three-dimensional configuration. This gives confidence that the results herein 
are comparable with those reported by others. 
Table 4-3: Comparison of Michaelis Constant estimated in wild type Jurkats, various human 
tissues and enzyme replacement therapies 
The Km values given for human tissues and ERT are taken from previous research using 
purified α-gal A. ERT uses recombinant α-gal A produced in Chinese hamster ovary (CHO) 
cells (Replagal, Shire Pharmaceuticals, UK), and human foreskin fibroblasts (Fabrazyme, 
Sanofi Genzyme, USA). Km: Michaelis Constant; ERT: Enzyme Replacement Therapy. 
 
Human 
cells or 
tissue 
Jurkat Plasma Spleen Liver Placenta ERT 
Replagal Fabrazyme 
Km 
(mM) 
1.6 1.9 2.5; 2.0 2.9 1.6 2.0 2.0; 4.0 
Refs. -- 
Desnick 
et al, 
1979 
Desnick 
et al, 
1979; 
Bishop 
& 
Desnick, 
1981 
Dean & 
Sweeley, 
1979 
Kusiak 
et al, 
1978 
Sugawara 
et al, 
2009 
Lee et al, 
2003 
Secondly the enzyme kinetics of overexpressed α-gal A within GLA-Jurkats, which had 
been transduced with lentivirus containing the GLA transgene, suggested that the Km 
of the enzyme appeared to increase with transgene copy number. At a low virus dose 
(0.4vg/cell) the enzyme made by GLA-Jurkats showed equal affinity to the 4MUG 
substrate as that made by untreated wild type Jurkats, but at high virus doses 
(>1.5vg/cell), the enzyme produced in Jurkats has significantly higher Km, suggesting 
lower affinity to 4MUG. This observation was not an artefact of increased Vmax. 
Indeed, reducing total protein concentration so that the Vmax of α-gal A from GLA-
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Jurkats (1.8vg/cell) was reduced to approximately the same as that from wild type 
Jurkats, resulted in even higher Km (Figure 4-10). A possible reason for this is that 
endogenous wild type α-gal A may be diluted out from the total protein since the 
majority of the enzyme will be manufactured from the transgene above 1vg/cell. 
The Km of α-gal A manufactured from the transgene are consistent with the values 
reported in previous research reported by (Meghdari et al., 2015).  The authors 
measured the kinetic properties of α-gal A purified from Pichia pastoris following 
electroporation of the yeast with plasmid containing the complementary DNA 
sequence, as reported by Bishop et al., (1986), that encodes mature human α-gal A.  
The sequence was confirmed as identical to the transgene used in the present thesis 
as explained earlier in this chapter. The Km of human α-gal A was 2.44 +/- 0.44 mM 
which agrees well with the Km of α-gal A manufactured by the transgene in Table 4-2. 
Meghdari et al, 2015 do not report the human GLA copy number and, since the 
authors used enzyme purified by double affinity chromatography and reported rate 
of hydrolysis of 4MUG in mmol/hr/mg, it is not possible to compare reaction rates or 
gene dosage. 
So in conclusion, lentivirus-mediated overexpression of α-gal A within Jurkats leads 
to virus dose-dependent increase in enzyme activity, suggesting appropriate post-
translational modifications and transportation to the lysosome. However, our kinetic 
studies show that the enzyme produced may have lower substrate affinity at high 
virus doses (from 1.5vg/cell upwards). These findings point to an important need to 
optimise virus dose in order to deliver maximum therapeutic benefit to Fabry disease 
patients. 
Patterns of glycosylation of aspartate residues on α-gal A varies considerably 
between tissue types in humans (Hrebicek and Ledvinova, 2010) and other organisms 
including the yeast Pichia pastoris (Chen et al., 2000). The relative distribution of 
complex and high-mannose oligosaccharides attached to the enzyme are important 
for enzyme stability (Ioannou et al., 1998, Matsuura et al., 1998), uptake by cells 
(Bekri, 2006), half-life within humans (Desnick et al., 1979) and cellular trafficking to 
the lysosome for catalytic activation (Kornfeld, 1986). The variation in Km across 
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human tissue types (Table 4-3) may be in part due to differences in glycosylation 
(Hrebicek and Ledvinova, 2010). A similar variation in Km is seen here in Jurkats 
following lentivirus-mediated overexpression of α-gal A (Table 4-2). It is possible that 
increase in Km with increasing transgene dose may be due to cellular congestion 
leading to impaired post-translational modification and cellular sorting to the 
lysosome for complete enzyme activation (Lodish et al., 2000).  
Two points limit the conclusions. Firstly Jurkats, as an immortalised cell line, are 
pseudo-diploid (ATCC, 2016). In calculations of viral transgene dose per cell it was 
assumed that on average the cells were diploid. Secondly, in order to compare GLA-
Jurkats (1.8vg/cell) with wild type Jurkats after adjusting Vmax to wild type velocity, 
total protein to assay GLA-Jurkat was diluted from 15µg, used to measure 
intracellular α-gal A activity throughout this thesis, to 0.3µg. This total protein 
content was outside the range of assay linearity confirmed in chapter 3, but results 
indicate there was sufficient α-gal A to give similar reaction rates, given the same 
substrate concentration, as in wild type Jurkats. In order to confirm the kinetic 
parameters measured for GLA-Jurkats at 1.8vg/cell it would be important to check 
linearity at the lower total protein level from these cells. However there was 
insufficient protein after completion of substrate saturation experiments to check 
this.  
Looking ahead, on translation α-gal A that evades capture by the golgi apparatus will 
be secreted, but may be recaptured by manose-6-phosphate receptors expressed on 
the plasma membrane, as long as the enzyme underwent the appropriate post-
translational modifications before release (Lodish et al., 2000). So the results here 
raise the question whether any α-gal A is released from treated cells following 
lentivirus-mediated overexpression, and whether the released enzyme may be taken 
up by untreated cells. The process of release and uptake of lysosomal enzymes is 
termed cross-correction and is vital for the therapeutic efficacy of gene delivery to 
treat Fabry disease. These important research questions will be addressed in the next 
chapter. 
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Chapter 5 Cross-correction in the Jurkat human cell-line and the effect 
of inhibiting mitochondrial complex I 
5.1 Introduction 
The previous chapter of this thesis demonstrates the ability of human cells to 
overexpress α-gal A following transduction by a lentivirus vector containing GLA. 
Fabry disease is a multi-systemic disorder resulting from accumulation of Gb3 in 
many tissue types including vasculature, renal cell-types and peripheral neurons 
(Desnick et al., 2001). From a therapeutic perspective, it is impractical to consider 
transduction of all cells in order to increase their intracellular α-gal A activity and 
degrade Gb3 stores. This raises the question whether there is a mechanism by which 
the therapeutic benefit of gene delivery may be extended from transduced to 
untransduced cells  
Landmark experiments in 1968 by Elizabeth Neufeld and colleagues were the first to 
demonstrate that a functional mechanism does exist by which lysosomal enzyme may 
transfer between cells with and without a functional allele of the enzyme-coding 
gene (Fratantoni et al., 1968). Cultured fibroblasts from patients with Hurlers and 
Hunters syndromes were used. These syndromes are genetically distinct lysosomal 
storage disorders effecting mucopolysaccharide (MPS) degradation and fibroblasts 
from patients accumulate intracellular MPS more than healthy cells. Co-culture of 
fibroblasts from either Hunters or Hurlers patients with healthy control fibroblasts 
resulted in reduction of rates of MPS accumulation within the disease cells to levels 
observed in the healthy cells. Even co-culture of fibroblasts from Hunters and Hurlers 
patients resulted in similar correction of MPS accumulation. It took two days of co-
culture with healthy cells for accumulated stores of MPS within disease fibroblasts to 
degrade by 75% (Fratantoni et al., 1968). These results suggest that the specific 
enzyme deficit in diseased cells may be corrected by being grown in close proximity 
to cells with normal levels of that enzyme  
Was the enzymatic correction observed by Neufeld and colleagues due to cell-cell 
fusion followed by genetic transfer of alleles, transfer of cytoplasmic material, or 
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transfer of functional enzyme through the culture medium? In 1974 Cantz and Kresse 
confirmed that it was the latter mechanism that was at work. Sandhoff disease is a 
lysosomal storage disorder of glycosphingolipid catalysis due to defective β-N-
acetylhexosaminidase. Cells from patients with Sandhoff disease accumulate 
substrates including glycoaminoglycans. Cantz and Kresse extracted functional 
enzyme from urine and homogenized fibroblasts from healthy individuals. They 
found that adding the enzyme to the growth media of cultured skin fibroblasts from 
patients with Sandhoff disease resulted in dose dependent depletion of intracellular 
glycoaminoglycans (Cantz and Kresse, 1974). Similarly O’Brien and colleagues used α-
acetylglucoaminidase isolated from human placenta to correct the metabolic deficit 
in MPS catabolism observed in cultured skin fibroblasts from Sanfilippo type B 
patients. Remarkably, purified enzyme added to culture media of the fibroblasts to 
give only 2% to 5% of normal intracellular activity was sufficient to clear 42% to 70% 
of stored keratin sulphate (O'Brien et al., 1970). Together these results show that 
only a small amount of transfer of functional enzyme between healthy and diseased 
cells in co-culture is necessary to significantly reduce substrate storage in the disease 
cells. Across the lysosomal storage diseases generally it is estimated that between 1% 
and 5% of normal intracellular activity is sufficient to correct the metabolic deficit in 
cells missing an enzyme (Desnick and Schuchman, 2012). 
The transfer of specific proteins from replete to deficient cells has been termed 
metabolic cooperativity or cross-correction and depends upon a cells ability to 
secrete and take-up functional lysosomal enzymes (Medin et al., 1996, Takenaka et 
al., 1999a, Takenaka et al., 1999b, Yoshimitsu et al., 2007). This process is illustrated 
in Figure 5-1 and has been demonstrated in skin fibroblasts and immortalised B cells 
from Fabry disease patients following transduction of cells in culture with 
amphotropic retrovirus containing the human α-gal A gene. The treated patient 
fibroblasts showed ten-fold increase in intracellular α-gal A activity in patient 
fibroblasts above the activity observed in healthy control fibroblasts. In transformed 
patient B cells however, treatment only increased the enzyme activity to a similar 
level as seen in healthy control cells. Media collected from corrected patient 
fibroblasts and B cells showed ten-fold increase, and 50% increase respectively, in 
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extracellular α-gal A activity compared to media from untreated control cells, after 
16 hours cell culture (Medin et al., 1996). The difference in secretion may reflect the 
difference in transduction efficiency of these cell types. 
 
 
Figure 5-1: A schematic showing the process of cross correction of untreated cells by cells 
containing a therapeutic gene coding for a deficient enzyme following gene therapy 
A therapeutic virus inserts a correct copy of a gene which overexpresses a functional 
enzyme which is otherwise missing into a patient’s cells. Subsequently these cells act as 
enzyme donors to neighbouring untreated cells which receive the enzyme through a process 
of release and uptake. In the case of α-gal A, most cell-types take-up the enzyme via a 
manose-6-phosphate dependent pathway. 
Uptake of functional α-gal A by untreated Fabry disease patient cells was assessed 
using culture media collected from the α-gal A-retrovirus-producer cell line. Patient 
fibroblasts incubated with this media for 3 hours showed manose 6 phosphate-
dependent uptake of functional α-gal A. Similarly uptake was seen by patient B cells 
(Medin et al., 1996). From these results it is unclear whether some of the increase in 
enzyme activity in the untreated patient cells was due to transduction by virus in the 
virus-producer cell media rather than uptake of exogenous functional α-gal A alone. 
None-the-less this early work by Medin and colleagues was encouraging because it 
suggests that the benefit of functional enzyme expression by gene therapy may 
extend far beyond treated cells. This attribute of cross correction is essential for the 
therapeutic efficacy of gene therapy to treat multisystemic disorders such a Fabry 
disease.  
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As discussed in Chapter 1 Introduction, Fabry disease is a lysosomal storage disorder 
(Kolter and Sandhoff, 1999, Sweeley and Klionsky, 1963). The lysosome controls 
metabolic homeostasis (Settembre et al., 2013). Storage of Gb3 within lysosomes 
would therefore be expected to interrupt cellular response to energy demand and 
supply (Machann et al., 2011, Palecek et al., 2010). Central to this is the 
mitochondrion (Heales et al., 1996, Osellame et al., 2012). Fabry disease potentially 
disrupts mitochondrial function in a number of ways: impaired mitophagy (Liebau et 
al., 2013, Nelson et al., 2014), oxidative stress (Shen et al., 2008, Chimenti et al., 2015, 
Lenaz et al., 2002), and membrane lipid imbalance (Das and Naim, 2009). Consistent 
with this, Lücke et al (2004) observed reduction in the activity of respiratory chain 
complexes I, IV and V in skin fibroblasts from Fabry disease patients compared to 
controls (Lucke et al., 2004). 
This raises a research question as to how damage to the mitochondrial respiratory 
chain in Fabry disease may affect the ability of cells to release and uptake functional 
α-gal A. The respiratory chain comprises five metaloenzyme complexes that are 
integral to the inner-mitochondrial membrane as shown in Figure 5-2. This system 
transfers high energy electrons from NADH to oxygen, releasing energy in a step-wise 
process which is harnessed to actively pump protons across the inner-mitochondrial 
membrane from the matrix, thereby creating an electrochemical proton gradient. 
Complex V is called ATP synthase and is not involved in electron transport but utilises 
passive translocation of protons back to the mitochondrial matrix to phosphorylate 
ADP (Osellame et al., 2012). 
Metabolic control theory has shown that the majority of control over oxygen 
consumption in mitochondria from rat heart and brain was with complex I (Rossignol 
et al., 2000). The importance of complex I in metabolic flux control was also 
supported by similar research in synaptic mitochondria (Davey et al., 1998, Telford et 
al., 2009). 
Complex I, called NADH-ubiquinone oxido-reductase, is a vital component of the 
respiratory chain. Firstly it recycles NADH through oxidation back to NAD+ which 
continually feeds the tricarboxylic acid cycle (TCA cycle) within the mitochondrial 
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matrix. Secondly, the liberated electron pair from NADH passes down the electron 
energy gradient, via the flavin mononucleotide (FMN) prosthetic group coupled to a 
chain of 7 iron-sulphur clusters, to reduce bound ubiquinone (Q10) to ubiquinol 
(Q10H2). Q10H2 then transports the electron pair to complex III and the rest of the 
respiratory chain for final delivery to oxygen, thereby maintaining the electron 
energy gradient. Finally the free energy released from the electrons by complex I is 
used to pump four protons across the inner mitochondrial membrane from the 
matrix, allowing oxidative phosphorylation to proceed (Hirst and Roessler, 2016). 
So, to address the research question raised in this chapter the following objectives 
were set: 
 Examine ability of transduced Jurkat cells to secret functional enzyme into 
the surrounding culture media. This culture media taken from GLA-Jurkats is 
termed “donor media”. 
 Examine ability of wild type Jurkat cells that are naive to treatment to take 
up exogenous enzyme from their surrounding media which comprises 75% 
donor media. 
 Treat Jurkat cells with rotenone, to assess whether this complex I inhibitor 
effects transduction efficiency, α-gal A secretion and uptake by target cells. 
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Figure 5-2: Mitochondrial respiratory chain 
The respiratory chain comprises four metaloenzyme complexes that are integral to the inner mitochondrial membrane. Together they are responsible 
for step-wise transfer of high energy electrons from NADH, or succinate, to oxygen to form water. The energy released by complexes I, III and IV is used to 
pump protons from the mitochondrial matrix into the inter-membrane space, thus creating an electrochemical proton gradient across the inner membrane (-
∆Ψm). ATP synthase is the fifth respiratory chain complex and contains a transmembrane channel (F0) through which protons passively return down the 
gradient to the mitochondrial matrix. The flow of protons within the channel causes F0 to rotate relative to a catalytic domain (F1), causing conformational 
change in the binding site of F1 leading to phosphorylation of ADP. This process is essential to aerobic cellular respiration and produces a rich harvest of energy 
in the form of ATP. CI, CII, CIII, CIV and CV represent Complex I (NADH-ubiquinone oxidoreductase), II (succinate-ubiquinone oxidoreductase), III (ubiquinol-
cytochrome C oxidoreductase), IV (cytochrome C oxidase) and V (ATP synthase) respectively. Image sourced from (Osellame et al., 2012).  
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5.2 Methods  
In secretion studies, transduced Jurkats were washed three times in PBS to remove 
any extracellular virus particles. Then cells were placed in fresh complete RPMI media 
for up to three days. Media samples were removed after zero, two and three days 
and centrifuged at 3,000rpm for 5 minutes. The supernatant was then collected and 
α-gal A and total β hex activities were measured in the supernatant from GLA-Jurkats 
using the supernatant assay described in Chapter 2 Materials and Methods. Since 
complete RMPI culture media made up half the reaction volume in the α-gal A assay, 
it was necessary to correct the measured activity for both auto-fluorescence and 
quenching effects of phenol red and foetal bovine serum. This was achieved for each 
sample of culture media using the 1nmol 4MU standards and blanks shown in Table 
5-1. 
Table 5-1: Content of standards and blanks used to measure alpha galactosidase in 
supernatant 
 Standard 
blank 
Standard Sample 
blank 
Sample  
Substrate, standard 
or water 
200µL H2O 
200µL standard 
(contains 1nmol 4MU) 
100µL 
substrate 
100µL 
substrate 
Culture media from 
GLA-Jurkats 
(supernatant) 
100µL 100µL 
100µL 
(added after 
incubation 
period) 
100µL 
Stopping buffer 
(1M Glycine-
NaOH) 
900µL 900µL 
1mL (added after the 
incubation period) 
Note 
Corrected Standard = Standard – 
standard blank 
--- --- 
 
Both sample and sample blank Eppendorf tubes were incubated at 300C for 2 hours 
and stopping buffer added to terminate hydrolysis. Sample was then added to the 
sample blank to take account of both auto-fluorescence of phenol red and foetal 
bovine serum within the culture media and their possible quenching effect on 
product fluorescence. The difference between standard and standard blank took 
 161 
 
account of quenching and auto-fluorescence by culture media on the fluorescence 
emitted by 1nmol 4MU standard.  
The collected donor media at the two-day point was mixed 3 in 4 with fresh RPMI 
media and then used to culture wild type Jurkats for two days. This ratio was 
consistent with that used by Neufeld’s laboratory (Fratantoni et al., 1968). To take 
account of degradation of over-expressed enzyme in the growth media over this 
period, a sample of the mixed donor culture media was also incubated in the same 
way without cells as a control. The reduction in α-gal A activity measured in the 
control mixture was subtracted from the reduction measured in the similar mixture 
exposed to wild type Jurkats to quantify the enzyme uptake from the culture media. 
Intracellular activity within receiver cells was measured and compared with enzyme 
activity in untreated wild-type Jurkats. 
To examine the effect of complex I inhibition on lentivirus-mediated transduction of 
Jurkats, and secretion and reuptake of overexpressed α-gal A, a rotenone (200µM) 
solution was prepared in absolute ethanol according to Aylett et al, 2013. The effect 
of 5µl rotenone solution on complex 1 and citrate synthase activities in 5x105 cells 
wild type Jurkats suspended in 10mL complete RPMI (final rotenone concentration 
100nM) was measured in the cells following two days incubation. Control cells were 
grown in the same volume of media with 5µl absolute ethanol to isolate the effect of 
rotenone alone on mitochondrial function. After 24 hours incubation at 37oC the cells 
were harvested (Aylett et al., 2013). 
In measuring complex I activity in the laboratory, potassium cyanide is used to inhibit 
complex IV, thereby preventing re-oxidation of ubiquinol to ubiquinone which would 
otherwise counteract the inhibitory effect of rotenone. 
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5.3 Secretion of alpha gal A by Jurkats overexpressing GLA 
Since the plasma α-gal A assay (Chapter 2 Methods and Materials) requires a 
relatively large volume of culture media (100μl), it was necessary to find out whether 
phenol-red and foetal bovine serum in complete RPMI interfered with fluorescence 
emitted from the hydrolysed product. The activity of α-gal A was measured in fresh 
culture media, and the effects of quenching and auto-fluorescence are shown in 
Table 5-2.  
 
Table 5-2: Baseline alpha-gal A fluorescence in culture media 
Fresh complete RPMI culture media was assayed according to the protocol for α-gal A 
activity in supernatant. Comparing the difference between the standard with and without 
media shows that there was a small amount of quenching of fluorescence produced by 1nmol 
standard. The standard blank shows there is slight auto-fluorescence in complete RPMI, 
probably due to the phenol red and foetal bovine serum within the culture media. 
 Standard 
without media 
Standard 
blank 
Substrate 
blank 
Standard Sample 
Fluoresence 
due to α-gal A 
392 1 14 383 15 
 
The baseline activity of α-gal A in complete RPMI was calculated from the data in 
Table 5-2 to be very low at 0.01nmol/hr/ml media, suggesting that the effect of cross 
correction should be detectable in culture media. The interference identified in Table 
5-2 was taken into account in subsequent experiments by continuing to use separate 
standards, standard blanks and substrate blanks for every supernatant sample 
analysed in this chapter.  
This method was then used to see whether GLA-Jurkats were able to secret 
overexpressed α-gal A into the surrounding media. A fresh harvest of lentivirus 
containing the GLA transgene was again prepared and titred by transduction into 
Jurkats cells and measured to be 3.68 x 107pfu/mL using qPCR. The washed GLA-
Jurkats, which ranged in transgene expression up to 0.8vg/cell were then grown in 
fresh media. The results in Figure 5-3 show that α-gal A activity increased in the 
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culture medium collected from the GLA-Jurkats compared with the baseline activity 
in complete RPMI. The increase in activity in the media was dependent upon both 
the intracellular α-gal A activity, and therefore GLA copy number, in the GLA-Jurkats 
and length of time in culture. There was a small increase in activity in supernatant 
from cells with increasing virus copy number, and this may be due to cell damage 
resulting in leakage of enzyme following centrifugation. 
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Figure 5-3: Secretion of α-gal A by GLA Jurkats 
A-gal A (A) and total β-hexosaminidase (B) activity was measured in the culture media 
supernatant collected after zero, two and three days incubation at 37oC with GLA-Jurkats 
containing between zero and 0.8vg/cells. The extracellular activity in supernatant is plotted 
against intracellular activity within the GLA-Jurkats. Secretion of α-gal A activity into the 
surrounding media by GLA-Jurkats increased with both intracellular activity and duration of 
incubation. Linear regression found that at day 0, R2=0.607 (P<0.001); day 2, R2=0.786 
(P<0.0001); and day 3, R2=0.796 (P<0.0001). Total-β hex in supernatant did not change with 
either incubation time or intracellular α-gal A activity within the GLA-Jurkats, suggesting 
secretion was not non-specific due to cell damage following transduction.  
  
A 
B 
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5.4 Uptake of α-gal A by wild type Jurkats 
Next, supernatant was collected from the GLA Jurkats after two days incubation. This 
time period was chosen because previous research found that lentivirus-mediated 
overexpression of α-gal A in Fabry disease patient fibroblasts resulted in clearance of 
stored Gb3 two days post-transduction (D'Costa et al., 2003). Figure 5-3 confirmed 
that two days incubation was sufficient for secretion of functional enzyme from GLA 
Jurkats to take place. The supernatant was mixed 3:1 with fresh complete RPMI to 
provide sufficient nutrients for cell growth. This is consistent with the method used 
by Neufeld and colleagues to demonstrate cross correction between fibroblasts 
taken from Hunters syndrome and from Hurlers syndrome patients (Fratantoni et al., 
1968). The mixed media was then incubated with wild type Jurkats, termed receiver 
cells, for two days. Results in Figure 5-4 show that intracellular α-gal A activity 
increased with initial activity within the culture media, but intracellular total β-hex 
activity was unchanged. Quantitative PCR confirmed no contamination of the wild 
type Jurkats with lentivirus, suggesting that the increase in α-gal A activity observed 
was not due to virus contamination in the receiver cells leading to GLA 
overexpression. These results possibly suggest uptake of functional enzyme by the 
wild type Jurkats from the culture media.  
Consistent with this, extracellular α-gal A activity decreased within the culture media 
following incubation with wild type Jurkats for two days, as shown in Figure 5-5A. 
During this incubation period, considerable degradation in enzyme activity within the 
culture media was observed (Figure 5-5B). However, after taking degradation into 
account there was slight but significant enzyme uptake from the culture media 
(Figure 5-6). 
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Figure 5-4: Uptake of alpha-galactosidase A and total beta hexosaminidase activity by wild 
type Jurkats from donor media overexpressing alpha galactosidase A 
The donor media comprised one part fresh complete RPMI and three parts culture 
media taken from donor cells (GLA-Jurkats) after two days culture. The receiver cells (wild 
type Jurkats) were incubated for two days in the donor media. Intracellular α-galactosidase 
A (A) and total β-hexosaminidase (B) activity was plotted against the initial (day zero) α-gal A 
activity in donor media. There is slight but significant increase in α-gal A activity in the 
receiver cells with increasing donor media activity, linear regression R2=0.450 (P<0.01), but 
no change in total β-hex activity. 
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Figure 5-5: Reduction in α-gal A activity in media during 48 hours incubation with and 
without treatment-naive Jurkats present 
A: Alpha-gal A activity in the donor media was measured before and after it was 
incubated with wild type Jurkats for two days. The graph presents the drop in activity 
observed. B: The drop in α-gal A activity in donor media measured before and activity 
incubation without cells present. This shows there is considerable degradation over two days 
incubation tending towards the baseline enzyme activity. The rate of degradation increases 
with initial enzyme activity in the donor media. 
A 
B 
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Figure 5-6: Uptake from donor media by wild type Jurkat (receiver cells) 
A. Reduction in α-gal A activity in donor media over the incubation period was plotted 
against the initial α-gal A activity in the donor media before incubation. The red line shows 
the reduction in enzyme activity in the presence of wild type Jurkats (R2=0.998); the blue line 
shows the degradation in enzyme activity over 48 hours incubation in the absence of Jurkats 
(R2=0.997). There was a statistically significant difference between the slopes of the lines 
(P<0.0001), showing that the reduction in enzyme activity in media with cells is greater than 
without cells. B. The difference between red and blue data points in A equates to reduction 
in α-gal A activity in the culture media due to uptake of the enzyme by wild type Jurkats 
(R2=0.917).  
 
A 
B 
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5.5 Effect of rotenone on cross-correction in Jurkats 
Next, we sought to model the metabolic deficit observed in cultured skin fibroblasts 
from patients with Fabry disease, in order to observe its possible effect on the 
efficacy of lentivirus-mediated delivery of GLA to human cells and subsequent 
secretion and uptake of overexpressed α-gal A. Rotenone inhibits the mitochondrial 
respiratory chain complex I that oxidises NADH and reduces ubiquinone. Inhibition of 
complex I leads to ATP deficiency and oxidative stress because electrons transported 
by NADH cannot be delivered to oxygen. Therefore rotenone was used in a series of 
experiments to model ATP deficiency and oxidative stress in Jurkat cells.  
Since the activity of complex I in whole cell homogenate will vary with mitochondrial 
content between cells, the activity of a second mitochondrial enzyme, citrate 
synthase, was analysed in Jurkats treated with and without rotenone for 24 hours. 
This treatment duration was based upon previous studies which used rotenone to 
inhibit Complex I (Aylett et al., 2013). Citrate synthase is a mitochondrial matrix 
enzyme that catalyses the rate limiting step in the TCA cycle. This enzyme speeds up 
the condensation reaction between acetyl coenzyme A, derived from pyruvate, 
amino acids or fatty acids, and oxaloacetate formed through the TCA cycle, to form 
citrate. Citrate synthase therefore enables continual hydrolysis of metabolic fuels.  
Figure 5-7 shows the effect of 24 hours treatment with 100nM rotenone on complex 
I activity within Jurkats. Citrate synthase activity was also measured to normalise 
complex I activity for variation in mitochondrial content in wild type Jurkats.  
  
 170 
 
 
U
nt
re
at
ed
R
ot
en
on
e
0
5
10
15
20
C
o
m
p
le
x
 I
 a
c
ti
v
it
y
(n
m
o
l/
m
in
/m
g
)
 
U
nt
re
at
ed
R
ot
en
on
e
0
50
100
150
200
C
it
ra
te
 s
y
n
th
a
s
e
 a
c
ti
v
it
y
(n
m
o
l/
m
in
/m
g
 p
ro
te
in
)
 
U
nt
re
at
ed
R
ot
en
on
e
0.00
0.05
0.10
0.15
R
a
ti
o
 o
f 
c
o
m
p
le
x
 I
 t
o
 c
it
ra
te
s
y
n
th
a
s
e
 a
c
ti
v
it
y
 
Figure 5-7: The effect of rotenone on mitochondrial complex I activity in wild type Jurkats 
100nM rotenone halved complex I activity compared with untreated controls (A). 
There was no effect on citrate synthase activity (B). The ratio of complex I activity to citrate 
synthase activity takes account of variation in mitochondrial content between treated and 
untreated cells and shows a significant reduction in normalised complex I activity (P<0.0001) 
(C). n=3 
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B 
C 
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ns 
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5.5.1 Effect of rotenone on lentivirus-mediated GLA transduction efficiency 
To examine the effect of mitochondrial complex I inhibition on the ability of human 
cells to be transduced by the lentivirus vector containing GLA, 3x105 wild type Jurkats 
were incubated with virus (3.68 x 107pfu/mL, volumes from 0 - 5µL) with or without 
100nM rotenone (final concentration in cell suspension) for 24 hours at 37°C. The 
cells were harvested and intracellular activity of α-gal A measured. Figure 5-8 shows 
there was no effect of 100nM rotenone on α-gal A activity compared with activity 
observed in untreated cells. Total β-hexosaminidase activity was also measured in 
the harvested cells and showed no change dependent on either virus load or 
rotenone treatment (Figure 5-9).  
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Figure 5-8: Efficiency of lentivirus-mediated overexpression of GLA with rotenone (n=3) 
Human Jurkats were transduced with zero to 5µL lentivirus containing GLA (3.68 x 
107viral particles per mL) in triplicate, with or without 100nM rotenone. (A) Shows α-gal A 
activity in cells following transduction with a range of virus volumes. Transduction with or 
without rotenone results in dose-dependent increase in the enzyme activity. (B) Area under 
the curve was calculated from the data and shows that inhibition of complex I does not affect 
the efficiency of lentivirus to transduce Jurkat cells. 
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Figure 5-9: Effect of rotenone treatment on total β-hex activity in GLA-Jurkats (n=3) 
There is no significant correlation between virus dose and enzyme activity in GLA-
Jurkats with and without rotenone treatment. Using student t test to compare untreated and 
treated groups shows there is no statistical difference in activity relating to rotenone 
treatment. 
  
 174 
 
5.5.2 Effect of rotenone on secretion of α-gal A by Jurkats overexpressing GLA. 
The GLA-Jurkats that were transduced in the absence of rotenone in the previous 
experiment were washed three times in PBS to remove free lentivirus and ethanol. 
The donor cells were then re-suspended in fresh complete RPMI with or without 
100nM or 50nM rotenone added. Culture media without rotenone treatment, was 
spiked with the same volume of absolute ethanol as the treated cells. The suspended 
cells were incubated for 24 hours at 37°C, after which the α-gal A activity within the 
media was measured.  
The control in Figure 5-10 shows that, consistent with the previous experiments in 
Section 5.3, the secretion of intracellular enzyme into the surrounding media 
increased proportional to GLA overexpression within the donor cells. Rotenone 
treatment significantly reduced the amount of enzyme activity secreted over two 
days, but there was apparently no difference in secretion in the presence of 50nM 
compared with 100nM (final concentration) rotenone. There was no effect of either 
virus dose or rotenone dose on the activity of total β-hexosaminidase in the culture 
media (Figure 5-11). 
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Figure 5-10: Effect of rotenone on secretion of alpha gal A into media by GLA-Jurkats 
The activity of α-gal A was measured in the media of GLA-Jurkats after 24 hours 
incubation with or without treatment with rotenone 50nM and 100nM final concentrations. 
(A) Curves showing enzyme release from GLA-Jurkats with or without rotenone treatment. 
The enzyme activity in media increased with the virus dose used to transduce the GLA-
Jurkats. The rate of increase was markedly lower in untreated media compared with 
untreated. Treatment with 100nM rotenone appeared to have the same effect on enzyme 
release as 50nM. (B) Difference in the enzyme release from GLA-Jurkats with or without 
100nM rotenone treatment was assessed using area under the curve. There was a significant 
fall in α-gal A release with complex I inhibition (P<0.001).  
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Figure 5-11: Secretion of total beta hex from GLA-Jurkats treated with rotenone 
There was no correlation between enzyme secretion from GLA-Jurkats with virus dose. 
Using student t test to compare untreated and 100nM rotenone groups shows there is no 
statistical difference in activity relating to rotenone treatment. 
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5.5.3 Effect of rotenone on uptake of alpha gal A by wild type Jurkats. 
Finally, the effect of complex I inhibition on uptake of overexpressed extracellular α-
gal A by wild type Jurkats was examined. Control culture media from the previous 
secretion experiment, shown in section 5.5.2, was collected and mixed 3:1 with fresh 
complete RPMI, consistent with the uptake experiment in section 5.4. The initial α-
gal A activity was measured in the mixed media before using it to incubate wild type 
Jurkats for 24 hours with/with-out 100nM rotenone. As a control, some of the mixed 
media was also incubated without cells for the same period of time. A volume of 
absolute ethanol was added to both the untreated cell group and the control group, 
equivalent to the volume of rotenone added to the treated group. After 24 hours the 
media was harvested and extracellular α-gal A activity was measured. In this way, the 
effect of rotenone alone was identified on enzyme uptake by wild-type (receiver) 
cells. 
Similar to as shown in section 5.4, 24 hours incubation of media resulted in overall 
loss of α-gal A activity in receiver-Jurkat supernatant with or without rotenone. The 
natural degradation component of this loss was observed in the control medium 
which was not exposed to cells. In both the rotenone-treated and untreated groups, 
the difference between overall loss of enzyme activity in the presence of wildtype 
Jurkats and loss due to natural degradation was calculated. This difference may be 
due to uptake of functional α-gal A by wild type Jurkats. Figure 5-12A shows that 
there is no statistically significant difference in uptake by the cells treated with and 
without 100nM rotenone for 24 hours. The area under the two lines was calculated 
and shown in Figure 5-12B. 
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Figure 5-12: Effect of rotenone on uptake of α-gal A by wild type Jurkats from culture media. 
Media taken from GLA-Jurkats was mixed 3 parts to 1 part fresh complete RPMI. The mixed media was added to wildtype Jurkats, with or without 
100nM rotenone, and incubated for 24 hours. To take account of ethanol solvent used to dissolve rotenone, untreated cells were incubated with the equivalent 
volume of ethanol added to the media. A. The graph shows α-gal A activity in culture media supernatant from the wild type Jurkats, after media degradation 
was taken into account. There is no statistically significant difference between slopes for untreated and treated cells following linear regression analysis. 
Untreated cells R2=0.917; Rotenone treated cells R2=0.911. B. There was no difference in the area under the curve for uptake of α-gal A activity from treated 
and untreated media used to incubate wild type Jurkats. 
A B 
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5.6 Conclusions 
The results in Figure 5-3 suggest that GLA-Jurkats are able to secrete functional α-gal 
A in both a time and virus dose dependent fashion. Although beyond three days the 
α-gal A activity within the culture media supernatant may continue to increase, it is 
possible that secretion reuptake by the GLA-Jurkats, and degradation of extracellular 
enzyme, may counteract any further rise. From Figure 5-3, two days appear to be 
sufficient for significant secretion of functional α-gal A. This agrees with previous 
research that found 48 hours was sufficient time for accumulated MPS to be 
significantly reduced in cells with either Hunters or Hurlers co-cultured with healthy 
cells (Fratantoni et al., 1968). Consequently, the uptake experiments shown in Figure 
5-4 and Figure 5-5 were carried out using culture media previously incubated with 
GLA-Jurkats for two days.  
The media used to incubate washed GLA-Jurkats for two days was re-incubated with 
wild type Jurkats for a further two days. Taking degradation of extracelluar enzyme 
activity during incubation into account, the results suggest significant evidence of 
uptake by wild type Jurkats (Figure 5-4 and Figure 5-6). This finding is supported by 
early research into using a lentivirus vector to deliver GLA to Fabry patient fibroblasts 
(Medin et al., 1996). This evidence is important because secretion and uptake of 
overexpressed α-gal A enzyme is essential for gene therapy to have therapeutic 
benefit against Fabry disease (Ruiz de Garibay et al., 2013). 
Next, inhibition of complex I using rotenone (Figure 5-7) appeared not to block 
transduction efficiency of lentivirus into Jurkat cells and subsequent overexpression 
of enzyme being made. This suggests that Fabry disease does not prevent cells 
treated with gene therapy from manufacturing therapeutic enzyme and is an 
encouraging finding for development of future gene delivery for patients. However, 
inhibition of complex I appeared to significantly reduce secretion of α-gal A from 
treated Jurkats over 24 hours by 63% (Figure 5-10). This effect may be due to a 
number of factors. Firstly, ATP is necessary for the budding-off of enzyme-containing 
vesicles from the trans-golgi network following the secretory pathway (Salamero et 
al., 1990). So, ATP deficiency due to complex I inhibition may therefore decrease 
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secretion as observed. Secondly, reduced α-gal A secretion in response to complex I 
inhibition may also be due to oxidative stress. Complex I inhibition is both a cause 
and effect of oxidative stress on the mitochondrial respiratory chain (Ventura et al., 
2002). If this is true, secretion of overexpressed α-gal A may therefore be enhanced 
by anti-oxidant treatments in combination with gene therapy. There may be great 
value in future work exploring the potential role of oxidative stress on inhibiting 
secretion.  
Finally, the observation that complex I inhibition had no effect on enzyme uptake by 
receiver cells (Figure 5-12) suggests that, if release of α-gal A by donor cells is 
preserved, cross correction could still occur. Thus correction of the metabolic deficit 
may be of importance to optimise gene therapy for the future. Further work is now 
required to see if transduction corrects mitochondrial dysfunction in Fabry disease 
patient cells. 
In conclusion, release of a-gal A from transfected cells has been demonstrated. 
Furthermore and consistent with the original cross contamination observations, 
uptake of enzyme by a target cell has been shown here. The finding that enzyme 
release is impaired when mitochondrial complex I is inhibited raises the possibility 
that cross correction could be compromised in Fabry disease. However, if enzyme 
replacement therapy or restoration of enzyme activity by gene transfer restores 
mitochondrial function then cross creation could proceed. Further work is now 
required to test this hypothesis. 
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Chapter 6 Alpha-galactosidase A activity in Fabry patient skin fibroblasts: 
efficiency of lentivirus-mediated overexpression 
6.1 Introduction 
The work presented so far in this thesis has been carried out in Jurkats. The reasons 
are firstly that, as an immortalised cell-line, Jurkats provide homogeneity between 
cultures, and relatively rapid and robust cell proliferation. They also exhibit low α-gal 
A activity relative to other cell-lines examined here, thus suggesting that this cell line 
may represent a useful model of enzyme deficiency and for examining the effects of 
α-gal A overexpression on cellular functions. Furthermore, as a lymphoblastic cell-
line, Jurkats represent a good target for initial assessment of lentivirus-mediated 
gene delivery to haematopoietic cells. So the results reported thus far could hold 
important potential implications for the design of future gene delivery to treat Fabry 
disease. 
The next stage is to begin to extend the work carried out in Jurkats using primary 
patient cells to see whether the findings so far hold true in a more clinically relevant 
cell type. Fabry disease is a multisystemic, metabolic disorder that effects nearly all 
cell types in humans, including fibroblasts of skin and heart, and myofibroblasts that 
support vascular smooth muscle. Some degree of Gb3 storage is typically seen in 
fibroblasts. Mitochondrial respiratory chain dysfunction was reported in skin 
fibroblasts from Fabry disease patients (Lucke et al., 2004). Fibroblasts are therefore 
potential participants in the pathophysiology of Fabry disease and clinically relevant 
targets for treatment. So, the overall aim of initial investigations is to assess whether 
fibroblasts from Fabry disease patients may be transduced by lentivirus made using 
the pRRLSIN.cPPT.PGK-GLA.WPRE vector plasmid. 
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6.2 Materials and Methods 
All materials and methods were as described in Chapter 2 Materials and Methods, 
except for the following additions. 
6.2.1 Human skin fibroblasts 
The cells shown in Table 6-1 were purchased from the Coriell Institute for Medical 
Research, New Jersey, USA, and delivered as live cultures. All cell donors were 
Caucasian males.  
 
Table 6-1: Human skin fibroblasts from Fabry disease patients and controls 
The table shows the identity of cells purchased from the Coriell Institute for Medical 
Research (New Jersey, USA). Fabry disease patients GM00881 and GM02769 were reported 
to be hemizygous for a point mutation replacing cytosine with thymine at nucleotide 658 of 
the complementary DNA sequence of the GLA gene. This mutation results in a stop codon in 
place of a codon for arginine, leading to truncation of the α-gal A protein at position 220 of 
the amino acid sequence. NA: not applicable.  
 
Cell ID Tissue of origin GLA genotype Age of donor at 
sampling 
GM00881 
Primary skin fibroblasts from 
males with previously reported 
classical Fabry disease 
phenotype 
c.658C>T 17 
GM02769 c.658C>T 18 
GM02775 
Maternal 1st cousin 
of GM02769 
16 
GM23815 
Primary skin fibroblasts from 
males, apparently healthy 
NA 22 
GM23964 NA 21 
GM23973 NA 19 
GM23975 NA 25 
GM23976 NA 22 
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All members of the control group were reported to be clinically normal with no 
known medical or neurological signs of disease. Except for doner GM23815, each 
control had previously undergone magnetic resonance imaging of the brain, 
neurological and neuro-psychological examinations, and review of medical records. 
All these examinations confirmed the control group were apparently healthy. 
Members of the control group were selected for this study based upon similar ages 
to the group affected by Fabry disease.  
Within the affected group, donor GM00881 displayed the phenotype for classical 
Fabry disease including undetectable α-gal A activity and lipid deposition in 
microvascular endothelium. Genetic analysis found a point mutation resulting in a 
premature stop codon within exon 5 of GLA. Donors GM02769 and GM02775 were 
within the same family. The proband, diagnosed first with classical Fabry disease, was 
GM02769 presented undetectable α-gal A activity and the same nonsense mutation 
within GLA as found in donor GM00881. Absent α-gal A activity was confirmed in 
donor GM02775. 
 
6.2.2 Cell culture reagents 
0.25% trypsin in EDTA       Life (Paisley, UK) 
Hams F10 medium with 25mM HEPES and L-Glutamine (Hams) Life (Paisley, UK) 
 
6.2.3 Fibroblast culture methods 
Apparently healthy control fibroblasts and fibroblasts from male Fabry disease 
patients shown in Table 6-1 were grown, according to suppliers instructions, in Hams 
medium, 14% FBS, 1% pen-strep at 37°C, 5% CO2. The cells formed an adherent 
monolayer so 0.25% trypsin in EDTA was used to dissociate the cells for passaging 1:2 
whenever the cells were confluent.  
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6.3 Results 
6.3.1 Growth rate in skin fibroblasts from healthy controls and Fabry disease 
patients 
Acquiring Fabry disease patient skin fibroblasts took considerable time. Two attempts 
to culture patient cells held in liquid nitrogen archives by the Department of Chemical 
Pathology, Great Ormond Street Hospital (London, UK) were unsuccessful. Cultured 
skin fibroblasts from Fabry disease patients and apparently healthy controls listed in 
Table 6-1 were eventually sourced from the Coriell Institute of Medical Research 
(New Jersey, USA). The cells were counted at two time points and the results are 
shown in Table 6-2, except for cells from Fabry disease patient donors GM02769 and 
GM02775, and control donor GM23975. Cells from these three donors grew very 
slowly and were quiescent after one month in culture. A second batch of cells from 
the same donors were purchased and cultured for experiments over three weeks, but 
cell growth data was not collected. 
The live cell count data was used to estimate rate of growth for each donor culture 
in terms of time required for the number of cells to double, as shown in Table 6-2. 
The results may suggest a difference in rates of growth between control and patient 
cells, but there was an insufficient number of patients in the affected group to carry 
out statistical comparison. Further work is necessary to confirm whether there is a 
difference in rate of growth between control and patient fibroblasts. 
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Table 6-2: Live cell count and rate of growth of Fabry disease patient and healthy control 
skin fibroblasts in culture 
Human skin fibroblasts were counted before transfer to T75 cell culture flasks for 
incubation according to the supplier’s instructions over various periods of time. The cells 
were then counted again and approximate doubling time calculated. The data shown is the 
average of two independent counts of cells from the same culture flask from each patient or 
control. Statistical comparison was not possible because data was collected for cells from 
only one Fabry disease patient. The reason for this was that GM02769 and GM02775, as well 
as control cells GM23975, had stopped growing in this experiment. 
 
Cell donor Supplier’s 
cell ID No: 
Initial cell 
count  
(x106 cells) 
Final cell 
count  
(x106 cells) 
Duration of 
culture 
period (days) 
Approximate 
doubling 
time (days) 
Fabry 
disease 
patient 
GM00881 0.8 1.6 10 10 
Apparently 
health 
controls 
GM23815 0.8 4.0 12 5 
GM23976 0.5 3.0 12 5 
GM23964 0.6 1.8 4 3 
GM23973 0.6 1.5 4 3 
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6.3.2 Alpha-galactosidase A activity is reduced in cultured skin fibroblasts from male 
patients with Fabry disease 
Cultured skin fibroblasts from five healthy controls and three male patients shown in 
Table 6-1 were harvested and the activity of α-gal A, together with a second control 
lysosomal hydrolytic enzyme β-galactosidase, was measured. The results are shown 
in Figure 6-1 and confirm that the fibroblasts cultured from patients exhibit 
significantly lower α-gal A activity compared with healthy controls. In comparison 
there was no difference in β-galactosidase activity between the two groups, 
confirming that the difference in α-gal A activity was not due to cell viability or global 
differences in the cellular lysosomal content. 
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Figure 6-1: Activity of alpha and beta galactosidase enzymes in cultured skin fibroblasts 
The activity of two hydrolytic lysosomal enzymes, β-gal acting as a control of both cell 
viability and lysosomal content, to assess α-gal A activity in fibroblast samples from healthy 
subjects and patients. A. Alpha-galactosidase A activity; there is a significant reduction in the 
activity of fibroblasts from patients compared to controls (P<0.01). B. Beta-galactosidase 
activity; there is no significant difference between the two groups. 
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6.3.3 Lentivirus-mediated overexpression of α-gal A in healthy control skin 
fibroblasts 
The lentivirus preparation used for this experiment was previously titred in Jurkat 
cells and found to contain 3.68 x 107viral particles per mL, as used in Chapter 5. 
Approximately 3.0 x 105 fibroblasts were transduced with a volume of lentivirus 
equivalent to an MOI of 0.6 based on the titre. This volume was chosen because our 
earlier work in Chapter 4 suggested that cells containing 0.4vg/cell manufactured 
enzyme with similar affinity as wild type enzyme, but cells containing at least 
1.5vg/cell overexpressed α-gal A with significantly less affinity to the synthetic 
substrate 4MUG. Based upon an idealised Poisson’s distribution, an MOI of 0.6 would 
transduce 30% to 40% cells with at least one copy of the viral genome containing GLA 
(Fehse et al., 2004). So, at this virus copy number α-gal A was expected to exhibit the 
same substrate affinity as healthy control cells.  
It is important to note that since titration and transduction were executed on 
different cell-types, it is not possible to make direct predictions of virus copy number 
within the transduced fibroblasts based upon the MOIs shown. However, the purpose 
of this experiment was not to assess enzyme activity in response to absolute virus 
doses, but to see the effect of GLA transgene delivery on intracellular α-gal A activity 
in healthy controls before and after transduction with lentivirus.  
So, to that end, the skin fibroblasts from the healthy control group shown in Table 
6-1 were transduced with 5µL lentivirus suspension (equivalent to MOI 0.6 in Jurkats), 
harvested and the intracellular activity of α-gal A measured. The activity was 
compared with the activity in untreated cells. The results, shown in Table 6-3, suggest 
that the lentivirus produced from the pRRLSIN.cPPT.PGK-GLA.WPRE vector plasmid 
is capable of infecting human skin fibroblasts to potentiate a highly significant 
increase in α-gal A activity. 
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Table 6-3: Lentivirus-mediated overexpression of alpha gal A in control human fibroblasts 
Healthy human fibroblasts were transduced with 5µL lentivirus suspension (equivalent 
to MOI of 0.6 in Jurkats) and intracellular α-gal A activity was measured. There is a significant 
increase in activity (P<0.0001), suggesting that human skin fibroblasts may be successfully 
transduced with lentivirus produced from vector plasmid pRRLSIN.cPPT.PGK-GLA.WPRE. SD: 
standard deviation 
 
 Control (n=5) GLA-Control (n=5) 
Mean activity +/- 1 SD 
(nmol/hr/mg protein) 
55.2 +/- 17.5 9430 +/- 1577 
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6.3.4 Lentivirus-mediated expression of α-gal A in skin fibroblasts from Fabry disease 
patients 
Next, attempts were made to transduce skin fibroblasts cultured from the Fabry 
disease patient group, shown in Table 6-1, with lentivirus containing GLA. After 
harvesting cells from the patient fibroblast cultures from the previous experiment 
shown in Section 6.3.2, there were insufficient cells from donor GM02775 to 
transduce. So results were only achieved for two of the three patient donors. In order 
to get some indication of relationship between relative transgene dose and α-gal A 
overexpression, 3.0 x 105 cells from each patient was treated with 3µL and 5µL 
lentivirus suspension (equivalent to MOIs of 0.4 and 0.6 in Jurkats). The results are 
shown in Table 6-4 and indicate a dose response in enzyme activity to amount of virus 
suspension delivered. 
 
Table 6-4: Lentivirus-mediated overexpression of alpha gal A in Fabry disease patient skin 
fibroblasts 
Dose-dependent increase in α-gal A activity in Fabry disease patient fibroblasts is 
shown in response to increasing volume of lentivirus suspension containing the GLA 
transgene (3µL and 5µL were equivalent to MOIs of 0.4 and 0.6 in Jurkats). Statistics not 
shown because each transduction has n=1 due to challenges of culturing the patient cells. 
SD: standard deviation 
 
 Untreated patient 
fibroblasts (n=3) 
Patient fibroblasts treated with: 
3μL virus (n=1) 5μL virus (n=1) 
Mean activity +/- 1SD 
(nmol/hr/mg protein) 
6.3 +/- 4.4 1455 2241 
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Finally, the results from the above transduction experiment in Fabry disease patient 
fibroblasts were compared to those obtained with healthy control fibroblasts and the 
findings are shown in Figure 6-2. The activity of α-gal A within the Fabry patient cells 
treated with 5μL virus exceeded by nearly forty-fold the physiological levels found in 
the healthy control cells. Although statistical analysis was not possible due to the low 
n number in the Fabry disease patient group, visual observation suggests that the 
efficiency of transduction of patient cells is lower than in healthy controls at the same 
virus dose.  
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Figure 6-2: Comparison of transduction of efficiency in skin fibroblasts from Fabry disease 
patients and healthy controls 
The overexpression of α-gal A in terms of activity was compared in skin fibroblasts 
from healthy controls (n=5) and a Fabry disease patient (n=1) following treatment with 5µL 
lentivirus suspension (volume equivalent to MOI 0.6 in Jurkats). The results suggest that 
transduction efficiency of the lentivirus may be lower in fibroblasts from Fabry disease 
patients than from healthy controls. 
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6.4 Conclusions 
The intent was to begin to extend the work carried out in Jurkats and to generate 
initial data using fibroblasts from Fabry disease patients. Results suggested that 
growth rate of patient cells may be lower than in control cells, but this observation 
was based on only one patient and needs to be further investigated in future work. 
A possible mechanisms for reduced rate of growth in Fabry fibroblasts may be 
reduced activity of mitochondrial respiratory chain complexes leading to reduced ATP 
bioavailability (Lucke et al., 2004). However, despite significant Gb3 storage in Fabry 
fibroblasts, their function does not appear to be compromised since there is no 
evidence that wound healing is impaired (Elleder, 2010). Apparently in contradiction 
to this, fibrosis is observed in developed cases, suggesting that fibroblast activity may 
actually increase in Fabry disease patients (Nagano et al., 2016, Weidemann et al., 
2013). In vitro cell culture does not provide fibroblasts with stimuli from the malleus 
of growth factors and cell-cell signalling which influence cell function in vivo. So 
future work investigating the effect of Fabry disease on fibroblast growth rates with 
higher n numbers should take this limitation into account. 
Results also showed that patient fibroblasts exhibited lower α-gal A activity than in 
control cells, and primary skin fibroblasts were amenable to transduction by the 
lentivirus containing the GLA transgene. In patient fibroblasts the overexpression 
corrected enzyme deficiency to supra-physiological levels, but was not as great as in 
control cells transduced with the same virus dose. This suggests that transduction 
efficiency may be compromised in Fabry disease, based on a single culture from one 
patient. Further investigations using higher n numbers of viable fibroblast culture 
from Fabry disease patients are needed to explore this hypothesis. A possible 
mechanism for reduction in efficiency of lentivirus to transduce Fabry fibroblasts may 
be accumulation of Gb3 at the plasma membrane reducing the expression of 
glycoproteins recognised by the lentivirus for cell binding and infection (Lund et al., 
2009, Ramkumar et al., 2009). Gb3 accumulation is known to reduce cholesterol 
content of cellular membranes, disrupting membrane fluidity and permeability (Das 
and Naim, 2009). This process may possibly influence virus endocytosis by target 
cells. 
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In conclusion, this preliminary work has raised questions regarding the effect of α-gal 
A deficiency on cell growth and ability to be transduced by therapeutic lentivirus. In 
the next chapter, these questions will be placed in the context of the overall thesis 
so that future work can be proposed which builds upon the understanding developed 
through this project.  
  
 194 
 
Chapter 7 Discussion 
7.1 General discussion 
Fabry disease is a progressive, multi-systemic and heterogeneous metabolic disorder 
caused by mutations in the X-linked gene GLA (NCBI: NM_000169.2) that codes for 
the lysosomal acid hydrolase α-gal A (Bishop et al., 1986, Brady et al., 1967, Calhoun 
et al., 1985). The predominant natural substrate of α-gal A is the glycosphingolipid 
Gb3 (Dean and Sweeley, 1979a, Sweeley and Klionsky, 1963). Two aspartate residues 
within the enzyme’s active site hydrolyses terminal galactose from Gb3 to produce 
lactosylceramide (Garman and Garboczi, 2004). This is an essential step in the 
sequential catalysis of globoside to ceramide within lysosomes (Kolter and Sandhoff, 
1999).  
Over the last three years the number of known pathogenic mutations detailed in the 
Human Gene Mutation Database in the GLA locus has increased from 600 to over 900 
(Stenson et al., 2009). These mutations result in α-gal A deficiency leading to Gb3 
accumulation in a wide variety of cell types. Notable sites of Gb3 storage in patients 
include endothelium, peripheral neurons, cardiomyocytes and renal podocytes 
(Desnick et al., 2001, Elleder, 2010, Hozumi et al., 1990). The reasons for the apparent 
instability of the GLA locus is unknown.  Possibly, mutations in GLA may confer some 
evolutionary advantage against pathogens because Gb3 plays an important role in 
immunity (Darmoise et al., 2010). Gb3 is the cell surface marker CD77 which is the 
sole receptor for Escherichia coli verotoxins (Tetaud et al., 2003), and natural 
resistance factor against HIV infection (Lund et al., 2009, Ramkumar et al., 2009). 
Though a single gene disorder, the phenotypic consequences of GLA mutations are 
complex. Symptoms of classical Fabry disease are devastating and life-threatening. 
They begin in early childhood and progress to effect cerebrovascular, cardiovascular 
and renal systems. There are non-classical variants of the disease which tend to be 
later-onset, milder and focused on one or more of these systems (Ko et al., 1996). 
Certain GLA mutations have been linked with classical and non-classical variants of 
the disease (Schiffmann et al., 2016), but generally genotype and phenotype do not 
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correlate (Gal, 2010); family members carrying the same mutation may present very 
different symptoms in different organs and cell-types (Ries and Gal, 2006).  
From the genetic and clinical picture it was logical to hypothesise that cell-types vary 
in terms of susceptibility to pathology resulting from GLA mutation and α-gal A 
deficiency. The present work therefore commenced with characterisation of α-
galactosidase activity in different human cell-types. Alpha-gal A activity, standardised 
for variation in lysosomal content, was significantly higher in the transformed 
embryonic kidney (293T) cell-line compared with primary fibroblasts and a 
hepatocarcinoma (Hu-H7) cell-line. Proteinuria is one of the early signs of FD in which 
glomeruli and distal tubules become major sites of Gb3 storage (Desnick et al., 2001, 
Hozumi et al., 1990). Gb3 clearance from renal podocytes in response to ERT is limited 
(Weidemann et al., 2013) and end-stage kidney failure is a notable cause of mortality 
amongst patients (Germain, 2010). Lyso-Gb3 stimulated release of fibrogenic 
cytokine TGF-β1 and other mediators of increased extracullular matrix production in 
cultured human podocytes (Sanchez-Nino et al., 2011). So kidney has important 
relevance, whereas liver and fibroblasts have lower relevance, in the pathophysiology 
of FD. In liver, Gb3 accumulation is low and limited to hepatocytes which do not show 
major signs of pathology. Gb3 accumulation in fibroblasts is significant but without 
signs of subsequent cell dysfunction in either wound healing or extracellular matrix 
production (Elleder, 2010). This may be because lyso-Gb3 does not stimulate 
fibroblast proliferation (Aerts et al., 2008), which suggests secondary mediators of 
tissue injury are not promoting pathogenic processes in fibroblasts (Weidemann et 
al., 2013).  
The evidence in support of the hypothesis is limited by the finding in skin fibroblasts 
of reduced respiratory chain enzyme activity in FD (Lucke et al., 2004), which may be 
due to Gb3 accumulation disrupting lipid composition of cellular membranes (Das 
and Naim, 2009). A further limitation is that the results here were in human 
immortalised cell-lines rather than primary cells. The transformation of cell-lines, 
whilst improving standardisation between cultures, may effect GLA expression and 
alter α-gal A activity. The morphology of human cell-lines are often different from 
their tissue of origin. To address this limitation, induced human pluripotent stem (iPS) 
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cells may be reprogrammed into relevant cell-types for further investigation (Raval 
et al., 2015).  
In wild type male CD1 mice, the standardised ratio of α-gal A against β-gal was 
significantly higher in murine skeletal muscle than brain, lung, liver, kidney, heart and 
spleen. Skeletal muscle shows limited clinical manifestations of FD. Although cases of 
osteopenia and osteoporosis have been identified in various studies of FD, it was 
unclear whether results were skewed by undetected vitamin D deficiencies (Germain, 
2010). Any involvement of skeletal muscle in FD is considerably less than 
cerebrovascular, cardiovascular and renal tissues (Elleder, 2010). So there is an 
apparent reversal of relationship between standardised ratio for α-gal A activity and 
susceptibility to Fabry disease in man and mouse. 
The murine model of Fabry disease in which GLA is knocked out, exhibits absent α-
gal A activity and Gb3 accumulation in various tissues, yet none of the clinical 
symptoms observed in patients (Ohshima et al., 1997, Ohshima et al., 1999). Perhaps 
the loss or reversal of tissue susceptibility suggested here in wild type mice relates to 
the absence of clinical phenotype reported in the GLA knock-out mouse. In 
considering this possibility it should be noted that the lysosomal enzyme assays used 
in the present work were only fully validated for human cells and tissues. To study 
lysosomal enzymes in murine tissues in detail, the assay should be re-evaluated.  
On diagnosis of Fabry disease, there are currently two forms of treatment available 
to patients: enzyme replacement therapy (ERT) (Schiffmann et al., 2001, Eng et al., 
2001) and small molecule chaperone therapy (Markham, 2016). In some cases, but 
not all, the clinical response to ERT may be a poor return for the psycho-social and 
physical burden of biweekly intravenous administration of recombinant protein that 
ERT imposes on patients. In comparison chaperone therapy is administered orally but 
is only applicable for amenable mutations which account for 35% - 50% of pathogenic 
mutations in GLA (Hughes et al., 2016, Markham, 2016). So, at least half of all Fabry 
disease patients will not benefit from this mode of treatment.  
Alternative therapies are therefore urgently required to treat Fabry disease. 
Substrate reduction therapy, an orally administered glucosylceramide synthase 
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inhibitor, has recently completed its first early-stage clinical trial in patients receiving 
ERT (Guerard et al., 2017). Another option is to address the root cause of the disorder 
by inserting a correct copy of GLA into patient cells to enable synthesis of functional 
α-gal A for long-term therapeutic benefit. This is the rationale behind gene therapy 
(Friedmann and Roblin, 1972).  
Since Fabry disease is due to monogenic loss-of-function mutations, it is a good 
candidate for gene therapy (Friedmann and Roblin, 1972). Lentivirus offers a potent 
method of gene delivery to both dividing and non-dividing cells with high 
transduction efficiency and clinical safety (Sakuma et al., 2012). So the work reported 
next explored the impact of lentivirus-mediated α-gal A overexpression in order to 
improve understanding of this important therapeutic option on the cellular level. 
A third generation lentivirus vector plasmid (pRRLSIN.cPPT.PGK-GLA.WPRE), 
containing a transgene encoding mature human α-gal A regulated by the human 
phosphoglycerate kinase promoter, was constructed at UCL GOSICH (London, UK) 
(Rajaraman, 2013). The vector was then transfected into a packaging cell-line to 
harvest concentrated lentivirus supernatant containing 2.8 x 107 pfu/mL in Chapter 4 
and 3.68 x 107 pfu/mL in Chapters 5 and 6. 
The characterisation of α-galactosidase in human cell types showed that the B-
lymphoblastic leukaemia cell-line called Jurkat exhibited low endogenous α-gal A 
activity relative to other cell-types tested.  Furthermore, as a cell-line originating from 
transformed haematopoietic progenitors, Jurkats may have some relevance to ex-
vivo gene therapy. Transduction of Jurkats by the lentivirus harvest resulted in a dose-
dependent increase in both the expression and activity of intracellular α-gal A, with 
no evidence of cell toxicity up to 1.8vg/cell. This is consistent with many previous 
studies that showed engineered vectors containing cDNA encoding human α-gal A 
can generate therapeutic GLA transgene expression in transduced target cells (Huang 
et al., 2017, Jung et al., 2001, Medin et al., 1996, Pacienza et al., 2012, Park et al., 
2003, Sharma et al., 2015, Sugimoto et al., 1995, Takenaka et al., 1999a, Takenaka et 
al., 2000, Takiyama et al., 1999, Yoshimitsu et al., 2006, Yoshimitsu et al., 2007, 
Yoshimitsu et al., 2004).  
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Enzyme kinetic studies were used to explore the catalytic efficacy of therapeutic 
enzyme produced as a result of transgene delivery. The findings suggested that as 
virus dose increases in transduced cells from 0.4vg/cell to 1.5vg/cell, the affinity of 
α-gal A to synthetic substrate 4MUG reduced, as indicated by increased Km. This 
appears to be the first study exploring the kinetic properties of α-gal A produced by 
transduced cells. The findings may point to need to optimise virus dose in order to 
deliver maximum therapeutic benefit to patients.  
The observed increase in Km, and corresponding decrease in affinity, with increasing 
transgene dose may be due to impaired cellular sorting because of congested 
lysosomal trafficking. For evidence to support this hypothesis, Lysotracker may be 
used with live-cell imaging to study the intracellular trafficking of fluorescence-
labelled α-gal A (Chazotte, 2011). The cells can be transduced by a lentivirus 
containing a hybrid transgene incorporating GLA and GFP. In this way the effect of 
various degrees of enzyme overexpression on lysosomal trafficking can be explored. 
Congested lysosomal trafficking may lead to impaired cellular sorting because of 
glycosylation defects. Glycosylation patterns are cell type-specific and may regulate 
tissue/plasma distribution, proportion of enzyme targeted for secretion, and dose-
response to ERT (Garman and Garboczi, 2004). 
As a haematopoietic progenitor, Jurkats are a highly relevant cell-line for 
investigation of gene therapy for Fabry disease. HSCs have been proposed as ideal 
targets for ex vivo gene delivery due to their ability to self-renew and to differentiate 
to give rise to all the cell-types of blood and tissue macrophages (Karlsson, 1991). 
Enzymatic correction of macrophages is important because they accumulate high 
levels of Gb3 through digesting globoside from within the plasma membranes of 
redundant, damaged or senescent erythrocytes (Dawson and Sweeley, 1970). Blood 
cells may subsequently cross correct parenchymal and stromal cells throughout the 
body (Fratantoni et al., 1968, Karlsson, 1991).  
Cross correction between transduced and treatment-naive cells in the development 
gene therapy for Fabry disease needs to be explored since Gb3 accumulation is widely 
distributed throughout patients and effects multiple organs (Desnick et al., 2001, 
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Elleder, 2010, Germain, 2010). This need is urgent because a clinical trial application 
for a “first in the world” gene therapy trial for Fabry disease using ex vivo lentivirus-
mediated transgene delivery to HSCs was recently accepted (Huang et al., 2017).  So, 
here Jurkat cells were transduced with the harvested lentivirus containing the GLA 
transgene. They showed virus dose- and time-dependent release of α-gal A activity 
out into their culture media during 3 days incubation. Media collected after two days 
incubation was collected and used to incubate treatment-naive Jurkats for a further 
two days, during which time the cells specifically took up α-gal A from the media. 
Together this demonstrated cross correction between Jurkats as observed previously 
in fibroblasts (Takenaka et al., 1999b) and immortalised lymphoblasts derived from 
Fabry disease patients (Medin et al., 1996).  
Fabry disease is known to interrupt energy metabolism in cardiomyocytes (Machann 
et al., 2011, Nagano et al., 2016, Palecek et al., 2010) and brain tissue (Itoh et al., 
2001). Furthermore, the activity of mitochondrial respiratory chain complexes is 
reduced in skin fibroblasts from patients (Lucke et al., 2004). In view of these affects, 
rotenone was used to inhibit the mitochondrial respiratory chain complex I in Jurkats. 
Complex I helps control ATP biosynthesis and its inhibition may model metabolic 
deficit with relevance to FD (Davey et al., 1998, Rossignol et al., 2000, Telford et al., 
2009). Here it was shown that Complex I inhibition had no effect on the transduction 
efficiency of the lentivirus on Jurkats. However, the ability of transduced Jurkats to 
secrete overexpressed α-gal A out into their surrounding media was reduced. No 
effect was observed on the ability of wild-type Jurkats to take up enzyme from 
collected media. These results hold implications since they suggest that the uptake 
of ERT into cells from plasma and interstitial fluid is not abrogated by mitochondrial 
dysfunction. 
Reduced secretion of α-gal A may be attributable to the low ATP bioavailability or 
increased oxidative stress resulting from Complex I inhibition (Osellame et al., 2012). 
ATP may be required to induce lysosomal enzyme release from polymophonuclear 
leukocytes (Becker and Henson, 1975). Oxidative stress accumulates during aging, 
resulting in increased size and number of lysosomes in cells (Hohn et al., 2017). There 
is evidence that secretion of lysosomal enzymes may decline with age (Carmona-
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Gutierrez et al., 2016), as suggested in polymophonuclear leucocytes (Suzuki et al., 
1983). 
Expanding this study to fibroblasts cultured from Fabry disease patients, cell culture 
data suggested the growth rate of fibroblasts cultured from Fabry disease patients 
may be slower than apparently healthy controls. If mitochondrial function in patient 
fibroblasts were measured, the findings here would be consistent with the possibility 
of respiratory chain defects within patient cells because the mitochondria regulates 
cell growth, division and death (Osellame et al., 2012). Lentivirus appeared to be less 
efficient at cellular transduction. Whilst a degree of caution needs to be applied when 
considering this preliminary result, it is of interest to note that rotenone treatment 
of Jurkat cells had no significant effect on transduction efficacy.  Such a finding may 
suggest that complex I inhibition alone is not sufficient to impair transduction and 
that other factors, occurring in Fabry cells, need to be considered, e.g. multiple 
respiratory chain inhibition (Lucke et al., 2004), substrate accumulation (Sweeley and 
Klionsky, 1963) and oxidative stress (Shen et al., 2008). Confirmation of this finding 
may indicate that consideration of impaired transduction may be required when 
considering the efficacy of gene therapy in patients with Fabry disease.  
In summary, the hypothesis based on results in human cell-lines and murine tissues 
is illustrated in Figure 7-1. Due to their relatively low endogenous α-gal A activity, the 
Jurkat human cell-line was carried forward for transduction experiments using an 
engineered lentivirus to overexpress α-gal A. Figure 7-2A shows kinetic studies which 
suggest the substrate affinity of overexpressed α-gal A reduces with increasing virus 
dose. Cross-correction, which is important for the efficacy of gene therapy, may be 
disrupted by mitochondrial deficits reported previously in Fabry disease. Cross-
correction occurs between transduced and naïve Jurkats (Figure 7-2B), so the effect 
of respiratory chain complex I inhibition on cross-correction is shown in Figure 7-2C. 
Finally, preliminary experiments carried out to extend this thesis into patient skin 
fibroblasts raised further hypotheses illustrated in Figure 7-3. The hypotheses made 
in this thesis lead to research questions, highlighted in red in Figure 7-1, Figure 7-2 
and Figure 7-3 to drive future work. 
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Figure 7-1: Hypothesised relationship between a-gal A and tissue susceptibility 
Characterisation of α-gal A in human cell-lines and murine tissues lead to the 
hypothesis that the activity of α-gal A, following standardisation for variations in lysosomal 
content between cell and tissue types, may positively correlate with involvement in the 
pathophysiology of Fabry disease. Findings were not conclusive but the research question, 
shown in red, was carried forward for future work. 
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Figure 7-2: Summary of results in Jurkat human B-lymphoblastic leukaemia cell-line 
A. Kinetic studies of overexpressed α-gal A using the synthetic substrate 4MUG 
following transduction of Jurkats found that Km, and therefore affinity with the substrate, 
declined with higher virus doses. This suggested that lower doses of gene therapy may be 
more clinically effective. B. Cross correction between transduced Jurkats and treatment-
naïve wild type Jurkats. C. Mitochondrial deficiency, reported previously in Fabry disease, 
was modelled in Jurkats using the respiratory chain complex I-inhibitor Rotenone. Rotenone 
reduced cross-correction in Jurkats by inhibiting release of α-gal A by transduced cells. 
A 
B 
C 
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Figure 7-3: Lentivirus-mediated α-gal A overexpression in skin fibroblasts cultured from 
patient with Fabry disease. 
Summary of hypotheses made based upon preliminary results in patient fibroblasts. 
Growth rate data suggested Fabry disease inhibited cell division. Transduction efficiency may 
be lower in Fabry patients compared with control, raising questions about possible 
interactions between lentivirus and the natural enzyme substrate Gb3. Lentivirus-mediated 
α-gal A overexpression in patient fibroblasts resulted in super-physiological enzyme activity. 
Since the earlier work found that substrate affinity reduced with high levels of 
overexpression, this raises questions about the possible effect of overexpression on 
lysosomal sorting and posttranslational enzyme modifications and maturation. 
 
 
 
 
 
 
 
 
 
 204 
 
7.2 Future work  
The thesis raises a number of points requiring further investigation. These were 
broken down into three key research questions shown in Figure 7-4. 
 
Figure 7-4: Research questions arising from this thesis which directs future work 
The future work is split into three pathways with a common starting point which is to 
procure and grow fibroblasts cultured from a larger cohort of patients with Fabry disease. 
Each pathway is driven by a research question which the current thesis has raised.  
 
Addressing the research questions shown in Figure 7-4 depends upon first procuring 
and growing fibroblast from more patients. All these work items are detailed in the 
following list:  
A. To overcome the low number of Fabry disease patients donating skin fibroblasts for 
results reported herein, more cultures must be purchased. This will enable any 
significant differences in growth rate and transduction efficiency to be identified. To 
overcome the challenges encountered in culturing fibroblasts, basic fibroblast 
growth factor may be used according to Abdian et al (2015) (Abdian et al., 2015). 
 
B. There is a need to investigate further the hypothesis that standardised ratio for α-gal 
A activity may correlate with tissue susceptibility in humans. To address this a range 
of relevant cell types may be derived from iPS cells grown from patient fibroblasts, 
e.g. cardiomyocytes, endothelium, neurons and podocytes (Raval et al., 2015). 
A. Culture fibroblasts from 
more patients
B. Does α-gal A activity in 
iPS-derived cell types 
correlate with disease 
susceptibility?
C. Is transduction efficiency 
and cross-correction 
effected by Gb3 storage, ROS 
and mitochondrial function 
in Fabry disease?
D. Are changes in substrate 
affinity associated with 
alterations in lysosomal 
sorting?
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C. Results here suggested α-gal A deficiency may cause reduced transduction efficiency 
in patient fibroblasts. This raises the research question whether reduced lentivirus 
efficacy is linked with Gb3 accumulation, oxidative stress and mitochondrial 
dysfunction; and whether these factors impact cross-correction. The following 
research is required to answer this question: 
 
o The lentivirus harvested in this study should be re-titred in fibroblasts from 
patients and controls in order to calculate accurate average virus dosing per 
cell.  This would also enable direct comparison of transduction efficiency in 
Jurkats and fibroblasts. 
 
o Measure the activity of respiratory chain enzymes and identify links with Gb3 
expression and markers of oxidative stress in fibroblasts from patients and 
controls, before and after transduction. Accumulation of Gb3 disrupts the 
lipid and cholesterol composition of cellular membranes which is important 
for permeability, integrity and membrane–associated processes such as the 
mitochondrial respiratory chain (Das and Naim, 2009). Gb3 storage in the 
lysosomal-endosomal compartments of vascular endothelium increases 
production of reactive oxygen species (ROS) which cause oxidative stress 
(Shen et al., 2008). Both Gb3 and ROS may affect global mitochondrial 
function with far wider implications for cellular metabolism than modelled 
in Jurkats by complex I inhibition (Lucke et al., 2004). 
 
o Correlate Gb3 expression with transduction efficacy. Gb3 is a natural 
resistance factor to HIV infection (Lund et al., 2009, Ramkumar et al., 2009). 
Possibly, as lentivirus is based upon the HIV virus structure, the low 
transduction efficiency in Fabry fibroblasts is due to Gb3 accumulation. 
 
o To see whether Fabry disease effects the ability of patient cells to cross-
correct, investigate whether cross-correction may occur between 
transduced and treatment-naïve fibroblasts from patients and controls. 
Subsequently link outcomes with the mitochondrial function data collected 
in item b. Results in Jurkats suggested release of α-gal A by transduced cells 
was reduced by complex I inhibition. Comparison between fibroblasts and 
Jurkats must take account of differences in virus dose and transduction 
efficiency.  
 
D. Examine the kinetic properties of α-gal A in transduced fibroblasts. The very high 
overexpression observed in transduced fibroblasts may not be producing enzyme of 
equal affinity to substrate as in untreated fibroblasts. Use cell imaging to explore the 
hypothesis that high transduction levels in Jurkats (above 0.4vg/cell) alters enzyme 
kinetics on 4MUG because of impaired cellular sorting due to congestion of 
lysosomal trafficking pathways. LysoTracker probes will allow study of enzyme 
trafficking to lysosomes in live cells before and after transduction with various doses 
of the lentivirus (Chazotte, 2011).  
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7.3 Conclusion 
This thesis has provided data that may impact on our understanding of the efficacy 
of ERT and gene therapy for Fabry Disease. Alpha-gal A activity may help predict 
susceptibility to enzyme deficiency. Through further study using iPS cells from patient 
fibroblasts to derive various tissue types of relevance to the disease pathophysiology, 
enzyme activity could potentially inform personalised targeting of therapy. 
Kinetic studies showed that at high virus dose the affinity of α-gal A to the synthetic 
substrate 4MUG decreases, suggesting a low dosage may have more clinical 
effectiveness. However the disease appears to lower the transduction efficiency of 
lentivirus to patient cells. Gene therapy dosage should therefore be optimised with 
consideration to these potential factors. Cross correction may possibly be enhanced 
by pre-treating patients with diets/agents that enhance mitochondrial function and 
antioxidant capacity, e.g. ketogenic diets prior to gene therapy. 
Through the proposed future work, it is hoped that the encouraging potential of 
lentivirus-mediated gene delivery shown here can be realised in clinical practice to 
improve outcomes for patients with this devastating and life-threatening disease. 
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Chapter 8 The thesis in three minutes 
This thesis was presented in three minutes to a potentially world-wide audience 
through the 2016 UK Three Minute Thesis (3MT) competition. The 3MT concept was 
developed by The University of Queensland, Australia, where the first competition 
was held in 2008. Since 2011 the competition has grown in popularity and spread 
internationally to over 600 universities (The University of Queensland, 2017).  
The aim of a 3MT presentation was to clearly convey to the general public, in an 
accessible and engaging style, my doctoral research and its potential impact for 
society. The competition rules required the presentation was spoken without props 
accept one static slide that was to be on display throughout the talk without 
animations, sound or video. The slide developed to help communicate my thesis is 
shown in Figure 8-1. Figure 8-2 is a quick response (QR) code for access to an online 
video of my talk available on the internet to all. My progress through the UCL and UK 
national competitions is shown in Figure 8-3. 
The lysosome was conceptualised as the “wheelie bin” of the cell. The audience was 
asked to imagine a situation arising if the waste removal company went permanently 
on strike: waste would accumulate in bins resulting in anxiety, illness and death to 
the householder. My talk explained that on a cellular level this situation is similar to 
Fabry disease in which enzyme deficiency results from mutations in GLA leading to 
accumulation of waste in lysosomes. Hence it was proposed that gene therapy, which 
inserts a correct copy of the GLA gene into patient cells using a virus vector, may be 
a good treatment. Investigating this possibility, the talk explained the results of my 
research shown in Figure 8-1. Gene delivery produced a dose-dependent increase in 
enzyme activity in target cells. A low dose produced an enzyme equally efficient at 
breaking down waste as in healthy cells, but a high dose produced an enzyme 
significantly less efficient. Importantly, these results were placed back into the 
context of the waste removal company, to help the audience appreciate the potential 
relevance of these findings for patients. A low dose gene therapy may be thought of 
as a single workman, focused on his job and efficient at clearing waste from bins. A 
high dose delivery is like a team of workman distracted by arguing and talking with 
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each other so that they can’t work efficiently. This point was summarised with the 
take home message that “less may be more”. The talk concluded with on-going work 
studying the potential of gene therapy to repair damage to the “power supply” of the 
cell, the mitochondria, in patient cells. The potential impact of this future work was 
highlighted by explaining that, if gene therapy could repair mitochondrial damage, 
this may be equivalent to giving back “cellular mojo” to enable cells to repair and 
save the lives of Fabry disease patients. 
My presentation won the 2016 UCL Final and came runner-up in the 2016 Vitae 3MT 
UK National Final that was held as part of the annual Vitae Career Researchers 
international conference (Figure 8-3). Participation in the 3MT competition not only 
improved my presentation and communication skills but inspired me in public 
engagement, teaching activities, and a successful grant application to the National 
Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond 
Street Institute of Child Health that funded Chapter 6 of this thesis.  
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Figure 8-1: The slide used in the UK Three Minute Thesis competition 2016 
A single slide, without animation, sound or video, was allowed to support a three 
minute presentation of the PhD thesis. Adaptations of this slide were subsequently used in a 
public engagement talk at the Biomedical Research Centre (BRC) Great Ormond Street 
Institute of Child Health (GOSICH) open day 2016 which was targeted to families and children. 
 
 
 
 
 
Figure 8-2: QR code to access a video of the UCL Three Minute Thesis 2016 competition 
The video was submitted for the UK national 3MT semi-final competition. As a result I 
was one of six selected for the UK national final held in Manchester in September 2016, at 
which I was a runner-up. The website accessed by the code is: 
 https://www.youtube.com/watch?v=poyot209O_k&amp=&feature=youtu.be 
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Figure 8-3: Rounds of the 2016 UCL and Vitae UK National Three Minute Thesis competition 
There were five rounds of competition. The first three were within UCL and 
participants were judged following their live presentations before an audience of students, 
researchers and academics. As winner of the 2016 UCL Final I went through to the UK 
Nationals which were organised by Vitae, part of Careers Research Advisory Centre (CRAC) 
Ltd. The Semi-Final was an on-line round in which a panel of judges selected 6 Finalists based 
upon video presentations by 56 winners from participating universities. The UK National Final 
was held live in Manchester at the Vitae Researcher Development International Conference.  
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